<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE chapter PUBLIC "-//ES//DTD book DTD version 5.5.0//EN//XML" "book550.dtd" [<!ENTITY b014-015-9780702070280 SYSTEM "b014-015-9780702070280" NDATA IMAGE><!ENTITY b014-016-9780702070280 SYSTEM "b014-016-9780702070280" NDATA IMAGE><!ENTITY b014-024-9780702070280 SYSTEM "b014-024-9780702070280" NDATA IMAGE><!ENTITY f014-001-9780702070280 SYSTEM "f014-001-9780702070280" NDATA IMAGE><!ENTITY f014-002-9780702070280 SYSTEM "f014-002-9780702070280" NDATA IMAGE><!ENTITY f014-003-9780702070280 SYSTEM "f014-003-9780702070280" NDATA IMAGE><!ENTITY f014-004-9780702070280 SYSTEM "f014-004-9780702070280" NDATA IMAGE><!ENTITY f014-005-9780702070280 SYSTEM "f014-005-9780702070280" NDATA IMAGE><!ENTITY f014-006-9780702070280 SYSTEM "f014-006-9780702070280" NDATA IMAGE><!ENTITY f014-007-9780702070280 SYSTEM "f014-007-9780702070280" NDATA IMAGE><!ENTITY f014-008-9780702070280 SYSTEM "f014-008-9780702070280" NDATA IMAGE><!ENTITY f014-009-9780702070280 SYSTEM "f014-009-9780702070280" NDATA IMAGE><!ENTITY f014-010-9780702070280 SYSTEM "f014-010-9780702070280" NDATA IMAGE><!ENTITY f014-011-9780702070280 SYSTEM "f014-011-9780702070280" NDATA IMAGE><!ENTITY f014-012-9780702070280 SYSTEM "f014-012-9780702070280" NDATA IMAGE><!ENTITY f014-013-9780702070280 SYSTEM "f014-013-9780702070280" NDATA IMAGE><!ENTITY f014-014-9780702070280 SYSTEM "f014-014-9780702070280" NDATA IMAGE><!ENTITY f014-015-9780702070280 SYSTEM "f014-015-9780702070280" NDATA IMAGE><!ENTITY icon01-9780702070280 SYSTEM "icon01-9780702070280" NDATA IMAGE><!ENTITY icon02-9780702070280 SYSTEM "icon02-9780702070280" NDATA IMAGE><!ENTITY icon03-9780702070280 SYSTEM "icon03-9780702070280" NDATA IMAGE><!ENTITY icon04-9780702070280 SYSTEM "icon04-9780702070280" NDATA IMAGE><!ENTITY icon05-9780702070280 SYSTEM "icon05-9780702070280" NDATA IMAGE><!ENTITY icon06-9780702070280 SYSTEM "icon06-9780702070280" NDATA IMAGE><!ENTITY u014-001-9780702070280 SYSTEM "u014-001-9780702070280" NDATA IMAGE><!ENTITY u014-002-9780702070280 SYSTEM "u014-002-9780702070280" NDATA IMAGE>]><chapter docsubtype="chp" id="c00014" version="5.5" xml:lang="en" xmlns="http://www.elsevier.com/xml/bk/dtd" xmlns:ce="http://www.elsevier.com/xml/common/dtd" xmlns:xlink="http://www.w3.org/1999/xlink"><info><ce:pii>B978-0-7020-7028-0.00014-7</ce:pii><ce:doi>10.1016/B978-0-7020-7028-0.00014-7</ce:doi><ce:isbn>978-0-7020-7028-0</ce:isbn><ce:copyright type="full-transfer" year="2018">Elsevier Ltd</ce:copyright></info><ce:floats><ce:figure id="f0020"><ce:label>Fig. 14.1</ce:label><ce:caption id="ca0010"><ce:simple-para id="sp0010" role="title">Normal distribution of body water and electrolytes.</ce:simple-para><ce:simple-para id="sp0015" role="caption">Schematic representation of volume (L = litres) and composition (dominant ionic species only shown) of the intracellular fluid (ICF) and extracellular fluid (ECF) in a 70 kg male. The main difference in composition between the plasma and interstitial fluid (ISF) is the presence of appreciable concentrations of protein in the plasma but not the ISF. The Na/K differential is maintained by the Na,K-adenosine triphosphatase (ATPase) pump.</ce:simple-para></ce:caption><ce:alt-text id="atte0010" role="short">Fig. 14.1</ce:alt-text><ce:link id="ln0030" locator="f014-001-9780702070280" xlink:href="pii:B9780702070280000147/f014-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0025"><ce:label>Fig. 14.2</ce:label><ce:caption id="ca0015"><ce:simple-para id="sp0020" role="title">The nephron.</ce:simple-para><ce:simple-para id="sp0025" role="caption">Letters A–D refer to tubular segments shown in more detail in <ce:cross-ref id="crf0295" refid="f0030">Figure 14.3</ce:cross-ref>. (aa = afferent arteriole; ea = efferent arteriole; md = macula densa)</ce:simple-para></ce:caption><ce:alt-text id="atte0015" role="short">Fig. 14.2</ce:alt-text><ce:link id="ln0035" locator="f014-002-9780702070280" xlink:href="pii:B9780702070280000147/f014-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0030"><ce:label>Fig. 14.3</ce:label><ce:caption id="ca0020"><ce:simple-para id="sp0030" role="title">Principal transport mechanisms in segments of the nephron.</ce:simple-para><ce:simple-para id="sp0035" role="caption">The apical membrane of tubular cells is the side facing the lumen and the basolateral membrane is the side facing the blood. Black circles indicate active transport pumps linked to ATP hydrolysis and white symbols indicate ion channels and transporter molecules. Details of the proportion of sodium reabsorbed, influence of regulatory factors, water permeability and sites of action for different classes of diuretics are shown. The SGLT2 inhibitors are primarily used for the treatment of diabetes but have diuretic properties by blocking SGLT2 in the proximal tubule. At the same site, acetazolamide inhibits carbonic anhydrase (CA), which, by reducing production of hydrogen ions by proximal tubular cells, inhibits sodium–hydrogen exchange through the NHE-3 transporter. Loop diuretics block the NKCC2 transporter in the loop of Henle, whereas thiazide diuretics block the NCCT channel in the early distal tubule. Amiloride and spironolactone block the ENaC channel in the late distal tubule and collecting ducts. See text for further details and abbreviations.</ce:simple-para></ce:caption><ce:alt-text id="atte0020" role="short">Fig. 14.3</ce:alt-text><ce:link id="ln0040" locator="f014-003-9780702070280" xlink:href="pii:B9780702070280000147/f014-003-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0035"><ce:label>Fig. 14.4</ce:label><ce:caption id="ca0025"><ce:simple-para id="sp0040" role="title">Mechanisms involved in the regulation of sodium transport.</ce:simple-para><ce:simple-para id="sp0045" role="caption">(ANP = atrial natriuretic peptide; BNP = brain natriuretic peptide; ECF = extracellular fluid; GFR = glomerular filtration rate; RAA = renin–angiotensin–aldosterone system; SNS = sympathetic nervous system. ⊕ indicates an effect to stimulate Na reabsorption and hence reduce Na excretion, while ⊖ indicates an effect to inhibit Na reabsorption and hence increase Na excretion)</ce:simple-para></ce:caption><ce:alt-text id="atte0025" role="short">Fig. 14.4</ce:alt-text><ce:link id="ln0045" locator="f014-004-9780702070280" xlink:href="pii:B9780702070280000147/f014-004-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0040"><ce:label>Fig. 14.5</ce:label><ce:caption id="ca0030"><ce:simple-para id="sp0055" role="title">Secondary mechanisms causing sodium excess and oedema in cardiac failure, cirrhosis and nephrotic syndrome.</ce:simple-para><ce:simple-para id="sp0060" role="caption">Primary renal retention of Na and water may also contribute to oedema formation when glomerular filtration rate is significantly reduced (see <ce:cross-ref id="crf0420" refid="b0045">Box 14.8</ce:cross-ref> and <ce:intra-ref id="ii0105" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0220">p. 395</ce:intra-ref>).</ce:simple-para></ce:caption><ce:alt-text id="atte0030" role="short">Fig. 14.5</ce:alt-text><ce:link id="ln0080" locator="f014-005-9780702070280" xlink:href="pii:B9780702070280000147/f014-005-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0045"><ce:label>Fig. 14.6</ce:label><ce:caption id="ca0035"><ce:simple-para id="sp0065" role="title">Mechanisms of renal water handling.</ce:simple-para><ce:simple-para id="sp0070" role="caption">(1) Filtrate from the proximal tubule is isosmotic to plasma and cortical interstitial fluid. (2) Water moves down its osmotic gradient, concentrating the filtrate but not diluting the interstitium, as the vasa recta carries away the water. (3) The filtrate is at its highest concentration at the bend of the loop and therefore the surrounding medulla is also concentrated. (4) NaCl is pumped out of the filtrate in the thick ascending limb and early distal tubule, increasing the interstitial fluid osmolality. (5) The filtrate has a concentration of 100 mOsmol/kg as it leaves the early distal tubule. <ce:bold>A</ce:bold> In the face of water deficit, vasopressin causes water permeability of the collecting ducts, resulting in osmotic reabsorption of water. <ce:bold>B</ce:bold> In the situation of water overload, vasopressin secretion is suppressed and urine remains dilute.</ce:simple-para></ce:caption><ce:alt-text id="atte0035" role="short">Fig. 14.6</ce:alt-text><ce:link id="ln0090" locator="f014-006-9780702070280" xlink:href="pii:B9780702070280000147/f014-006-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0050"><ce:label>Fig. 14.7</ce:label><ce:caption id="ca0040"><ce:simple-para id="sp0080" role="title">Hyponatraemia and the brain.</ce:simple-para><ce:simple-para id="sp0085" role="caption">Numbers represent osmolality (osmo) in mOsmol/kg.</ce:simple-para></ce:caption><ce:alt-text id="atte0040" role="short">Fig. 14.7</ce:alt-text><ce:link id="ln0105" locator="f014-007-9780702070280" xlink:href="pii:B9780702070280000147/f014-007-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0055"><ce:label>Fig. 14.8</ce:label><ce:caption id="ca0045"><ce:simple-para id="sp0090" role="title">Algorithm for the diagnosis of hyponatraemia.</ce:simple-para><ce:simple-para id="sp0095" role="caption">(ECF = extracellular fluid; SIADH = syndrome of inappropriate antidiuretic hormone (vasopressin) secretion)</ce:simple-para></ce:caption><ce:alt-text id="atte0045" role="short">Fig. 14.8</ce:alt-text><ce:copyright type="other" year="2014"/><ce:link id="ln0115" locator="f014-008-9780702070280" xlink:href="pii:B9780702070280000147/f014-008-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0060"><ce:label>Fig. 14.9</ce:label><ce:caption id="ca0050"><ce:simple-para id="sp0100" role="title">Feedback control of plasma potassium concentration.</ce:simple-para></ce:caption><ce:alt-text id="atte0050" role="short">Fig. 14.9</ce:alt-text><ce:link id="ln0130" locator="f014-009-9780702070280" xlink:href="pii:B9780702070280000147/f014-009-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0065"><ce:label>Fig. 14.10</ce:label><ce:caption id="ca0055"><ce:simple-para id="sp0105" role="title">Relationship between pH, <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> (in mmHg) and plasma bicarbonate concentration (in mmol/L).</ce:simple-para><ce:simple-para id="sp0110" role="caption">*Note that changes in HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> concentration are also part of the renal correction for sustained metabolic acid–base disturbances as long as the kidney itself is not the cause of the primary disturbance.</ce:simple-para></ce:caption><ce:alt-text id="atte0055" role="short">Fig. 14.10</ce:alt-text><ce:link id="ln0155" locator="f014-010-9780702070280" xlink:href="pii:B9780702070280000147/f014-010-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0070"><ce:label>Fig. 14.11</ce:label><ce:caption id="ca0060"><ce:simple-para id="sp0115" role="title">Generation and maintenance of metabolic alkalosis during prolonged vomiting.</ce:simple-para><ce:simple-para id="sp0120" role="caption">Loss of H<ce:sup loc="post">+</ce:sup>Cl<ce:sup loc="post">−</ce:sup> generates metabolic alkalosis, which is maintained by renal changes.</ce:simple-para></ce:caption><ce:alt-text id="atte0060" role="short">Fig. 14.11</ce:alt-text><ce:link id="ln0175" locator="f014-011-9780702070280" xlink:href="pii:B9780702070280000147/f014-011-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0080"><ce:label>Fig. 14.12</ce:label><ce:caption id="ca0065"><ce:simple-para id="sp0125" role="title">Structure of lipoproteins.</ce:simple-para></ce:caption><ce:alt-text id="atte0065" role="short">Fig. 14.12</ce:alt-text><ce:link id="ln0205" locator="f014-012-9780702070280" xlink:href="pii:B9780702070280000147/f014-012-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0085"><ce:label>Fig. 14.13</ce:label><ce:caption id="ca0070"><ce:simple-para id="sp0130" role="title">Absorption, transport and storage of lipids.</ce:simple-para><ce:simple-para id="sp0135" role="caption">Pathways of lipid transport are shown; in addition, cholesterol ester transfer protein exchanges triglyceride and cholesterol ester between very low-density lipoprotein/chylomicrons and high-/low-density lipoprotein, and free fatty acids released from peripheral lipolysis can be taken up in the liver. (ABCA1/ABCG1 = adenosine triphosphate-binding cassette A1/G1; Apo = apolipoprotein; BA = bile acids; C = cholesterol; CE = cholesterol ester; FFA = free fatty acids; HDL = mature high-density lipoprotein; HL = hepatic lipase; HMGCoAR = hydroxy-methyl-glutaryl-co-enzyme A reductase; IDL = intermediate-density lipoprotein; iHDL = immature high-density lipoprotein; LCAT = lecithin cholesterol acyl transferase; LDL = low-density lipoprotein; LDLR = low-density lipoprotein receptor (Apo B100 receptor); LPL = lipoprotein lipase; PCSK9 = proprotein convertase subtilisin kexin 9; SRB1 = scavenger receptor B1; TG = triglyceride; VLDL = very low-density lipoprotein)</ce:simple-para></ce:caption><ce:alt-text id="atte0070" role="short">Fig. 14.13</ce:alt-text><ce:link id="ln0210" locator="f014-013-9780702070280" xlink:href="pii:B9780702070280000147/f014-013-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0090"><ce:label>Fig. 14.14</ce:label><ce:caption id="ca0075"><ce:simple-para id="sp0160" role="title">Flow chart for the drug treatment of hyperlipidaemia.</ce:simple-para><ce:simple-para id="sp0165" role="caption">*Interrupt treatment if creatine kinase is more than 5–10 times the upper limit of normal, or if elevated with muscle symptoms, or if alanine aminotransferase is more than 2–3 times the upper limit. To convert triglyceride (TG) in mmol/L to mg/dL, multiply by 88. To convert low-density lipoprotein (LDL)-C in mmol/L to mg/dL, multiply by 38.</ce:simple-para></ce:caption><ce:alt-text id="atte0075" role="short">Fig. 14.14</ce:alt-text><ce:link id="ln0245" locator="f014-014-9780702070280" xlink:href="pii:B9780702070280000147/f014-014-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:figure id="f0095"><ce:label>Fig. 14.15</ce:label><ce:caption id="ca0080"><ce:simple-para id="sp0170" role="title">Haem biosynthetic pathway and enzyme defects responsible for the porphyrias.</ce:simple-para><ce:simple-para id="sp0175" role="caption">(ALA = δ-aminolaevulinic acid; CoA = co-enzyme A; N = neurovisceral; P = photosensitive; PBG = porphobilinogen)</ce:simple-para></ce:caption><ce:alt-text id="atte0080" role="short">Fig. 14.15</ce:alt-text><ce:link id="ln0260" locator="f014-015-9780702070280" xlink:href="pii:B9780702070280000147/f014-015-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure><ce:textbox id="b0015" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0025" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000147/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0085" role="short">Image 1</ce:alt-text></ce:inline-figure>14.2</ce:label><ce:alt-text id="atte0090" role="short">14.2</ce:alt-text><ce:textbox-head><ce:title id="tit0020">How to interpret urea and electrolytes results<ce:cross-ref id="crf0250" refid="fn0010">*</ce:cross-ref><ce:footnote id="fn0010"><ce:label>*</ce:label><ce:note-para id="np0010">The term urea and electrolytes (U&#x0026;Es) refers to urea, electrolyes and creatinine. In some countries this is abbreviated to EUC (electrolytes/urea/creatinine).</ce:note-para></ce:footnote></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0020"><ce:section-title id="st0020">Sodium</ce:section-title><ce:para id="p0305"><ce:list id="ulist0090"><ce:list-item id="u0270"><ce:label>•</ce:label><ce:para id="p0310">Largely reflects changes in sodium and water balance</ce:para></ce:list-item><ce:list-item id="u0275"><ce:label>•</ce:label><ce:para id="p0315">See ‘<ce:cross-ref id="crf0255" refid="s0280">Hypernatraemia</ce:cross-ref>’ and ‘<ce:cross-ref id="crf0260" refid="s0230">Hyponatraemia</ce:cross-ref>’ (<ce:cross-ref id="crf9035" refid="p1345">pp. 358</ce:cross-ref> and <ce:cross-ref id="crf9040" refid="s0230">357</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0025"><ce:section-title id="st0025">Potassium</ce:section-title><ce:para id="p0320"><ce:list id="ulist0095"><ce:list-item id="u0280"><ce:label>•</ce:label><ce:para id="p0325">May reflect K shifts in and out of cells</ce:para></ce:list-item><ce:list-item id="u0285"><ce:label>•</ce:label><ce:para id="p0330">Low levels usually mean excessive losses (gastrointestinal or renal)</ce:para></ce:list-item><ce:list-item id="u0290"><ce:label>•</ce:label><ce:para id="p0335">High levels usually mean renal dysfunction</ce:para></ce:list-item><ce:list-item id="u0295"><ce:label>•</ce:label><ce:para id="p0340">See ‘<ce:cross-ref id="crf0265" refid="s0315">Hypokalaemia</ce:cross-ref>’ and ‘<ce:cross-ref id="crf0270" refid="s0340">Hyperkalaemia</ce:cross-ref>’ (<ce:cross-ref id="crf9045" refid="s0310">pp. 361</ce:cross-ref> and <ce:cross-ref id="crf9050" refid="p1775">362</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0030"><ce:section-title id="st0030">Chloride</ce:section-title><ce:para id="p0345"><ce:list id="ulist0100"><ce:list-item id="u0300"><ce:label>•</ce:label><ce:para id="p0350">Generally changes in parallel with plasma Na</ce:para></ce:list-item><ce:list-item id="u0305"><ce:label>•</ce:label><ce:para id="p0355">Low in metabolic alkalosis</ce:para></ce:list-item><ce:list-item id="u0310"><ce:label>•</ce:label><ce:para id="p0360">High in some forms of metabolic acidosis</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0035"><ce:section-title id="st0035">Bicarbonate</ce:section-title><ce:para id="p0365"><ce:list id="ulist0105"><ce:list-item id="u0315"><ce:label>•</ce:label><ce:para id="p0370">Abnormal in acid–base disorders</ce:para></ce:list-item><ce:list-item id="u0320"><ce:label>•</ce:label><ce:para id="p0375">See <ce:cross-ref id="crf0275" refid="b0095">Box 14.18</ce:cross-ref> (<ce:cross-ref id="crf9055" refid="p2145">p. 365</ce:cross-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0040"><ce:section-title id="st0040">Urea</ce:section-title><ce:para id="p0380"><ce:list id="ulist0110"><ce:list-item id="u0325"><ce:label>•</ce:label><ce:para id="p0385">Increased with a fall in glomerular filtration rate (GFR), reduced renal perfusion or urine flow rate, and in high protein intake or catabolic states</ce:para></ce:list-item><ce:list-item id="u0330"><ce:label>•</ce:label><ce:para id="p0390">See <ce:intra-ref id="ii0045" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0045">page 386</ce:intra-ref></ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0045"><ce:section-title id="st0045">Creatinine</ce:section-title><ce:para id="p0395"><ce:list id="ulist0115"><ce:list-item id="u0335"><ce:label>•</ce:label><ce:para id="p0400">Increased with a fall in GFR, in individuals with high muscle mass, and with some drugs</ce:para></ce:list-item><ce:list-item id="u0340"><ce:label>•</ce:label><ce:para id="p0405">See <ce:intra-ref id="ii0050" xlink:href="pii:B978-0-7020-7028-0.00015-9#f0030">Fig. 15.2</ce:intra-ref> (<ce:intra-ref id="ii0055" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0080">p. 387</ce:intra-ref>)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0020" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0050" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0095" role="short">Image 2</ce:alt-text></ce:inline-figure>14.3</ce:label><ce:alt-text id="atte0100" role="short">14.3</ce:alt-text><ce:textbox-head><ce:title id="tit0025">Clinical features of hypovolaemia and hypervolaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0520"><ce:display><ce:table frame="topbot" id="t0015"><ce:alt-text id="atte0105" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Hypovolaemia</entry><entry align="left">Hypervolaemia</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Symptoms</ce:bold></entry><entry align="left"><ce:list id="ulist0125"><ce:list-item id="u0360"><ce:para id="p0525">Thirst</ce:para></ce:list-item><ce:list-item id="u0365"><ce:para id="p0530">Dizziness on standing</ce:para></ce:list-item><ce:list-item id="u0370"><ce:para id="p0535">Weakness</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0130"><ce:list-item id="u0375"><ce:para id="p0540">Ankle swelling</ce:para></ce:list-item><ce:list-item id="u0380"><ce:para id="p0545">Abdominal swelling</ce:para></ce:list-item><ce:list-item id="u0385"><ce:para id="p0550">Breathlessness</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Signs</ce:bold></entry><entry align="left"><ce:list id="ulist0135"><ce:list-item id="u0395"><ce:para id="p0560">Postural hypotension</ce:para></ce:list-item><ce:list-item id="u0400"><ce:para id="p0565">Tachycardia</ce:para></ce:list-item><ce:list-item id="u0405"><ce:para id="p0570">Dry mouth</ce:para></ce:list-item><ce:list-item id="u0410"><ce:para id="p0575">Reduced skin turgor</ce:para></ce:list-item><ce:list-item id="u0415"><ce:para id="p0580">Reduced urine output</ce:para></ce:list-item><ce:list-item id="u0420"><ce:para id="p0585">Weight loss</ce:para></ce:list-item><ce:list-item id="u0425"><ce:para id="p0590">Delirium, stupor</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0140"><ce:list-item id="u0430"><ce:para id="p0595">Peripheral oedema</ce:para></ce:list-item><ce:list-item id="u0435"><ce:para id="p0600">Raised JVP</ce:para></ce:list-item><ce:list-item id="u0440"><ce:para id="p0605">Pulmonary crepitations</ce:para></ce:list-item><ce:list-item id="u0445"><ce:para id="p0610">Pleural effusion</ce:para></ce:list-item><ce:list-item id="u0450"><ce:para id="p0615">Ascites</ce:para></ce:list-item><ce:list-item id="u0455"><ce:para id="p0620">Weight gain</ce:para></ce:list-item><ce:list-item id="u0460"><ce:para id="p0625">Hypertension (sometimes)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0050">(JVP = jugular venous pressure)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0025" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0055" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0110" role="short">Image 3</ce:alt-text></ce:inline-figure>14.4</ce:label><ce:alt-text id="atte0115" role="short">14.4</ce:alt-text><ce:textbox-head><ce:title id="tit0030">Causes of hypovolaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0635"><ce:display><ce:table frame="topbot" id="t0020"><ce:alt-text id="atte0120" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mechanism</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Inadequate sodium intake</ce:bold></entry><entry align="left">Environmental deprivation, inadequate therapeutic replacement</entry></row><row rowsep="1"><entry align="left"><ce:bold>Gastrointestinal sodium loss</ce:bold></entry><entry align="left">Vomiting, diarrhoea, nasogastric suction, external fistula</entry></row><row rowsep="1"><entry align="left"><ce:bold>Skin sodium loss</ce:bold></entry><entry align="left">Excessive sweating, burns</entry></row><row rowsep="1"><entry align="left"><ce:bold>Renal sodium loss</ce:bold></entry><entry align="left">Diuretic therapy, mineralocorticoid deficiency, tubulointerstitial disease</entry></row><row rowsep="1"><entry align="left"><ce:bold>Internal sequestration</ce:bold><ce:cross-ref id="crf0350" refid="tn0010"><ce:bold>*</ce:bold></ce:cross-ref></entry><entry align="left">Bowel obstruction, peritonitis, pancreatitis, crush injury</entry></row><row><entry align="left"><ce:bold>Reduced blood volume</ce:bold></entry><entry align="left">Acute blood loss</entry></row></tbody></tgroup><ce:table-footnote id="tn0010"><ce:label>*</ce:label><ce:note-para id="np0015">A cause of circulatory volume depletion, although total body sodium and water may be normal or increased.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0030" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0060" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0125" role="short">Image 4</ce:alt-text></ce:inline-figure>14.5</ce:label><ce:alt-text id="atte0130" role="short">14.5</ce:alt-text><ce:textbox-head><ce:title id="tit0035">Basic daily water and electrolyte requirements</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0675"><ce:display><ce:table frame="topbot" id="t0025"><ce:alt-text id="atte0135" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left"/><entry align="left">Requirement per kg</entry><entry align="left">Typical 70 kg adult</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Water</ce:bold></entry><entry align="left">35–45 mL/kg</entry><entry align="left">2.45–3.15 L/24 hrs</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sodium</ce:bold></entry><entry align="left">1.5–2 mmol/kg</entry><entry align="left">105–140 mmol/24 hrs</entry></row><row><entry align="left"><ce:bold>Potassium</ce:bold></entry><entry align="left">1.0–1.5 mmol/kg</entry><entry align="left">70–105 mmol/24 hrs</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0035" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0065" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0140" role="short">Image 5</ce:alt-text></ce:inline-figure>14.6</ce:label><ce:alt-text id="atte0145" role="short">14.6</ce:alt-text><ce:textbox-head><ce:title id="tit0040">Composition of some isotonic intravenous fluids</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0680"><ce:display><ce:table frame="topbot" id="t0030"><ce:alt-text id="atte0150" role="short">Unlabelled table</ce:alt-text><tgroup cols="6"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><colspec colname="col6" colnum="6"/><thead><row rowsep="1"><entry align="left">Fluid</entry><entry align="left">D-glucose</entry><entry align="left">Calories</entry><entry align="left">Na<ce:sup loc="post">+</ce:sup> (mmol/L)</entry><entry align="left">Cl<ce:sup loc="post">−</ce:sup> (mmol/L)</entry><entry align="left">Other (mmol/L)</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>5% dextrose</ce:bold></entry><entry align="left">50 g</entry><entry align="left">200</entry><entry align="left">0</entry><entry align="left">0</entry><entry align="left">0</entry></row><row rowsep="1"><entry align="left"><ce:bold>Normal (0.9%) saline</ce:bold></entry><entry align="left">0</entry><entry align="left">0</entry><entry align="left">154</entry><entry align="left">154</entry><entry align="left">0</entry></row><row><entry align="left"><ce:bold>Hartmann's solution</ce:bold></entry><entry align="left">0</entry><entry align="left">0</entry><entry align="left">131</entry><entry align="left">111</entry><entry align="left">K<ce:sup loc="post">+</ce:sup> 5<ce:br/>Ca<ce:sup loc="post">2+</ce:sup> 2<ce:br/>Lactate<ce:sup loc="post">−</ce:sup> 29</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0040" role="alt3"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0070" locator="icon03-9780702070280" xlink:href="pii:B9780702070280000147/icon03-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0155" role="short">Image 6</ce:alt-text></ce:inline-figure>14.7</ce:label><ce:alt-text id="atte0160" role="short">14.7</ce:alt-text><ce:textbox-head><ce:title id="tit0045">How to assess fluid and electrolyte balance in hospitalised patients</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0125"><ce:section-title id="st0125">Step 1: assess clinical volume status</ce:section-title><ce:para id="p0685"><ce:list id="ulist0150"><ce:list-item id="u0475"><ce:label>•</ce:label><ce:para id="p0690">Examine patient for signs of hypovolaemia or hypervolaemia (see <ce:cross-ref id="crf0375" refid="b0020">Box 14.3</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0480"><ce:label>•</ce:label><ce:para id="p0695">Check daily weight change</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0130"><ce:section-title id="st0130">Step 2: review fluid balance chart</ce:section-title><ce:para id="p0700"><ce:list id="ulist0155"><ce:list-item id="u0485"><ce:label>•</ce:label><ce:para id="p0705">Check total volumes IN and OUT on previous day (IN–OUT is positive by ~400 mL in normal balance, reflecting insensible fluid losses of ~800 mL and metabolic water generation of ~400 mL)</ce:para></ce:list-item><ce:list-item id="u0490"><ce:label>•</ce:label><ce:para id="p0710">Check cumulative change in daily fluid balance over previous 3–5 days</ce:para></ce:list-item><ce:list-item id="u0495"><ce:label>•</ce:label><ce:para id="p0715">Correlate chart figures with weight change and clinical volume status to estimate net fluid balance</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0135"><ce:section-title id="st0135">Step 3: assess ongoing pathological process</ce:section-title><ce:para id="p0720"><ce:list id="ulist0160"><ce:list-item id="u0500"><ce:label>•</ce:label><ce:para id="p0725">Check losses from gastrointestinal tract and surgical drains</ce:para></ce:list-item><ce:list-item id="u0505"><ce:label>•</ce:label><ce:para id="p0730">Estimate increased insensible losses (e.g. in fever) and internal sequestration (‘third space’)</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0140"><ce:section-title id="st0140">Step 4: check plasma U&#x0026;Es (see <ce:cross-ref id="crf0380" refid="b0015">Box 14.2</ce:cross-ref>)</ce:section-title><ce:para id="p0735"><ce:list id="ulist0165"><ce:list-item id="u0510"><ce:label>•</ce:label><ce:para id="p0740">Check plasma Na as marker of relative water balance</ce:para></ce:list-item><ce:list-item id="u0515"><ce:label>•</ce:label><ce:para id="p0745">Check plasma K as a guide to extracellular K balance</ce:para></ce:list-item><ce:list-item id="u0520"><ce:label>•</ce:label><ce:para id="p0750">Check HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> as a clue to acid–base disorder</ce:para></ce:list-item><ce:list-item id="u0525"><ce:label>•</ce:label><ce:para id="p0755">Check urea and creatinine to monitor renal function</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0145"><ce:section-title id="st0145">Step 5: prescribe appropriate intravenous fluid replacement therapy</ce:section-title><ce:para id="p0760"><ce:list id="ulist0170"><ce:list-item id="u0530"><ce:label>•</ce:label><ce:para id="p0765">Replace basic water and electrolytes each day (see <ce:cross-ref id="crf0385" refid="b0030">Box 14.5</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0535"><ce:label>•</ce:label><ce:para id="p0770">Allow for anticipated oral intake and pathological fluid loss</ce:para></ce:list-item><ce:list-item id="u0540"><ce:label>•</ce:label><ce:para id="p0775">Adjust amounts of water (if IV, usually given as isotonic 5% dextrose), sodium and potassium according to plasma electrolyte results</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0045" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0075" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0165" role="short">Image 7</ce:alt-text></ce:inline-figure>14.8</ce:label><ce:alt-text id="atte0170" role="short">14.8</ce:alt-text><ce:textbox-head><ce:title id="tit0050">Causes of sodium and water excess</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0800"><ce:display><ce:table frame="topbot" id="t0035"><ce:alt-text id="atte0175" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mechanism</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Impaired renal function</ce:bold></entry><entry align="left">Primary renal disease</entry></row><row rowsep="1"><entry align="left"><ce:bold>Primary hyperaldosteronism</ce:bold><ce:cross-ref id="crf0400" refid="tn0015"><ce:bold>*</ce:bold></ce:cross-ref></entry><entry align="left">Conn's syndrome</entry></row><row><entry align="left"><ce:bold>Secondary hyperaldosteronism</ce:bold><ce:br/>(see <ce:cross-ref id="crf0405" refid="f0040">Fig. 14.5</ce:cross-ref>)</entry><entry align="left">Congestive cardiac failure<ce:br/>Cirrhotic liver disease<ce:br/>Nephrotic syndrome<ce:br/>Protein-losing enteropathy<ce:br/>Malnutrition<ce:br/>Idiopathic/cyclical oedema<ce:br/>Renal artery stenosis<ce:cross-ref id="crf0410" refid="tn0015">*</ce:cross-ref></entry></row></tbody></tgroup><ce:table-footnote id="tn0015"><ce:label>*</ce:label><ce:note-para id="np0020">Conditions in this box <ce:italic>other than</ce:italic> primary hyperaldosteronism and renal artery stenosis are typically associated with generalised oedema.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0050" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0085" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0180" role="short">Image 8</ce:alt-text></ce:inline-figure>14.9</ce:label><ce:alt-text id="atte0185" role="short">14.9</ce:alt-text><ce:textbox-head><ce:title id="tit0055">Adverse effects of loop-acting and thiazide diuretics</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0900"><ce:display><ce:table frame="topbot" id="t0040"><ce:alt-text id="atte0190" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Renal side-effects</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0185"><ce:list-item id="u0575"><ce:label>•</ce:label><ce:para id="p0905">Hypovolaemia</ce:para></ce:list-item><ce:list-item id="u0580"><ce:label>•</ce:label><ce:para id="p0910">Hyponatraemia</ce:para></ce:list-item><ce:list-item id="u0585"><ce:label>•</ce:label><ce:para id="p0915">Hypokalaemia</ce:para></ce:list-item><ce:list-item id="u0590"><ce:label>•</ce:label><ce:para id="p0920">Metabolic alkalosis</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0190"><ce:list-item id="u0595"><ce:label>•</ce:label><ce:para id="p0925">Hyperuricaemia</ce:para></ce:list-item><ce:list-item id="u0600"><ce:label>•</ce:label><ce:para id="p0930">Hypomagnesaemia</ce:para></ce:list-item><ce:list-item id="u0605"><ce:label>•</ce:label><ce:para id="p0935">Hypercalciuria (loop)</ce:para></ce:list-item><ce:list-item id="u0610"><ce:label>•</ce:label><ce:para id="p0940">Hypocalciuria (thiazide)</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Metabolic side-effects</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0195"><ce:list-item id="u0615"><ce:label>•</ce:label><ce:para id="p0945">Glucose intolerance/hyperglycaemia</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0200"><ce:list-item id="u0620"><ce:label>•</ce:label><ce:para id="p0950">Hyperlipidaemia</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Miscellaneous side-effects</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0205"><ce:list-item id="u0625"><ce:label>•</ce:label><ce:para id="p0955">Hypersensitivity reactions</ce:para></ce:list-item><ce:list-item id="u0630"><ce:label>•</ce:label><ce:para id="p0960">Erectile dysfunction</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0210"><ce:list-item id="u0635"><ce:label>•</ce:label><ce:para id="p0965">Acute pancreatitis/cholecystitis (thiazides)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0055" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0095" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0195" role="short">Image 9</ce:alt-text></ce:inline-figure>14.10</ce:label><ce:alt-text id="atte0200" role="short">14.10</ce:alt-text><ce:textbox-head><ce:title id="tit0060">Causes of hyponatraemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1080"><ce:display><ce:table frame="topbot" id="t0045"><ce:alt-text id="atte0205" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Volume status</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Hypovolaemic</ce:bold></entry><entry align="left"><ce:list id="ulist0230"><ce:list-item id="u0685"><ce:para id="p1085">Renal sodium losses:<ce:list id="ulist0235"><ce:list-item id="u0690"><ce:para id="p1090">Diuretic therapy (especially thiazides)</ce:para></ce:list-item><ce:list-item id="u0695"><ce:para id="p1095">Adrenocortical failure</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0700"><ce:para id="p1100">Gastrointestinal sodium losses:<ce:list id="ulist0240"><ce:list-item id="u0705"><ce:para id="p1105">Vomiting</ce:para></ce:list-item><ce:list-item id="u0710"><ce:para id="p1110">Diarrhoea</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0715"><ce:para id="p1115">Skin sodium losses:<ce:list id="ulist0245"><ce:list-item id="u0720"><ce:para id="p1120">Burns</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Euvolaemic</ce:bold></entry><entry align="left"><ce:list id="ulist0250"><ce:list-item id="u0725"><ce:para id="p1125">Primary polydipsia</ce:para></ce:list-item><ce:list-item id="u0730"><ce:para id="p1130">Excessive electrolyte-free water infusion</ce:para></ce:list-item><ce:list-item id="u0735"><ce:para id="p1135">SIADH</ce:para></ce:list-item><ce:list-item id="u0740"><ce:para id="p1140">Hypothyroidism</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Hypervolaemic</ce:bold></entry><entry align="left"><ce:list id="ulist0255"><ce:list-item id="u0745"><ce:para id="p1145">Congestive cardiac failure</ce:para></ce:list-item><ce:list-item id="u0750"><ce:para id="p1150">Cirrhosis</ce:para></ce:list-item><ce:list-item id="u0755"><ce:para id="p1155">Nephrotic syndrome</ce:para></ce:list-item><ce:list-item id="u0760"><ce:para id="p1160">Chronic kidney disease (during free water intake)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0075">(SIADH = syndrome of inappropriate antidiuretic hormone (vasopressin) secretion; see <ce:cross-ref id="crf0455" refid="b0060">Box 14.11</ce:cross-ref>).</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0060" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0100" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0210" role="short">Image 10</ce:alt-text></ce:inline-figure>14.11</ce:label><ce:alt-text id="atte0215" role="short">14.11</ce:alt-text><ce:textbox-head><ce:title id="tit0065">Causes and diagnosis of syndrome of inappropriate antidiuretic hormone secretion</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:section id="s0250"><ce:section-title id="st0250">Causes</ce:section-title><ce:para id="p1185"><ce:list id="ulist0260"><ce:list-item id="u0765"><ce:label>•</ce:label><ce:para id="p1190">Tumours</ce:para></ce:list-item><ce:list-item id="u0770"><ce:label>•</ce:label><ce:para id="p1195">Central nervous system disorders: stroke, trauma, infection, psychosis, porphyria</ce:para></ce:list-item><ce:list-item id="u0775"><ce:label>•</ce:label><ce:para id="p1200">Pulmonary disorders: pneumonia, tuberculosis, obstructive lung disease</ce:para></ce:list-item><ce:list-item id="u0780"><ce:label>•</ce:label><ce:para id="p1205">Drugs: anticonvulsants, psychotropics, antidepressants, cytotoxics, oral hypoglycaemic agents, opiates</ce:para></ce:list-item><ce:list-item id="u0785"><ce:label>•</ce:label><ce:para id="p1210">Idiopathic</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0255"><ce:section-title id="st0255">Diagnosis</ce:section-title><ce:para id="p1215"><ce:list id="ulist0265"><ce:list-item id="u0790"><ce:label>•</ce:label><ce:para id="p1220">Low plasma sodium concentration (typically &#x003C; 130 mmol/L)</ce:para></ce:list-item><ce:list-item id="u0795"><ce:label>•</ce:label><ce:para id="p1225">Low plasma osmolality (&#x003C; 275 mOsmol/kg)</ce:para></ce:list-item><ce:list-item id="u0800"><ce:label>•</ce:label><ce:para id="p1230">Urine osmolality not minimally low (typically &#x003E; 100 mOsmol/kg)</ce:para></ce:list-item><ce:list-item id="u0805"><ce:label>•</ce:label><ce:para id="p1235">Urine sodium concentration not minimally low (&#x003E; 30 mmol/L)</ce:para></ce:list-item><ce:list-item id="u0810"><ce:label>•</ce:label><ce:para id="p1240">Low–normal plasma urea, creatinine, uric acid</ce:para></ce:list-item><ce:list-item id="u0815"><ce:label>•</ce:label><ce:para id="p1245">Clinical euvolaemia</ce:para></ce:list-item><ce:list-item id="u0820"><ce:label>•</ce:label><ce:para id="p1250">Absence of adrenal, thyroid, pituitary or renal insufficiency</ce:para></ce:list-item><ce:list-item id="u0825"><ce:label>•</ce:label><ce:para id="p1255">No recent use of diuretics</ce:para></ce:list-item><ce:list-item id="u0830"><ce:label>•</ce:label><ce:para id="p1260">Exclusion of other causes of hyponatraemia (see <ce:cross-ref id="crf0480" refid="b0055">Box 14.10</ce:cross-ref>)</ce:para></ce:list-item><ce:list-item id="u0835"><ce:label>•</ce:label><ce:para id="p1265">Appropriate clinical context (above)</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0065" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0110" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0220" role="short">Image 11</ce:alt-text></ce:inline-figure>14.12</ce:label><ce:alt-text id="atte0225" role="short">14.12</ce:alt-text><ce:textbox-head><ce:title id="tit0070">Symptoms and severity of hyponatraemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1280"><ce:display><ce:table frame="topbot" id="t0050"><ce:alt-text id="atte0230" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Severity</entry><entry align="left">Serum sodium</entry><entry align="left">Symptoms</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Mild</ce:bold></entry><entry align="left">130–135 mmol/L</entry><entry align="left">None</entry></row><row rowsep="1"><entry align="left"><ce:bold>Moderate</ce:bold></entry><entry align="left">125–129 mmol/L</entry><entry align="left"><ce:list id="ulist0270"><ce:list-item id="u0840"><ce:para id="p1285">Nausea</ce:para></ce:list-item><ce:list-item id="u0845"><ce:para id="p1290">Delirium</ce:para></ce:list-item><ce:list-item id="u0850"><ce:para id="p1295">Headache</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Severe</ce:bold></entry><entry align="left">&#x003C; 124 mmol/L</entry><entry align="left"><ce:list id="ulist0275"><ce:list-item id="u0855"><ce:para id="p1300">Vomiting</ce:para></ce:list-item><ce:list-item id="u0860"><ce:para id="p1305">Somnolence</ce:para></ce:list-item><ce:list-item id="u0865"><ce:para id="p1310">Seizures</ce:para></ce:list-item><ce:list-item id="u0870"><ce:para id="p1315">Coma</ce:para></ce:list-item><ce:list-item id="u0875"><ce:para id="p1320">Cardiorespiratory arrest</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0070" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0120" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0235" role="short">Image 12</ce:alt-text></ce:inline-figure>14.13</ce:label><ce:alt-text id="atte0240" role="short">14.13</ce:alt-text><ce:textbox-head><ce:title id="tit0075">Causes of hypernatraemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1360"><ce:display><ce:table frame="topbot" id="t0055"><ce:alt-text id="atte0245" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Volume status</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Hypovolaemic</ce:bold></entry><entry align="left"><ce:list id="ulist0280"><ce:list-item id="u0880"><ce:para id="p1365">Renal sodium losses:</ce:para></ce:list-item><ce:list-item id="u0885"><ce:para id="p1370">Diuretic therapy (especially osmotic diuretic, or loop diuretic during water restriction)</ce:para></ce:list-item><ce:list-item id="u0890"><ce:para id="p1375">Glycosuria (hyperglycaemic hyperosmolar state, <ce:intra-ref id="ii0145" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0375">p. 738</ce:intra-ref>)</ce:para></ce:list-item><ce:list-item id="u0895"><ce:para id="p1380">Gastrointestinal sodium losses:</ce:para></ce:list-item><ce:list-item id="u0900"><ce:para id="p1385">Colonic diarrhoea</ce:para></ce:list-item><ce:list-item id="u0905"><ce:para id="p1390">Skin sodium losses:</ce:para></ce:list-item><ce:list-item id="u0910"><ce:para id="p1395">Excessive sweating</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Euvolaemic</ce:bold></entry><entry align="left">Diabetes insipidus (central or nephrogenic) (<ce:intra-ref id="ii0150" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1580">p. 687</ce:intra-ref>)</entry></row><row><entry align="left"><ce:bold>Hypervolaemic</ce:bold></entry><entry align="left"><ce:list id="ulist0285"><ce:list-item id="u0915"><ce:para id="p1400">Enteral or parenteral feeding</ce:para></ce:list-item><ce:list-item id="u0920"><ce:para id="p1405">Intravenous or oral salt administration</ce:para></ce:list-item><ce:list-item id="u0925"><ce:para id="p1410">Chronic kidney disease (during water restriction)</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0075" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0125" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000147/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0250" role="short">Image 13</ce:alt-text></ce:inline-figure>14.14</ce:label><ce:alt-text id="atte0255" role="short">14.14</ce:alt-text><ce:textbox-head><ce:title id="tit0080">Hyponatraemia and hypernatraemia in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1435"><ce:list id="ulist0290"><ce:list-item id="u0930"><ce:label>•</ce:label><ce:para id="p1440"><ce:bold>Decline in GFR</ce:bold>: older patients are predisposed to both hyponatraemia and hypernatraemia, mainly because, as glomerular filtration rate declines with age, the capacity of the kidney to dilute or concentrate the urine is impaired.</ce:para></ce:list-item><ce:list-item id="u0935"><ce:label>•</ce:label><ce:para id="p1445"><ce:bold>Hyponatraemia</ce:bold>: occurs when free water intake continues in the presence of a low dietary salt intake and/or diuretic drugs (particularly thiazides).</ce:para></ce:list-item><ce:list-item id="u0940"><ce:label>•</ce:label><ce:para id="p1450"><ce:bold>Vasopressin release</ce:bold>: water retention is aggravated by any condition that stimulates vasopressin release, especially heart failure. Moreover, the vasopressin response to non-osmotic stimuli may be brisker in older subjects. Appropriate water restriction may be a key part of management.</ce:para></ce:list-item><ce:list-item id="u0945"><ce:label>•</ce:label><ce:para id="p1455"><ce:bold>Hypernatraemia</ce:bold>: occurs when water intake is inadequate, due to physical restrictions preventing access to drinks and/or blunted thirst. Both are frequently present in patients with advanced dementia or following a severe stroke.</ce:para></ce:list-item><ce:list-item id="u0950"><ce:label>•</ce:label><ce:para id="p1460"><ce:bold>Dietary salt</ce:bold>: hypernatraemia is aggravated if dietary supplements or medications with a high sodium content (especially effervescent preparations) are administered. Appropriate prescription of fluids is a key part of management.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0080" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0135" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0260" role="short">Image 14</ce:alt-text></ce:inline-figure>14.15</ce:label><ce:alt-text id="atte0265" role="short">14.15</ce:alt-text><ce:textbox-head><ce:title id="tit0085">Causes of hypokalaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1500"><ce:display><ce:figure id="f9000"><ce:alt-text id="atte0270" role="short">Unlabelled image</ce:alt-text><ce:link id="ln9000" locator="b014-015-9780702070280" xlink:href="pii:B9780702070280000147/b014-015-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0085" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0140" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0275" role="short">Image 15</ce:alt-text></ce:inline-figure>14.16</ce:label><ce:alt-text id="atte0280" role="short">14.16</ce:alt-text><ce:textbox-head><ce:title id="tit0090">Causes of hyperkalaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p1800"><ce:display><ce:figure id="f9005"><ce:alt-text id="atte0285" role="short">Unlabelled image</ce:alt-text><ce:link id="ln9005" locator="b014-016-9780702070280" xlink:href="pii:B9780702070280000147/b014-016-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0090" role="alt6"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0145" locator="icon06-9780702070280" xlink:href="pii:B9780702070280000147/icon06-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0290" role="short">Image 16</ce:alt-text></ce:inline-figure>14.17</ce:label><ce:alt-text id="atte0295" role="short">14.17</ce:alt-text><ce:textbox-head><ce:title id="tit0095">Treatment of severe hyperkalaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2020"><ce:display><ce:table frame="topbot" id="t0070"><ce:alt-text id="atte0300" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Objective</entry><entry align="left">Therapy</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Stabilise cell membrane potential</ce:bold><ce:cross-ref id="crf0570" refid="tn0020"><ce:bold><ce:sup loc="post">1</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left">IV calcium gluconate (10 mL of 10% solution)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Shift K<ce:sup loc="post">+</ce:sup> into cells</ce:bold></entry><entry align="left"><ce:list id="ulist0480"><ce:list-item id="u1360"><ce:para id="p2025">Inhaled β<ce:inf loc="post">2</ce:inf>-adrenoceptor agonist</ce:para></ce:list-item><ce:list-item id="u1365"><ce:para id="p2030">IV glucose (50 mL of 50% solution) and insulin (5 IU Actrapid)</ce:para></ce:list-item><ce:list-item id="u1370"><ce:para id="p2035">IV sodium bicarbonate<ce:cross-ref id="crf0575" refid="tn0025"><ce:sup loc="post">2</ce:sup></ce:cross-ref></ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Remove K<ce:sup loc="post">+</ce:sup> from body</ce:bold></entry><entry align="left"><ce:list id="ulist0485"><ce:list-item id="u1375"><ce:para id="p2040">IV furosemide and normal saline<ce:cross-ref id="crf0580" refid="tn0030"><ce:sup loc="post">3</ce:sup></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u1380"><ce:para id="p2045">Ion-exchange resin (e.g. Resonium) orally or rectally</ce:para></ce:list-item><ce:list-item id="u1385"><ce:para id="p2050">Dialysis</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup><ce:table-footnote id="tn0020"><ce:label>1</ce:label><ce:note-para id="np0025">If severe hyperkalaemia (K<ce:sup loc="post">+</ce:sup> typically &#x003E; 6.5 mmol/L).</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0025"><ce:label>2</ce:label><ce:note-para id="np0030">If acidosis present.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0030"><ce:label>3</ce:label><ce:note-para id="np0035">If adequate residual renal function.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0010" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0020" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0305" role="short">Image 17</ce:alt-text></ce:inline-figure>14.1</ce:label><ce:alt-text id="atte0310" role="short">14.1</ce:alt-text><ce:textbox-head><ce:title id="tit0015">Range of analytical modalities used in the clinical biochemistry laboratory</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p0295"><ce:display><ce:table frame="topbot" id="t0010"><ce:alt-text id="atte0315" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Analytical modality</entry><entry align="left">Analyte</entry><entry align="left">Typical applications</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Ion-selective electrodes</ce:bold></entry><entry align="left">Blood gases, electrolytes (Na, K, Cl)</entry><entry align="left">Point-of-care testing (POCT)<ce:br/>High-throughput analysers</entry></row><row rowsep="1"><entry align="left"><ce:bold>Colorimetric chemical reaction or coupled enzymatic reaction</ce:bold></entry><entry align="left">Simple mass or concentration measurement (creatinine, phosphate)<ce:br/>Simple enzyme activity</entry><entry align="left">High-throughput analysers</entry></row><row rowsep="1"><entry align="left"><ce:bold>Ligand assay</ce:bold><ce:br/>(usually immunoassay)</entry><entry align="left">Specific proteins<ce:br/>Hormones<ce:br/>Drugs</entry><entry align="left">Increasingly available for POCT or high-throughput analysers</entry></row><row rowsep="1"><entry align="left"><ce:bold>Chromatography</ce:bold>: gas chromatography (GC), high-performance liquid chromatography (HPLC), thin-layer chromatography (TLC)</entry><entry align="left">Organic compounds</entry><entry align="left">Therapeutic drug monitoring (TDM)</entry></row><row rowsep="1"><entry align="left"><ce:bold>Mass spectroscopy (MS)</ce:bold></entry><entry align="left"/><entry align="left">Drug screening (drugs of misuse)<ce:br/>Vitamins<ce:br/>Biochemical metabolites</entry></row><row rowsep="1"><entry align="left"><ce:bold>Spectrophotometry, turbidimetry, nephelometry, fluorimetry</ce:bold></entry><entry align="left">Haemoglobin derivatives<ce:br/>Specific proteins<ce:br/>Immunoglobulins</entry><entry align="left">Xanthochromia<ce:br/>Lipoproteins<ce:br/>Paraproteins</entry></row><row rowsep="1"><entry align="left"><ce:bold>Electrophoresis</ce:bold></entry><entry align="left">Proteins<ce:br/>Some enzymes</entry><entry align="left">Paraproteins<ce:br/>Isoenzyme analysis</entry></row><row rowsep="1"><entry align="left"><ce:bold>Atomic absorption (AA)</ce:bold><ce:br/><ce:bold>Inductively coupled plasma/mass spectroscopy (ICP-MS)</ce:bold></entry><entry align="left">Trace elements and metals</entry><entry align="left">Quantitation of heavy metals</entry></row><row><entry align="left"><ce:bold>Molecular diagnostics</ce:bold></entry><entry align="left">Nucleic acid quantification and/or sequence</entry><entry align="left">Inherited and somatic cell mutations (<ce:intra-ref id="ii0010" xlink:href="pii:B978-0-7020-7028-0.00003-2#c00003">Ch. 3</ce:intra-ref>)<ce:br/>Genetic polymorphisms (<ce:intra-ref id="ii0015" xlink:href="pii:B978-0-7020-7028-0.00003-2#c00003">Ch. 3</ce:intra-ref>)<ce:br/>Variations in rates of drug metabolism (<ce:intra-ref id="ii0020" xlink:href="pii:B978-0-7020-7028-0.00002-0#c00002">Ch. 2</ce:intra-ref>)<ce:br/>Microbial diagnosis (<ce:intra-ref id="ii0025" xlink:href="pii:B978-0-7020-7028-0.00006-8#c00006">Ch. 6</ce:intra-ref>)</entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0095" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0160" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0320" role="short">Image 18</ce:alt-text></ce:inline-figure>14.18</ce:label><ce:alt-text id="atte0325" role="short">14.18</ce:alt-text><ce:textbox-head><ce:title id="tit0100">Principal patterns of acid–base disturbance</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2105"><ce:display><ce:table frame="topbot" id="t0075"><ce:alt-text id="atte0330" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Disturbance</entry><entry align="left">Blood H<ce:sup loc="post">+</ce:sup></entry><entry align="left">Primary change</entry><entry align="left">Compensatory response</entry><entry align="left">Predicted compensation</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Metabolic acidosis</ce:bold></entry><entry align="left">&#x003E; 40<ce:cross-ref id="crf0600" refid="tn0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> &#x003C; 24 mmol/L</entry><entry align="left"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> &#x003C; 5.33 kPa<ce:cross-ref id="crf0605" refid="tn0040"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> fall in kPa = 0.16 × HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> fall in mmol/L</entry></row><row rowsep="1"><entry align="left"><ce:bold>Metabolic alkalosis</ce:bold></entry><entry align="left">&#x003C; 40<ce:cross-ref id="crf0610" refid="tn0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left">HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> &#x003E; 24 mmol/L</entry><entry align="left"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> &#x003E; 5.33 kPa<ce:cross-ref id="crf0615" refid="tn0040"><ce:sup loc="post">2</ce:sup></ce:cross-ref><ce:sup loc="post">,</ce:sup><ce:cross-ref id="crf0620" refid="tn0045"><ce:sup loc="post">3</ce:sup></ce:cross-ref></entry><entry align="left"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> rise in kPa = 0.08 × HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> rise in mmol/L</entry></row><row rowsep="1"><entry align="left"><ce:bold>Respiratory acidosis</ce:bold></entry><entry align="left">&#x003E; 40<ce:cross-ref id="crf0625" refid="tn0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> &#x003E; 5.33 kPa<ce:cross-ref id="crf0630" refid="tn0040"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> &#x003E; 24 mmol/L</entry><entry align="left">Acute: HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> rise in mmol/L = 0.75 × <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> rise in kPa<ce:br/>Chronic: HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> rise in mmol/L = 2.62 × <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> rise in kPa</entry></row><row><entry align="left"><ce:bold>Respiratory alkalosis</ce:bold></entry><entry align="left">&#x003C; 40<ce:cross-ref id="crf0635" refid="tn0035"><ce:sup loc="post">1</ce:sup></ce:cross-ref></entry><entry align="left"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> &#x003C; 5.33 kPa<ce:cross-ref id="crf0640" refid="tn0040"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> &#x003C; 24 mmol/L</entry><entry align="left">Acute: HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> fall in mmol/L = 1.50 × <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> fall in kPa<ce:br/>Chronic: HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> fall in mmol/L = 3.75 × <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> fall in kPa</entry></row></tbody></tgroup><ce:table-footnote id="tn0035"><ce:label>1</ce:label><ce:note-para id="np0040">H<ce:sup loc="post">+</ce:sup> of 40 nmol/L = pH of 7.40.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0040"><ce:label>2</ce:label><ce:note-para id="np0045"><ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> of 5.33 kPa = 40 mmHg.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0045"><ce:label>3</ce:label><ce:note-para id="np0050"><ce:italic>PCO</ce:italic><ce:inf loc="post">2</ce:inf> does not rise above 7.33 kPa (55 mmHg) because hypoxia then intervenes to drive respiration.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0100" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0165" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0335" role="short">Image 19</ce:alt-text></ce:inline-figure>14.19</ce:label><ce:alt-text id="atte0340" role="short">14.19</ce:alt-text><ce:textbox-head><ce:title id="tit0105">Causes of metabolic acidosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2120"><ce:display><ce:table frame="topbot" id="t0080"><ce:alt-text id="atte0345" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Disorder</entry><entry align="left">Mechanism</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Normal anion gap</ce:bold></entry></row><row rowsep="0"><entry align="left">Ingestion or infusion of inorganic acid</entry><entry align="left">Therapeutic infusion of or poisoning with NH<ce:inf loc="post">4</ce:inf>Cl, HCl</entry></row><row rowsep="0"><entry align="left">Gastrointestinal HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> loss</entry><entry align="left">Loss of HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> in diarrhoea, small bowel fistula, urinary diversion procedure</entry></row><row rowsep="1"><entry align="left">Renal tubular acidosis (RTA)</entry><entry align="left">Urinary loss of HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup> in proximal RTA; impaired tubular acid secretion in distal RTA</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Increased anion gap</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left">Endogenous acid load</entry></row><row rowsep="0"><entry align="left">Diabetic ketoacidosis</entry><entry align="left">Accumulation of ketones<ce:cross-ref id="crf0650" refid="tn0050"><ce:sup loc="post">1</ce:sup></ce:cross-ref> with hyperglycaemia (<ce:intra-ref id="ii0225" xlink:href="pii:B978-0-7020-7028-0.00020-2#p0880">p. 735</ce:intra-ref>)</entry></row><row rowsep="0"><entry align="left">Starvation ketosisAlcoholic ketoacidosis</entry><entry align="left">Accumulation of ketones without hyperglycaemia (<ce:intra-ref id="ii0230" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0085">p. 725</ce:intra-ref>)</entry></row><row rowsep="0"><entry align="left">Lactic acidosis</entry><entry align="left">Shock, liver disease, drugs</entry></row><row rowsep="1"><entry align="left">Kidney disease</entry><entry align="left">Accumulation of organic acids</entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left">Exogenous acid load</entry></row><row rowsep="0"><entry align="left">Aspirin poisoning</entry><entry align="left">Accumulation of salicylate<ce:cross-ref id="crf0655" refid="tn0055"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry></row><row rowsep="0"><entry align="left">Methanol poisoning</entry><entry align="left">Accumulation of formate</entry></row><row><entry align="left">Ethylene glycol poisoning</entry><entry align="left">Accumulation of glycolate, oxalate</entry></row></tbody></tgroup><ce:table-footnote id="tn0050"><ce:label>1</ce:label><ce:note-para id="np0055">Ketones include acid anions acetoacetate and β-hydroxybutyrate (<ce:intra-ref id="ii0235" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0085">p. 725</ce:intra-ref>).</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0055"><ce:label>2</ce:label><ce:note-para id="np0060">Salicylate poisoning is also associated with respiratory alkalosis due to direct ventilatory stimulation.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0105" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0170" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0350" role="short">Image 20</ce:alt-text></ce:inline-figure>14.20</ce:label><ce:alt-text id="atte0355" role="short">14.20</ce:alt-text><ce:textbox-head><ce:title id="tit0110">Causes of renal tubular acidosis</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2150"><ce:display><ce:table frame="topbot" id="t0085"><ce:alt-text id="atte0360" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Proximal renal tubular acidosis (type II RTA)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0495"><ce:list-item id="u1405"><ce:label>•</ce:label><ce:para id="p2155">Inherited:<ce:list id="ulist0500"><ce:list-item id="u1410"><ce:para id="p2160">Fanconi's syndrome</ce:para></ce:list-item><ce:list-item id="u1415"><ce:para id="p2165">Cystinosis</ce:para></ce:list-item><ce:list-item id="u1420"><ce:para id="p2170">Wilson's disease</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1425"><ce:label>•</ce:label><ce:para id="p2175">Paraproteinaemia:<ce:list id="ulist0505"><ce:list-item id="u1430"><ce:para id="p2180">Myeloma</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1435"><ce:label>•</ce:label><ce:para id="p2185">Amyloidosis</ce:para></ce:list-item><ce:list-item id="u1440"><ce:label>•</ce:label><ce:para id="p2190">Hyperparathyroidism</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0510"><ce:list-item id="u1445"><ce:label>•</ce:label><ce:para id="p2195">Heavy metal toxicity:<ce:list id="ulist0515"><ce:list-item id="u1450"><ce:para id="p2200">Lead, cadmium and mercury poisoning</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1455"><ce:label>•</ce:label><ce:para id="p2205">Drugs:<ce:list id="ulist0520"><ce:list-item id="u1460"><ce:para id="p2210">Carbonic anhydrase inhibitors</ce:para></ce:list-item><ce:list-item id="u1465"><ce:para id="p2215">Ifosfamide</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Classical distal renal tubular acidosis (type I RTA)</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0525"><ce:list-item id="u1470"><ce:label>•</ce:label><ce:para id="p2220">Inherited</ce:para></ce:list-item><ce:list-item id="u1475"><ce:label>•</ce:label><ce:para id="p2225">Autoimmune diseases:<ce:list id="ulist0530"><ce:list-item id="u1480"><ce:para id="p2230">Systemic lupus erythematosus</ce:para></ce:list-item><ce:list-item id="u1485"><ce:para id="p2235">Sjögren's syndrome</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0535"><ce:list-item id="u1490"><ce:label>•</ce:label><ce:para id="p2240">Hyperglobulinaemia</ce:para></ce:list-item><ce:list-item id="u1495"><ce:label>•</ce:label><ce:para id="p2245">Toxins and drugs:<ce:list id="ulist0540"><ce:list-item id="u1500"><ce:para id="p2250">Toluene</ce:para></ce:list-item><ce:list-item id="u1505"><ce:para id="p2255">Lithium</ce:para></ce:list-item><ce:list-item id="u1510"><ce:para id="p2260">Amphotericin</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Hyperkalaemic distal renal tubular acidosis (type IV RTA)</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0545"><ce:list-item id="u1515"><ce:label>•</ce:label><ce:para id="p2265">Hypoaldosteronism (primary or secondary)</ce:para></ce:list-item><ce:list-item id="u1520"><ce:label>•</ce:label><ce:para id="p2270">Obstructive nephropathy</ce:para></ce:list-item><ce:list-item id="u1525"><ce:label>•</ce:label><ce:para id="p2275">Renal transplant rejection</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0550"><ce:list-item id="u1530"><ce:label>•</ce:label><ce:para id="p2280">Drugs:<ce:list id="ulist0555"><ce:list-item id="u1535"><ce:para id="p2285">Amiloride</ce:para></ce:list-item><ce:list-item id="u1540"><ce:para id="p2290">Spironolactone</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0110" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0180" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0365" role="short">Image 21</ce:alt-text></ce:inline-figure>14.21</ce:label><ce:alt-text id="atte0370" role="short">14.21</ce:alt-text><ce:textbox-head><ce:title id="tit0115">Causes of hypomagnesaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2450"><ce:display><ce:table frame="topbot" id="t0090"><ce:alt-text id="atte0375" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mechanism</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Inadequate intake</ce:bold></entry><entry align="left"><ce:list id="ulist0565"><ce:list-item id="u1555"><ce:para id="p2455">Starvation</ce:para></ce:list-item><ce:list-item id="u1560"><ce:para id="p2460">Malnutrition</ce:para></ce:list-item><ce:list-item id="u1565"><ce:para id="p2465">Alcoholism</ce:para></ce:list-item><ce:list-item id="u1570"><ce:para id="p2470">Parenteral alimentation</ce:para></ce:list-item></ce:list></entry></row><row rowsep="0"><entry align="left"><ce:bold>Excessive losses</ce:bold></entry><entry align="left"/></row><row rowsep="0"><entry align="left">Gastrointestinal</entry><entry align="left"><ce:list id="ulist0570"><ce:list-item id="u1575"><ce:para id="p2475">Prolonged vomiting/nasogastric aspiration</ce:para></ce:list-item><ce:list-item id="u1580"><ce:para id="p2480">Chronic diarrhoea/laxative abuse</ce:para></ce:list-item><ce:list-item id="u1585"><ce:para id="p2485">Malabsorption</ce:para></ce:list-item><ce:list-item id="u1590"><ce:para id="p2490">Small bowel bypass surgery</ce:para></ce:list-item><ce:list-item id="u1595"><ce:para id="p2495">Fistulae</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left">Urinary</entry><entry align="left"><ce:list id="ulist0575"><ce:list-item id="u1600"><ce:para id="p2500">Diuretic therapy</ce:para></ce:list-item><ce:list-item id="u1605"><ce:para id="p2505">Alcohol</ce:para></ce:list-item><ce:list-item id="u1610"><ce:para id="p2510">Tubulotoxic drugs:<ce:list id="ulist0580"><ce:list-item id="u1615"><ce:para id="p2515">Gentamicin</ce:para></ce:list-item><ce:list-item id="u1620"><ce:para id="p2520">Cisplatin</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1625"><ce:para id="p2525">Volume expansion</ce:para></ce:list-item><ce:list-item id="u1630"><ce:para id="p2530">Diabetic ketoacidosis</ce:para></ce:list-item><ce:list-item id="u1635"><ce:para id="p2535">Post-obstructive diuresis</ce:para></ce:list-item><ce:list-item id="u1640"><ce:para id="p2540">Recovery from acute tubular necrosis</ce:para></ce:list-item><ce:list-item id="u1645"><ce:para id="p2545">Inherited tubular transport defect:<ce:list id="ulist0585"><ce:list-item id="u1650"><ce:para id="p2550">Bartter's syndrome</ce:para></ce:list-item><ce:list-item id="u1655"><ce:para id="p2555">Gitelman's syndrome</ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u1660"><ce:para id="p2560">Primary renal magnesium wasting</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Miscellaneous</ce:bold></entry><entry align="left"><ce:list id="ulist0590"><ce:list-item id="u1665"><ce:para id="p2565">Acute pancreatitis</ce:para></ce:list-item><ce:list-item id="u1670"><ce:para id="p2570">Foscarnet therapy</ce:para></ce:list-item><ce:list-item id="u1675"><ce:para id="p2575">Proton pump inhibitor therapy</ce:para></ce:list-item><ce:list-item id="u1680"><ce:para id="p2580">Hungry bone syndrome</ce:para></ce:list-item><ce:list-item id="u1685"><ce:para id="p2585">Diabetes mellitus</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0115" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0185" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0380" role="short">Image 22</ce:alt-text></ce:inline-figure>14.22</ce:label><ce:alt-text id="atte0385" role="short">14.22</ce:alt-text><ce:textbox-head><ce:title id="tit0120">Causes of hypophosphataemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2635"><ce:display><ce:table frame="topbot" id="t0095"><ce:alt-text id="atte0390" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><thead><row rowsep="1"><entry align="left">Mechanism</entry><entry align="left">Examples</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Redistribution into cells</ce:bold></entry><entry align="left"><ce:list id="ulist0595"><ce:list-item id="u1690"><ce:para id="p2640">Refeeding after starvation</ce:para></ce:list-item><ce:list-item id="u1695"><ce:para id="p2645">Respiratory alkalosis</ce:para></ce:list-item><ce:list-item id="u1700"><ce:para id="p2650">Treatment for diabetic ketoacidosis</ce:para></ce:list-item></ce:list></entry></row><row rowsep="1"><entry align="left"><ce:bold>Inadequate intake or absorption</ce:bold></entry><entry align="left"><ce:list id="ulist0600"><ce:list-item id="u1705"><ce:para id="p2655">Malnutrition</ce:para></ce:list-item><ce:list-item id="u1710"><ce:para id="p2660">Malabsorption</ce:para></ce:list-item><ce:list-item id="u1715"><ce:para id="p2665">Chronic diarrhoea</ce:para></ce:list-item><ce:list-item id="u1720"><ce:para id="p2670">Phosphate binders</ce:para></ce:list-item><ce:list-item id="u1725"><ce:para id="p2675">Antacids</ce:para></ce:list-item><ce:list-item id="u1730"><ce:para id="p2680">Vitamin D deficiency or resistance</ce:para></ce:list-item></ce:list></entry></row><row><entry align="left"><ce:bold>Increased renal excretion</ce:bold></entry><entry align="left"><ce:list id="ulist0605"><ce:list-item id="u1735"><ce:para id="p2685">Hyperparathyroidism</ce:para></ce:list-item><ce:list-item id="u1740"><ce:para id="p2690">Extracellular fluid volume expansion with diuresis</ce:para></ce:list-item><ce:list-item id="u1745"><ce:para id="p2695">Osmotic diuretics</ce:para></ce:list-item><ce:list-item id="u1750"><ce:para id="p2700">Fanconi's syndrome</ce:para></ce:list-item><ce:list-item id="u1755"><ce:para id="p2705">Familial hypophosphataemic rickets</ce:para></ce:list-item><ce:list-item id="u1760"><ce:para id="p2710">Tumour-induced hypophosphataemic rickets</ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0120" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0190" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0395" role="short">Image 23</ce:alt-text></ce:inline-figure>14.23</ce:label><ce:alt-text id="atte0400" role="short">14.23</ce:alt-text><ce:textbox-head><ce:title id="tit0125">Glycogen storage diseases</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2810"><ce:display><ce:table frame="topbot" id="t0100"><ce:alt-text id="atte0405" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row rowsep="1"><entry align="left">Type</entry><entry align="left">Eponym</entry><entry align="left">Enzyme deficiency</entry><entry align="left">Clinical features and complications</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>I</ce:bold></entry><entry align="left">Von Gierke</entry><entry align="left">Glucose-6-phosphatase</entry><entry align="left">Childhood presentation, hypoglycaemia, hepatomegaly</entry></row><row rowsep="1"><entry align="left"><ce:bold>II</ce:bold></entry><entry align="left">Pompe</entry><entry align="left">α-glucosidase (acid maltase)</entry><entry align="left">Classical presentation in infancy, muscle weakness (may be severe)</entry></row><row rowsep="1"><entry align="left"><ce:bold>III</ce:bold></entry><entry align="left">Cori</entry><entry align="left">Glycogen debrancher enzyme</entry><entry align="left">Childhood presentation, hepatomegaly, mild hypoglycaemia</entry></row><row rowsep="1"><entry align="left"><ce:bold>IV</ce:bold></entry><entry align="left">Andersen</entry><entry align="left">Brancher enzyme</entry><entry align="left">Presentation in infancy, severe muscle weakness (may affect heart), cirrhosis</entry></row><row rowsep="1"><entry align="left"><ce:bold>V</ce:bold></entry><entry align="left">McArdle</entry><entry align="left">Muscle glycogen phosphorylase</entry><entry align="left">Exercise-induced fatigue and myalgia</entry></row><row rowsep="1"><entry align="left"><ce:bold>VI</ce:bold></entry><entry align="left">Hers</entry><entry align="left">Liver phosphorylase</entry><entry align="left">Mild hepatomegaly</entry></row><row rowsep="1"><entry align="left"><ce:bold>VII</ce:bold></entry><entry align="left">Tarui</entry><entry align="left">Muscle phosphofructokinase</entry><entry align="left">Exercise-induced fatigue and myalgia</entry></row><row rowsep="1"><entry align="left"><ce:bold>IX</ce:bold><ce:cross-ref id="crf0710" refid="tn0060"><ce:bold><ce:sup loc="post">1</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left"/><entry align="left">Liver phosphorylase kinase</entry><entry align="left">Mild hepatomegaly</entry></row><row rowsep="1"><entry align="left"><ce:bold>0</ce:bold></entry><entry align="left"/><entry align="left">Hepatic glycogen synthase</entry><entry align="left">Fasting hypoglycaemia, post-prandial hyperglycaemia</entry></row><row><entry align="left"><ce:bold>X</ce:bold><ce:cross-ref id="crf0715" refid="tn0065"><ce:bold><ce:sup loc="post">2</ce:sup></ce:bold></ce:cross-ref></entry><entry align="left"/><entry align="left">Muscle phosphoglycerate mutase</entry><entry align="left">Exercise-induced myoglobinuria</entry></row></tbody></tgroup><ce:table-footnote id="tn0060"><ce:label>1</ce:label><ce:note-para id="np0065">Note that type VIII has been merged into type IX and no longer exists as a separate entity.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0065"><ce:label>2</ce:label><ce:note-para id="np0070">Recent progress in molecular genetics has recognised a number of additional, rarer types of glycogen storage disease. These are not shown in this table, which stops at type X.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0125" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0195" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0410" role="short">Image 24</ce:alt-text></ce:inline-figure>14.24</ce:label><ce:alt-text id="atte0415" role="short">14.24</ce:alt-text><ce:textbox-head><ce:title id="tit0130">Lysosomal storage diseases</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2825"><ce:display><ce:figure id="f0075"><ce:alt-text id="atte0420" role="short">Unlabelled image</ce:alt-text><ce:link id="ln0200" locator="b014-024-9780702070280" xlink:href="pii:B9780702070280000147/b014-024-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0130" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0225" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0425" role="short">Image 25</ce:alt-text></ce:inline-figure>14.25</ce:label><ce:alt-text id="atte0430" role="short">14.25</ce:alt-text><ce:textbox-head><ce:title id="tit0135">Causes of secondary hyperlipidaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p2945"><ce:display><ce:table frame="topbot" id="t0105"><ce:alt-text id="atte0435" role="short">Unlabelled table</ce:alt-text><tgroup cols="2"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Secondary hypercholesterolaemia</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Moderately common</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0620"><ce:list-item id="u1795"><ce:label>•</ce:label><ce:para id="p2950">Drugs:<ce:list id="ulist0625"><ce:list-item id="u1800"><ce:para id="p2955">Diuretics</ce:para></ce:list-item><ce:list-item id="u1805"><ce:para id="p2960">Ciclosporin</ce:para></ce:list-item><ce:list-item id="u1810"><ce:para id="p2965">Glucocorticoids</ce:para></ce:list-item><ce:list-item id="u1815"><ce:para id="p2970">Androgens</ce:para></ce:list-item><ce:list-item id="u1820"><ce:para id="p2975">Antiretroviral agents</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0630"><ce:list-item id="u1825"><ce:label>•</ce:label><ce:para id="p2980">Hypothyroidism</ce:para></ce:list-item><ce:list-item id="u1830"><ce:label>•</ce:label><ce:para id="p2985">Pregnancy</ce:para></ce:list-item><ce:list-item id="u1835"><ce:label>•</ce:label><ce:para id="p2990">Cholestatic liver disease</ce:para></ce:list-item></ce:list></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Less common</ce:bold></entry></row><row rowsep="0"><entry align="left"><ce:list id="ulist0635"><ce:list-item id="u1840"><ce:label>•</ce:label><ce:para id="p2995">Nephrotic syndrome</ce:para></ce:list-item><ce:list-item id="u1845"><ce:label>•</ce:label><ce:para id="p3000">Anorexia nervosa</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0640"><ce:list-item id="u1850"><ce:label>•</ce:label><ce:para id="p3005">Porphyria</ce:para></ce:list-item><ce:list-item id="u1855"><ce:label>•</ce:label><ce:para id="p3010">Hyperparathyroidism</ce:para></ce:list-item></ce:list></entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Secondary hypertriglyceridaemia</ce:bold></entry></row><row role="thead2" rowsep="0"><entry namest="col1" nameend="col2" align="left"><ce:bold>Common</ce:bold></entry></row><row><entry align="left"><ce:list id="ulist0645"><ce:list-item id="u1860"><ce:label>•</ce:label><ce:para id="p3015">Type 2 diabetes mellitus</ce:para></ce:list-item><ce:list-item id="u1865"><ce:label>•</ce:label><ce:para id="p3020">Chronic renal disease</ce:para></ce:list-item><ce:list-item id="u1870"><ce:label>•</ce:label><ce:para id="p3025">Abdominal obesity</ce:para></ce:list-item><ce:list-item id="u1875"><ce:label>•</ce:label><ce:para id="p3030">Excess alcohol</ce:para></ce:list-item><ce:list-item id="u1880"><ce:label>•</ce:label><ce:para id="p3035">Hepatocellular disease</ce:para></ce:list-item></ce:list></entry><entry align="left"><ce:list id="ulist0650"><ce:list-item id="u1885"><ce:label>•</ce:label><ce:para id="p3040">Drugs:<ce:list id="ulist0655"><ce:list-item id="u1890"><ce:para id="p3045">β-blockers</ce:para></ce:list-item><ce:list-item id="u1895"><ce:para id="p3050">Retinoids</ce:para></ce:list-item><ce:list-item id="u1900"><ce:para id="p3055">Glucocorticoids</ce:para></ce:list-item><ce:list-item id="u1905"><ce:para id="p3060">Antiretroviral agents</ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></entry></row></tbody></tgroup></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0135" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0230" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0440" role="short">Image 26</ce:alt-text></ce:inline-figure>14.26</ce:label><ce:alt-text id="atte0445" role="short">14.26</ce:alt-text><ce:textbox-head><ce:title id="tit0140">Classification of hyperlipidaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3070"><ce:display><ce:table frame="topbot" id="t0110"><ce:alt-text id="atte0450" role="short">Unlabelled table</ce:alt-text><tgroup cols="5"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><colspec colname="col5" colnum="5"/><thead><row rowsep="1"><entry align="left">Disease</entry><entry align="left">Elevated lipid results</entry><entry align="left">Elevated lipoprotein</entry><entry align="left">CHD risk</entry><entry align="left">Pancreatitis risk</entry></row></thead><tbody><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Predominant hypercholesterolaemia</ce:bold></entry></row><row rowsep="0"><entry align="left">Polygenic (majority)</entry><entry align="left">TC ± TG</entry><entry align="left">LDL ± VLDL</entry><entry align="left">+</entry><entry align="left">–</entry></row><row rowsep="0"><entry align="left">Familial hypercholesterolaemia (LDLR defect, defective Apo B100, increased function of <ce:italic>PCSK9</ce:italic>)</entry><entry align="left">TC ± TG</entry><entry align="left">LDL ± VLDL</entry><entry align="left">+++</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left">Hyperalphalipoproteinaemia</entry><entry align="left">TC ± TG</entry><entry align="left">HDL</entry><entry align="left">–</entry><entry align="left">–</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Predominant hypertriglyceridaemia</ce:bold></entry></row><row rowsep="0"><entry align="left">Polygenic (majority)</entry><entry align="left">TG</entry><entry align="left">VLDL ± LDL</entry><entry align="left">Variable</entry><entry align="left">+</entry></row><row rowsep="0"><entry align="left">Lipoprotein lipase deficiency</entry><entry align="left">TG ≫ TC</entry><entry align="left">Chylo</entry><entry align="left">?</entry><entry align="left">+++</entry></row><row rowsep="1"><entry align="left">Familial hypertriglyceridaemia</entry><entry align="left">TG &#x003E; TC</entry><entry align="left">VLDL ± Chylo</entry><entry align="left">?</entry><entry align="left">++</entry></row><row role="thead1" rowsep="0"><entry namest="col1" nameend="col5" align="left"><ce:bold>Mixed hyperlipidaemia</ce:bold></entry></row><row rowsep="0"><entry align="left">Polygenic (majority)</entry><entry align="left">TC + TG</entry><entry align="left">VLDL + LDL</entry><entry align="left">Variable</entry><entry align="left">+</entry></row><row rowsep="0"><entry align="left">Familial combined hyperlipidaemia<ce:cross-ref id="crf0760" refid="tn0070">*</ce:cross-ref></entry><entry align="left">TC and/or TG</entry><entry align="left">LDL and/or VLDL</entry><entry align="left">++</entry><entry align="left">+</entry></row><row><entry align="left">Dysbetalipoproteinaemia<ce:cross-ref id="crf0765" refid="tn0070">*</ce:cross-ref></entry><entry align="left">TC and/or TG</entry><entry align="left">IDL</entry><entry align="left">+++</entry><entry align="left">+</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0140">+ = slightly increased risk; ++ = increased risk; +++ = greatly increased risk; ? = risk unclear</ce:simple-para><ce:simple-para id="sp0145">(Apo B100 = apolipoprotein B100; CHD = coronary heart disease; Chylo = chylomicrons; HDL = high-density lipoprotein; IDL = intermediate-density lipoprotein; LDL = low-density lipoprotein; LDLR = low-density lipoprotein receptor; TC = total cholesterol; TG = triglycerides; VLDL = very low-density lipoprotein)</ce:simple-para></ce:legend><ce:table-footnote id="tn0070"><ce:label>*</ce:label><ce:note-para id="np0075">Familial combined hyperlipidaemia and dysbetalipoproteinaemia may also present as predominant hypercholesterolaemia or predominant hypertriglyceridaemia.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0140" role="alt4"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0235" locator="icon04-9780702070280" xlink:href="pii:B9780702070280000147/icon04-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0455" role="short">Image 27</ce:alt-text></ce:inline-figure>14.27</ce:label><ce:alt-text id="atte0460" role="short">14.27</ce:alt-text><ce:textbox-head><ce:title id="tit0145">Familial hypercholesterolaemia in adolescence</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3085"><ce:list id="ulist0660"><ce:list-item id="u1910"><ce:label>•</ce:label><ce:para id="p3090"><ce:bold>Statin treatment</ce:bold>: may be required from the age of about 10. It does not compromise normal growth and maturation.</ce:para></ce:list-item><ce:list-item id="u1915"><ce:label>•</ce:label><ce:para id="p3095"><ce:bold>Smoking</ce:bold>: patients should be strongly advised not to smoke.</ce:para></ce:list-item><ce:list-item id="u1920"><ce:label>•</ce:label><ce:para id="p3100"><ce:bold>Adherence to medication:</ce:bold> critically important to the success of treatment. Simple regimens should be used and education and support provided.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0145" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0240" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0465" role="short">Image 28</ce:alt-text></ce:inline-figure>14.28</ce:label><ce:alt-text id="atte0470" role="short">14.28</ce:alt-text><ce:textbox-head><ce:title id="tit0150">Miscellaneous and rare forms of hyperlipidaemia</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3155"><ce:display><ce:table frame="topbot" id="t0115"><ce:alt-text id="atte0475" role="short">Unlabelled table</ce:alt-text><tgroup cols="3"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><thead><row rowsep="1"><entry align="left">Condition</entry><entry align="left">Lipoprotein pattern</entry><entry align="left">CVD risk</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>Tangier disease</ce:bold></entry><entry align="left">Very low HDL, low TC</entry><entry align="left">+</entry></row><row rowsep="1"><entry align="left"><ce:bold>Apo A1 deficiency</ce:bold></entry><entry align="left">Very low HDL</entry><entry align="left">++</entry></row><row rowsep="1"><entry align="left"><ce:bold>Apo A1 Milano</ce:bold></entry><entry align="left">Very low HDL</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>Fish eye disease</ce:bold></entry><entry align="left">Very low HDL, high TG</entry><entry align="left">–</entry></row><row rowsep="1"><entry align="left"><ce:bold>LCAT deficiency</ce:bold></entry><entry align="left">Very low HDL, high TG</entry><entry align="left">?</entry></row><row rowsep="1"><entry align="left"><ce:bold>Autosomal recessive FH</ce:bold></entry><entry align="left">Very high LDL</entry><entry align="left">++</entry></row><row rowsep="1"><entry align="left"><ce:bold>Sitosterolaemia</ce:bold></entry><entry align="left">High plant sterols including sitosterol</entry><entry align="left">+</entry></row><row><entry align="left"><ce:bold>Cerebrotendinous xanthomatosis</ce:bold></entry><entry align="left">Bile acid defect (cholestanol accumulation)</entry><entry align="left">+</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0150">+ = slightly increased risk; ++ = increased risk.</ce:simple-para><ce:simple-para id="sp0155">(CVD = cardiovascular disease; FH = familial hypercholesterolaemia; HDL = high-density lipoprotein; LCAT = lecithin cholesterol acyl transferase; LDL = low-density lipoprotein; TC = total cholesterol; TG = triglycerides)</ce:simple-para></ce:legend></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0150" role="alt2"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0250" locator="icon02-9780702070280" xlink:href="pii:B9780702070280000147/icon02-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0480" role="short">Image 29</ce:alt-text></ce:inline-figure>14.29</ce:label><ce:alt-text id="atte0485" role="short">14.29</ce:alt-text><ce:textbox-head><ce:title id="tit0155">Management of hyperlipidaemia in old age</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3330"><ce:list id="ulist0675"><ce:list-item id="u1975"><ce:label>•</ce:label><ce:para id="p3335"><ce:bold>Prevalence of atherosclerotic cardiovascular disease</ce:bold>: greatest in old age.</ce:para></ce:list-item><ce:list-item id="u1980"><ce:label>•</ce:label><ce:para id="p3340"><ce:bold>Associated cardiovascular risk</ce:bold>: lipid levels become less predictive, as do other risk factors apart from age itself.</ce:para></ce:list-item><ce:list-item id="u1985"><ce:label>•</ce:label><ce:para id="p3345"><ce:bold>Benefit of statin therapy</ce:bold>: maintained up to the age of 80 years but evidence is lacking beyond this.</ce:para></ce:list-item><ce:list-item id="u1990"><ce:label>•</ce:label><ce:para id="p3350"><ce:bold>Life expectancy and statin therapy</ce:bold>: lives saved by intervention are associated with shorter life expectancy than in younger patients, and so the impact of statins on quality-adjusted life years is smaller in old age.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0155" role="alt5"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0255" locator="icon05-9780702070280" xlink:href="pii:B9780702070280000147/icon05-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0490" role="short">Image 30</ce:alt-text></ce:inline-figure>14.30</ce:label><ce:alt-text id="atte0495" role="short">14.30</ce:alt-text><ce:textbox-head><ce:title id="tit0160">Dyslipidaemia in pregnancy</ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3355"><ce:list id="ulist0680"><ce:list-item id="u1995"><ce:label>•</ce:label><ce:para id="p3360"><ce:bold>Lipid metabolism</ce:bold>: lipid and lipoprotein levels increase during pregnancy. This includes an increase in low-density lipoprotein cholesterol, which resolves post-partum. Remnant dyslipidaemia and hypertriglyceridaemia may be exacerbated during pregnancy.</ce:para></ce:list-item><ce:list-item id="u2000"><ce:label>•</ce:label><ce:para id="p3365"><ce:bold>Treatment</ce:bold>: dyslipidaemia is rarely thought to warrant urgent treatment so pharmacological therapy is usually contraindicated when conception or pregnancy is anticipated. Teratogenicity has been reported with systemically absorbed agents, and non-absorbed agents may interfere with nutrient bioavailability.</ce:para></ce:list-item><ce:list-item id="u2005"><ce:label>•</ce:label><ce:para id="p3370"><ce:bold>Monitoring</ce:bold>: while still uncommon among women of child-bearing age, cardiovascular disease is increasing in prevalence. Pre-conception cardiovascular review should be considered for women at high risk to optimise medications for pregnancy and to ensure that the patient will be able to withstand the demands of pregnancy and labour.</ce:para></ce:list-item></ce:list></ce:para></ce:sections></ce:textbox-body></ce:textbox><ce:textbox id="b0160" role="alt1"><ce:label><ce:inline-figure baseline="0.0"><ce:link id="ln0265" locator="icon01-9780702070280" xlink:href="pii:B9780702070280000147/icon01-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/><ce:alt-text id="atte0500" role="short">Image 31</ce:alt-text></ce:inline-figure>14.31</ce:label><ce:alt-text id="atte0505" role="short">14.31</ce:alt-text><ce:textbox-head><ce:title id="tit0165">Diagnostic biochemical findings in the porphyrias<ce:cross-ref id="crf0835" refid="tn0075"><ce:sup loc="post">1</ce:sup></ce:cross-ref></ce:title></ce:textbox-head><ce:textbox-body><ce:sections><ce:para id="p3410"><ce:display><ce:table frame="topbot" id="t0120"><ce:alt-text id="atte0510" role="short">Unlabelled table</ce:alt-text><tgroup cols="4"><colspec colname="col1" colnum="1"/><colspec colname="col2" colnum="2"/><colspec colname="col3" colnum="3"/><colspec colname="col4" colnum="4"/><thead><row><entry rowsep="0" align="left"/><entry namest="col2" nameend="col4" rowsep="1" align="center">Elevated porphyrins and precursors</entry></row><row role="tcolhead1" rowsep="1"><entry align="left">Condition</entry><entry align="left">Blood</entry><entry align="left">Urine</entry><entry align="left">Faeces</entry></row></thead><tbody><row rowsep="1"><entry align="left"><ce:bold>ALA dehydratase deficiency (plumboporphyria)</ce:bold></entry><entry align="left">Proto IX<ce:cross-ref id="crf0840" refid="tn0080"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left">ALA, Copro III<ce:cross-ref id="crf0845" refid="tn0080"><ce:sup loc="post">2</ce:sup></ce:cross-ref></entry><entry align="left"/></row><row rowsep="1"><entry align="left"><ce:bold>Acute intermittent porphyria (AIP)</ce:bold></entry><entry align="left"/><entry align="left">ALA, PBG</entry><entry align="left"/></row><row rowsep="1"><entry align="left"><ce:bold>Congenital erythropoietic porphyria (CEP)</ce:bold></entry><entry align="left">Uro I</entry><entry align="left">Uro I</entry><entry align="left">Copro I</entry></row><row rowsep="1"><entry align="left"><ce:bold>Porphyria cutanea tarda (PCT)</ce:bold></entry><entry align="left"/><entry align="left">Uro I</entry><entry align="left">Isocopro</entry></row><row rowsep="1"><entry align="left"><ce:bold>Hereditary coproporphyria (HCP)</ce:bold></entry><entry align="left"/><entry align="left">ALA, PBG, Copro III</entry><entry align="left">Copro III</entry></row><row rowsep="1"><entry align="left"><ce:bold>Variegate porphyria (VP)</ce:bold></entry><entry align="left"/><entry align="left">ALA, PBG, Copro III</entry><entry align="left">Proto IX</entry></row><row><entry align="left"><ce:bold>Erythropoietic protoporphyria (EPP)</ce:bold></entry><entry align="left">Proto IX</entry><entry align="left"/><entry align="left">Proto IX</entry></row></tbody></tgroup><ce:legend><ce:simple-para id="sp0180">(ALA = δ-aminolaevulinic acid; Isocopro = isocoproporphyrin; PBG = porphobilinogen; Uro = uroporphyrin)</ce:simple-para></ce:legend><ce:table-footnote id="tn0075"><ce:label>1</ce:label><ce:note-para id="np0080">Refer to <ce:cross-ref id="crf0850" refid="f0095">Figure 14.15</ce:cross-ref> for metabolic pathways.</ce:note-para></ce:table-footnote><ce:table-footnote id="tn0080"><ce:label>2</ce:label><ce:note-para id="np0085">The paradoxical rise in coproporphyrin III (Copro III) and protoporphyrin (Proto) in this very rare condition is poorly understood.</ce:note-para></ce:table-footnote></ce:table></ce:display></ce:para></ce:sections></ce:textbox-body></ce:textbox></ce:floats><ce:label>14</ce:label><ce:title id="tit0010">Clinical biochemistry and metabolic medicine</ce:title><ce:author-group id="aug0010"><ce:author author-id="B9780702070280000147-d36eb9ec998562511453fd9bdffd98fa" id="au0010"><ce:given-name>A</ce:given-name><ce:surname>Mather</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0015"><ce:author author-id="B9780702070280000147-d8130044d71c2f8c18340ca723bdd115" id="au0015"><ce:given-name>L</ce:given-name><ce:surname>Burnett</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0020"><ce:author author-id="B9780702070280000147-082a4fd84b3f4c90ebbecce41e247ba1" id="au0020"><ce:given-name>DR</ce:given-name><ce:surname>Sullivan</ce:surname></ce:author></ce:author-group><ce:author-group id="aug0025"><ce:author author-id="B9780702070280000147-66eae02624b4cd3d18d5095b1e7a26fb" id="au0025"><ce:given-name>P</ce:given-name><ce:surname>Stewart</ce:surname></ce:author></ce:author-group><outline id="out0010"><ce:list id="ulist0010"><ce:list-item id="u0010"><ce:para id="p0010"><ce:bold>Clinical examination in biochemical and metabolic disorders</ce:bold> <ce:cross-ref id="crf0010" refid="s0010"><ce:bold>346</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0015"><ce:para id="p0015"><ce:bold>Biochemical investigations</ce:bold> <ce:cross-ref id="crf0015" refid="s0015"><ce:bold>348</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0020"><ce:para id="p0020"><ce:bold>Water and electrolyte homeostasis</ce:bold> <ce:cross-ref id="crf0020" refid="s0050"><ce:bold>349</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0025"><ce:para id="p0025"><ce:bold>Sodium homeostasis</ce:bold> <ce:cross-ref id="crf0025" refid="s0055"><ce:bold>349</ce:bold></ce:cross-ref><ce:list id="ulist0015"><ce:list-item id="u0030"><ce:para id="p0030">Functional anatomy and physiology <ce:cross-ref id="crf0030" refid="s0060">349</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0035"><ce:para id="p0035">Presenting problems in sodium and water balance <ce:cross-ref id="crf0035" refid="s0090">352</ce:cross-ref><ce:list id="ulist0020"><ce:list-item id="u0040"><ce:para id="p0040">Hypovolaemia <ce:cross-ref id="crf0040" refid="s0095">352</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0045"><ce:para id="p0045">Hypervolaemia <ce:cross-ref id="crf0045" refid="s0150">353</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0050"><ce:para id="p0050"><ce:bold>Water homeostasis</ce:bold> <ce:cross-ref id="crf0050" refid="s0215"><ce:bold>355</ce:bold></ce:cross-ref><ce:list id="ulist0025"><ce:list-item id="u0055"><ce:para id="p0055">Functional anatomy and physiology <ce:cross-ref id="crf0055" refid="s0220">355</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0060"><ce:para id="p0060">Presenting problems in regulation of osmolality <ce:cross-ref id="crf0060" refid="s0225">356</ce:cross-ref><ce:list id="ulist0030"><ce:list-item id="u0065"><ce:para id="p0065">Hyponatraemia <ce:cross-ref id="crf0065" refid="s0230">357</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0070"><ce:para id="p0070">Hypernatraemia <ce:cross-ref id="crf0070" refid="s0280">358</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0075"><ce:para id="p0075"><ce:bold>Potassium homeostasis</ce:bold> <ce:cross-ref id="crf0075" refid="s0300"><ce:bold>360</ce:bold></ce:cross-ref><ce:list id="ulist0035"><ce:list-item id="u0080"><ce:para id="p0080">Functional anatomy and physiology <ce:cross-ref id="crf0080" refid="s0305">360</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0085"><ce:para id="p0085">Presenting problems in potassium homeostasis <ce:cross-ref id="crf0085" refid="s0310">361</ce:cross-ref><ce:list id="ulist0040"><ce:list-item id="u0090"><ce:para id="p0090">Hypokalaemia <ce:cross-ref id="crf0090" refid="s0315">361</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0095"><ce:para id="p0095">Hyperkalaemia <ce:cross-ref id="crf0095" refid="s0340">362</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0100"><ce:para id="p0100"><ce:bold>Acid–base homeostasis</ce:bold> <ce:cross-ref id="crf0100" refid="s0365"><ce:bold>363</ce:bold></ce:cross-ref><ce:list id="ulist0045"><ce:list-item id="u0105"><ce:para id="p0105">Functional anatomy and physiology <ce:cross-ref id="crf0105" refid="s0370">363</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0110"><ce:para id="p0110">Presenting problems in acid–base balance <ce:cross-ref id="crf0110" refid="s0380">364</ce:cross-ref><ce:list id="ulist0050"><ce:list-item id="u0115"><ce:para id="p0115">Metabolic acidosis <ce:cross-ref id="crf0115" refid="s0385">364</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0120"><ce:para id="p0120">Metabolic alkalosis <ce:cross-ref id="crf0120" refid="s0410">366</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0125"><ce:para id="p0125">Respiratory acidosis <ce:cross-ref id="crf0125" refid="s0435">367</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0130"><ce:para id="p0130">Respiratory alkalosis <ce:cross-ref id="crf0130" refid="s0440">367</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0135"><ce:para id="p0135">Mixed acid–base disorders <ce:cross-ref id="crf0135" refid="s0445">367</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0140"><ce:para id="p0140"><ce:bold>Calcium homeostasis</ce:bold> <ce:cross-ref id="crf0140" refid="s0450"><ce:bold>367</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0145"><ce:para id="p0145"><ce:bold>Magnesium homeostasis</ce:bold> <ce:cross-ref id="crf0145" refid="s0455"><ce:bold>367</ce:bold></ce:cross-ref><ce:list id="ulist0055"><ce:list-item id="u0150"><ce:para id="p0150">Functional anatomy and physiology <ce:cross-ref id="crf0150" refid="s0460">367</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0155"><ce:para id="p0155">Presenting problems in magnesium homeostasis <ce:cross-ref id="crf0155" refid="s0465">367</ce:cross-ref><ce:list id="ulist0060"><ce:list-item id="u0160"><ce:para id="p0160">Hypomagnesaemia <ce:cross-ref id="crf0160" refid="s0470">368</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0165"><ce:para id="p0165">Hypermagnesaemia <ce:cross-ref id="crf0165" refid="s0490">368</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0170"><ce:para id="p0170"><ce:bold>Phosphate homeostasis</ce:bold> <ce:cross-ref id="crf0170" refid="s0495"><ce:bold>368</ce:bold></ce:cross-ref><ce:list id="ulist0065"><ce:list-item id="u0175"><ce:para id="p0175">Functional anatomy and physiology <ce:cross-ref id="crf0175" refid="s0500">368</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0180"><ce:para id="p0180">Presenting problems in phosphate homeostasis <ce:cross-ref id="crf0180" refid="s0505">368</ce:cross-ref><ce:list id="ulist0070"><ce:list-item id="u0185"><ce:para id="p0185">Hypophosphataemia <ce:cross-ref id="crf0185" refid="s0510">368</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0190"><ce:para id="p0190">Hyperphosphataemia <ce:cross-ref id="crf0190" refid="s0535">369</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0195"><ce:para id="p0195"><ce:bold>Disorders of amino acid metabolism</ce:bold> <ce:cross-ref id="crf0195" refid="s0555"><ce:bold>369</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0200"><ce:para id="p0200"><ce:bold>Disorders of carbohydrate metabolism</ce:bold> <ce:cross-ref id="crf0200" refid="s0575"><ce:bold>370</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="o9000"><ce:para id="p9000"><ce:bold>Disorders of complex lipid metabolism</ce:bold> <ce:cross-ref id="crf9000" refid="s0595"><ce:bold>370</ce:bold></ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0205"><ce:para id="p0205"><ce:bold>Lipids and lipoprotein metabolism</ce:bold> <ce:cross-ref id="crf0205" refid="s0600"><ce:bold>370</ce:bold></ce:cross-ref><ce:list id="ulist0075"><ce:list-item id="u0210"><ce:para id="p0210">Functional anatomy and physiology <ce:cross-ref id="crf0210" refid="s0605">371</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0215"><ce:para id="p0215">Lipids and cardiovascular disease <ce:cross-ref id="crf0215" refid="s0625">373</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0220"><ce:para id="p0220">Investigations <ce:cross-ref id="crf0220" refid="s0630">373</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="u0225"><ce:para id="p0225">Presenting problems in lipid metabolism <ce:cross-ref id="crf0225" refid="s0635">373</ce:cross-ref><ce:list id="olist9000"><ce:list-item id="o9005"><ce:para id="p9005">Hypercholesterolaemia <ce:cross-ref id="crf9005" refid="s0640">373</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="o9010"><ce:para id="p9010">Hypertriglyceridaemia <ce:cross-ref id="crf9010" refid="s0645">374</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="o9015"><ce:para id="p9015">Mixed hyperlipidaemia <ce:cross-ref id="crf9015" refid="s0650">375</ce:cross-ref></ce:para></ce:list-item><ce:list-item id="o9020"><ce:para id="p9020">Rare dyslipidaemias <ce:cross-ref id="crf9020" refid="s0655">375</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0230"><ce:para id="p0230">Principles of management <ce:cross-ref id="crf0230" refid="s0660">375</ce:cross-ref></ce:para></ce:list-item></ce:list></ce:para></ce:list-item><ce:list-item id="u0235"><ce:para id="p0235"><ce:bold>The porphyrias</ce:bold> <ce:cross-ref id="crf0235" refid="s0735"><ce:bold>378</ce:bold></ce:cross-ref></ce:para></ce:list-item></ce:list></outline><ce:sections><ce:section id="s0010"><ce:section-title id="st0010">Clinical examination in biochemical and metabolic disorders</ce:section-title><ce:para id="p0240">Many biochemical and metabolic disorders are clinically silent or present with non-specific manifestations, and are first detected by laboratory testing. Several abnormalities can be picked up by history and physical examination, however, as summarised below.</ce:para><ce:para id="p0245"><ce:display><ce:figure id="f0010"><ce:alt-text id="atte0515" role="short">Unlabelled image</ce:alt-text><ce:source>Insets: (ankle oedema) From Huang H-W, Wong L-S, Lee C-H. Sarcoidosis with bilateral leg lymphedema as the initial presentation: a review of the literature. Dermatologica Sinica 2016; 34:29–32; (raised jugular venous pressure) Newby D, Grubb N. Cardiology: an illustrated colour text. Edinburgh: Churchill Livingstone, Elsevier Ltd; 2005; (cherry-red spots) Vieira de Rezende Pinto WB, Sgobbi de Souza PV, Pedroso JL, et al. Variable phenotype and severity of sialidosis expressed in two siblings presenting with ataxia and macular cherry-red spots. J Clin Neurosci 2013; 20:1327–1328; (photosensitive rash) Ferri FF. Ferri's Color atlas and text of clinical medicine. Philadelphia: Saunders, Elsevier Inc.; 2009; courtesy of the Institute of Dermatology, London.</ce:source><ce:link id="ln0010" locator="u014-001-9780702070280" xlink:href="pii:B9780702070280000147/u014-001-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display><ce:display><ce:figure id="f0015"><ce:alt-text id="atte0520" role="short">Unlabelled image</ce:alt-text><ce:copyright type="other" year="2013"/><ce:link id="ln0015" locator="u014-002-9780702070280" xlink:href="pii:B9780702070280000147/u014-002-9780702070280" xlink:role="http://data.elsevier.com/vocabulary/ElsevierContentTypes/23.4" xlink:type="simple"/></ce:figure></ce:display>There is a worldwide trend towards increased use of laboratory-based diagnostic investigations, and biochemical investigations in particular. In the health-care systems of developed countries, it has been estimated that 60–70% of all critical decisions taken in regard to patients, and over 90% of data stored in electronic medical records systems, involve a laboratory service or result.</ce:para><ce:para id="p0250">This chapter covers a diverse group of disorders affecting adults that are not considered elsewhere in this book, whose primary manifestation is in abnormalities of biochemistry laboratory results, or whose underlying pathophysiology involves disturbance in specific biochemical pathways.</ce:para></ce:section><ce:section id="s0015"><ce:section-title id="st0015">Biochemical investigations</ce:section-title><ce:para id="p0255">There are three broad reasons why a clinician may request a biochemical laboratory investigation:<ce:list id="ulist0080"><ce:list-item id="u0240"><ce:label>•</ce:label><ce:para id="p0260">to screen an asymptomatic subject for the presence of disease</ce:para></ce:list-item><ce:list-item id="u0245"><ce:label>•</ce:label><ce:para id="p0265">to assist in diagnosis of a patient's presenting complaint</ce:para></ce:list-item><ce:list-item id="u0250"><ce:label>•</ce:label><ce:para id="p0270">to monitor changes in test results, as a marker of disease progression or response to treatment.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0275">Contemporary medical practice has become increasingly reliant on laboratory investigation and, in particular, on biochemical investigation. This has been associated with extraordinary improvements in the analytical capacity and speed of laboratory instrumentation and the following operational trends:<ce:list id="ulist0085"><ce:list-item id="u0255"><ce:label>•</ce:label><ce:para id="p0280">Large central biochemistry laboratories feature extensive use of automation and information technology. Specimens are transported from clinical areas to the laboratory using high-speed transport systems (such as pneumatic tubes) and identified with machine-readable labels (such as bar codes). Laboratory instruments have been miniaturised and integrated with robot transport systems to enable multiple rapid analyses of a single sample. Statistical process control techniques are used to assure the quality of analytical results, and increasingly to monitor other aspects of the laboratory, such as the time taken to complete the analysis (‘turn-around time’).</ce:para></ce:list-item><ce:list-item id="u0260"><ce:label>•</ce:label><ce:para id="p0285">Point-of-care testing (POCT) brings selected laboratory analytical systems into clinical areas, to the patient's bedside or even connected to an individual patient. These systems allow the clinician to receive results almost instantaneously for immediate treatment of the patient, although often with lesser precision or at greater cost than using a central laboratory.</ce:para></ce:list-item><ce:list-item id="u0265"><ce:label>•</ce:label><ce:para id="p0290">The diversity of analyses has widened considerably with the introduction of many techniques borrowed from the chemical or other industries (<ce:cross-ref id="crf0240" refid="b0010">Box 14.1</ce:cross-ref><ce:float-anchor refid="b0010"/>).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0300">Good medical practice involves the appropriate ordering of laboratory investigations and correct interpretation of test results (<ce:cross-ref id="crf0245" refid="b0015">Box 14.2</ce:cross-ref><ce:float-anchor refid="b0015"/>). The key principles, including the concepts of sensitivity and specificity, are described on <ce:intra-ref id="ii0060" xlink:href="pii:B978-0-7020-7028-0.00001-9#s0040">page 4</ce:intra-ref>. Reference intervals for laboratory results are provided in <ce:intra-ref id="ii0065" xlink:href="pii:B978-0-7020-7028-0.00035-4#c00035">Chapter 35</ce:intra-ref>. Many laboratory investigations can be subject to variability arising from whether the sample is being taken in the fed or fasted state; the timing of sample collection, in relation to diurnal variation of analytes; dosage intervals for therapeutic drug monitoring; sample type, such as serum plasma; use of anticoagulants, such as EDTA, which can interfere with some assays; or artefacts, such as taking a venous sample proximal to the site of an intravenous infusion. It is therefore important for clinical and laboratory staff to communicate effectively and for clinicians to follow local recommendations concerning collection and transport of samples in the appropriate container and with appropriate labelling.</ce:para></ce:section><ce:section id="s0050"><ce:section-title id="st0050">Water and electrolyte homeostasis</ce:section-title><ce:para id="p0410">Total body water (TBW) is approximately 60% of body weight in an adult male, although the proportion is somewhat more for infants and less for women. In a 70 kg man TBW is therefore about 40 L. Approximately 25 L is located inside cells (the intracellular fluid or ICF), while the remaining 15 L is in the extracellular fluid (ECF) compartment (<ce:cross-ref id="crf0280" refid="f0020">Fig. 14.1</ce:cross-ref><ce:float-anchor refid="f0020"/>). Most of the ECF (approximately 12 L) is interstitial fluid, which is within the tissues but outside cells, whereas the remainder (about 3 L) is in the plasma compartment.</ce:para><ce:para id="p0415">The ion composition between the main body fluid compartments intracellularly and extracellularly is illustrated in <ce:cross-ref id="crf0285" refid="f0020">Figure 14.1</ce:cross-ref>. The dominant positively charged ion (cation) within cells is potassium, whereas phosphates and negatively charged proteins constitute the major intracellular negatively charged ions (anions). In the ECF the dominant cation is sodium, while chloride and, to a lesser extent, bicarbonate are the most important ECF anions. An important difference between the intravascular (plasma) and interstitial compartments of the ECF is that only plasma contains significant concentrations of protein.</ce:para><ce:para id="p0420">The major force maintaining the difference in cation concentrations between the ICF and ECF is the sodium–potassium pump (Na,K-activated adenosine triphosphatase (ATPase)), which is present in all cell membranes. Maintenance of these gradients is essential for many cell processes, including the excitability of conducting tissues such as nerve and muscle. The difference in protein content between the plasma and the interstitial fluid compartment is maintained by the impermeability of the capillary wall to protein. This protein concentration gradient (the colloid osmotic, or oncotic, pressure of the plasma) contributes to the balance of forces across the capillary wall that favour fluid retention within the plasma compartment.</ce:para><ce:para id="p0425">The concentration of sodium in the ECF plays a pivotal role in determining plasma osmolality and thereby controlling intracellular volume through changes in water balance between the intracellular and extracellular space. In contrast, plasma volume is largely controlled by total body sodium, which determines volume change. Therefore, disturbances in water homeostasis typically present with biochemical abnormalities such as hyponatraemia or hypernatraemia, whereas disturbances in sodium homeostasis present with hypervolaemia or hypovolaemia as the result of expansion or contraction of ECF volume, respectively.</ce:para></ce:section><ce:section id="s0055"><ce:section-title id="st0055">Sodium homeostasis</ce:section-title><ce:para id="p0430">Most of the body's sodium is located in the ECF, where it is by far the most abundant cation. Accordingly, total body sodium is the principal determinant of ECF volume. Sodium intake varies widely between individuals, ranging between 50 and 250 mmol/24 hrs. The kidneys can compensate for these wide variations in sodium intake by increasing excretion of sodium when there is sodium overload, and retaining sodium in the presence of sodium depletion, to maintain normal ECF volume and plasma volume.</ce:para><ce:section id="s0060"><ce:section-title id="st0060">Functional anatomy and physiology</ce:section-title><ce:para id="p0435">The functional unit for renal excretion is the nephron (<ce:cross-ref id="crf0290" refid="f0025">Fig. 14.2</ce:cross-ref><ce:float-anchor refid="f0025"/>). Blood undergoes ultrafiltration in the glomerulus, generating a fluid that is free from cells and protein and which resembles plasma in its electrolyte composition. This is delivered into the renal tubules, where reabsorption of water and various electrolytes occurs. (More detail on the structure and function of the glomerulus is given in <ce:intra-ref id="ii0070" xlink:href="pii:B978-0-7020-7028-0.00015-9#c00015">Ch. 15</ce:intra-ref>.) The glomerular filtration rate (GFR) is approximately 125 mL/min (equivalent to 180 L/24 hrs) in a normal adult. Over 99% of the filtered fluid is reabsorbed into the blood in the peritubular capillaries during its passage through successive segments of the nephron, largely as a result of tubular reabsorption of sodium. The processes mediating sodium reabsorption, and the factors that regulate it, are key to understanding clinical disturbances and pharmacological interventions of sodium and fluid balance.</ce:para><ce:para id="p0440">The nephron can be divided into at least four different functional segments in terms of sodium reabsorption (<ce:cross-ref id="crf0300" refid="f0030">Fig. 14.3</ce:cross-ref><ce:float-anchor refid="f0030"/>).</ce:para><ce:section id="s0065"><ce:section-title id="st0065">Proximal renal tubule</ce:section-title><ce:para id="p0445">About 65% of the filtered sodium load is reabsorbed in the proximal renal tubule. The cellular mechanisms are complex but some of the key features are shown in <ce:cross-ref id="crf0305" refid="f0030">Figure 14.3A</ce:cross-ref>. Filtered sodium in the luminal fluid enters the proximal tubular cell through transporters in the apical membrane that couple sodium transport to the entry of glucose, amino acid, phosphate and other organic molecules. Entry of sodium into the tubular cells at this site is also linked to secretion of H<ce:sup loc="post">+</ce:sup> ions, through the sodium–hydrogen exchanger (NHE-3). Intracellular H<ce:sup loc="post">+</ce:sup> ions are generated within tubular cells from the breakdown of carbonic acid, which is produced from carbon dioxide and water under the influence of carbonic anhydrase. Large numbers of Na,K-ATPase pumps are present on the basolateral membrane of tubular cells, which transport sodium from the cells into the blood. In addition, a large component of the transepithelial flux of sodium, water and other dissolved solutes occurs through gaps <ce:italic>between</ce:italic> the cells (the ‘shunt’ pathway). Overall, fluid and electrolyte reabsorption is almost isotonic in this segment, as water reabsorption is matched very closely to sodium fluxes, such that the osmolality of fluid passing into the loop of Henle is very similar to that of plasma. A component of this water flow also passes <ce:italic>through</ce:italic> the cells, via aquaporin-1 (AQP-1) water channels, which are not sensitive to hormonal regulation.</ce:para></ce:section><ce:section id="s0070"><ce:section-title id="st0070">Loop of Henle</ce:section-title><ce:para id="p0450">The thick ascending limb of the loop of Henle (<ce:cross-ref id="crf0310" refid="f0030">Fig. 14.3B</ce:cross-ref>) reabsorbs a further 25% of the filtered sodium but is impermeable to water, resulting in dilution of the luminal fluid. The primary driving force is the Na,K-ATPase on the basolateral cell membrane, but in this segment sodium enters the cell from the lumen through a specific carrier molecule, the Na,K,2Cl co-transporter (‘triple co-transporter’, or NKCC2), which allows electroneutral entry of these ions into the renal tubular cell by balancing transport of anions (Na<ce:sup loc="post">+</ce:sup>/K<ce:sup loc="post">+</ce:sup>) with cations (Cl<ce:sup loc="post">−</ce:sup>). Some of the potassium accumulated inside the cell recirculates across the apical membrane back into the lumen through a specific potassium channel (ROMK), providing a continuing supply of potassium to match the high concentrations of sodium and chloride in the lumen. A small positive transepithelial potential difference exists in the lumen of this segment relative to the interstitium, and this serves to drive cations such as sodium, potassium, calcium and magnesium between the cells, forming a reabsorptive shunt pathway.</ce:para></ce:section><ce:section id="s0075"><ce:section-title id="st0075">Early distal renal tubule</ce:section-title><ce:para id="p0455">About 6% of filtered sodium is reabsorbed in the early distal tubule (also called distal convoluted tubule) (<ce:cross-ref id="crf0315" refid="f0030">Fig. 14.3C</ce:cross-ref>), again driven by the activity of the basolateral Na,K-ATPase. In this segment, entry of sodium into the cell from the luminal fluid occurs through a sodium–chloride co-transport carrier (NCCT). This segment is also impermeable to water, resulting in further dilution of the luminal fluid. There is no significant transepithelial flux of potassium in this segment, but calcium is reabsorbed through the mechanism shown in <ce:cross-ref id="crf0320" refid="f0030">Figure 14.3C</ce:cross-ref>: a basolateral sodium–calcium exchanger leads to low intracellular concentrations of calcium, promoting calcium entry from the luminal fluid through a calcium channel.</ce:para></ce:section><ce:section id="s0080"><ce:section-title id="st0080">Late distal renal tubule and collecting ducts</ce:section-title><ce:para id="p0460">The late distal tubule and cortical collecting duct are anatomically and functionally continuous (<ce:cross-ref id="crf0325" refid="f0030">Fig. 14.3D</ce:cross-ref>). Here, sodium entry from the luminal fluid occurs through the epithelial sodium channel (ENaC), generating a substantial lumen-negative transepithelial potential difference. This sodium flux into the tubular cells is balanced by secretion of potassium and hydrogen ions into the lumen and by reabsorption of chloride ions. Potassium is accumulated in the cell by the basolateral Na,K-ATPase, and passes into the luminal fluid down its electrochemical gradient, through an apical potassium channel (ROMK). Chloride ions pass largely between cells. Hydrogen ion secretion is mediated by an H<ce:sup loc="post">+</ce:sup>-ATPase located on the luminal membrane of the intercalated cells, which constitute approximately one-third of the epithelial cells in this segment of the nephron. The distal tubule and collecting duct have a variable permeability to water, depending on circulating levels of vasopressin (antidiuretic hormone, ADH). All ion transport processes in this segment are stimulated by the steroid hormone aldosterone, which can increase sodium reabsorption in this segment to a maximum of 2–3% of the filtered sodium load.</ce:para><ce:para id="p0465">Less than 1% of sodium reabsorption occurs in the medullary collecting duct, where it is inhibited by atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP).</ce:para></ce:section><ce:section id="s0085"><ce:section-title id="st0085">Regulation of sodium transport</ce:section-title><ce:para id="p0470">The amount of sodium excreted by the kidney is dependent on the filtered load of sodium (which is largely determined by GFR) and the control of tubular sodium reabsorption. A number of interrelated mechanisms serve to maintain whole-body sodium balance, and hence ECF volume, by matching urinary sodium excretion to sodium intake (<ce:cross-ref id="crf0330" refid="f0035">Fig. 14.4</ce:cross-ref><ce:float-anchor refid="f0035"/>), and controlling those two processes.</ce:para><ce:para id="p0475">Important sensing mechanisms include volume receptors in the cardiac atria and the intrathoracic veins, as well as pressure receptors located in the central arterial tree (aortic arch and carotid sinus) and the afferent arterioles within the kidney. A further afferent signal is generated within the kidney itself: the enzyme renin is released from specialised smooth muscle cells in the walls of the afferent and efferent arterioles, at the point where they make contact with the early distal tubule (at the macula densa; see <ce:cross-ref id="crf0335" refid="f0025">Fig. 14.2</ce:cross-ref>) to form the juxtaglomerular apparatus. Renin release is stimulated by:<ce:list id="ulist0120"><ce:list-item id="u0345"><ce:label>•</ce:label><ce:para id="p0480">reduced perfusion pressure in the afferent arteriole</ce:para></ce:list-item><ce:list-item id="u0350"><ce:label>•</ce:label><ce:para id="p0485">increased sympathetic nerve activity</ce:para></ce:list-item><ce:list-item id="u0355"><ce:label>•</ce:label><ce:para id="p0490">decreased sodium chloride concentration in the distal tubular fluid.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0495">Renin acts on the peptide substrate, angiotensinogen (which is produced by the liver), to produce angiotensin I, which is cleaved by angiotensin-converting enzyme (ACE), largely in the pulmonary capillary bed, to produce angiotensin II (see <ce:intra-ref id="ii0075" xlink:href="pii:B978-0-7020-7028-0.00018-4#f0115">Fig. 18.18</ce:intra-ref>, <ce:intra-ref id="ii0080" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0930">p. 666</ce:intra-ref>). Angiotensin II has multiple actions: it stimulates proximal tubular sodium reabsorption and release of aldosterone from the zona glomerulosa of the adrenal cortex, and causes vasoconstriction of small arterioles. Aldosterone amplifies sodium retention by its action on the cortical collecting duct. The net effect of activation of the renin–angiotensin system is to raise blood pressure and cause sodium and water retention, thereby correcting hypovolaemia.</ce:para><ce:para id="p0500">Changes in GFR alter peritubular hydrostatic pressure and oncotic pressure in opposite directions, resulting in a change in sodium reabsorption. In particular, with hypovolaemia, and a reduction in hydrostatic pressure and an increase in oncotic pressure, there is an increase in sodium reabsorption.</ce:para><ce:para id="p0505">The sympathetic nervous system also acts to increase sodium retention, both through haemodynamic mechanisms (afferent arteriolar vasoconstriction and GFR reduction) and by direct stimulation of proximal tubular sodium reabsorption. In contrast, other humoral mediators, such as the natriuretic peptides, which inhibit sodium reabsorption, contribute to natriuresis during periods of sodium and volume excess.</ce:para><ce:para id="p0510">Increases in sodium intake cause hypervolaemia, which increases renal perfusion and GFR and suppresses renin production through increased delivery of sodium into the macula densa. This sets in motion a train of events opposite to those that occur in hypovolaemia, to cause an increase in sodium excretion.</ce:para></ce:section></ce:section><ce:section id="s0090"><ce:section-title id="st0090">Presenting problems in sodium and water balance</ce:section-title><ce:para id="p0515">When the balance of sodium intake and excretion is disturbed, any tendency for plasma sodium concentration to change is usually corrected by the osmotic mechanisms controlling water balance (<ce:cross-ref id="crf9060" refid="s0050">p. 349</ce:cross-ref>). As a result, disorders in sodium balance present chiefly as alterations in the ECF volume, resulting in hypovolaemia or hypervolaemia, rather than as an alteration in plasma sodium concentration. Clinical manifestations of altered ECF volume are illustrated in <ce:cross-ref id="crf0340" refid="b0020">Box 14.3</ce:cross-ref><ce:float-anchor refid="b0020"/>.</ce:para><ce:section id="s0095"><ce:section-title id="st0095">Hypovolaemia</ce:section-title><ce:para id="p0630">Hypovolaemia is defined as a reduction in circulating blood volume. The most common causes are loss or sequestration of sodium-containing fluids or acute blood loss, as summarised in <ce:cross-ref id="crf0345" refid="b0025">Box 14.4</ce:cross-ref><ce:float-anchor refid="b0025"/>.</ce:para><ce:section id="s0100"><ce:section-title id="st0100">Pathogenesis</ce:section-title><ce:para id="p0640">Loss of sodium-containing fluid triggers the changes in renal sodium handling and activation of the renin–angiotensin system that were described on <ce:cross-ref id="crf9065" refid="s0050">page 349</ce:cross-ref>. Loss of whole blood, as in acute haemorrhage, is another cause of hypovolaemia, and elicits the same mechanisms for the conservation of sodium and water as loss of sodium-containing fluid.</ce:para></ce:section><ce:section id="s0105"><ce:section-title id="st0105">Clinical features</ce:section-title><ce:para id="p0645">Hypovolaemia is primarily a clinical diagnosis, based on characteristic symptoms such as thirst, dizziness and weakness along with characteristic clinical signs (see <ce:cross-ref id="crf0355" refid="b0020">Box 14.3</ce:cross-ref>) in the context of a relevant precipitating illness.</ce:para></ce:section><ce:section id="s0110"><ce:section-title id="st0110">Investigations</ce:section-title><ce:para id="p0650">Serum sodium concentrations are usually normal in hypovolaemia. The GFR is usually maintained unless the hypovolaemia is very severe or prolonged, but urinary flow rate is reduced as a consequence of activation of sodium- and water-retaining mechanisms in the nephron. Serum creatinine, which reflects GFR, is usually normal, but serum urea concentration is typically elevated due to a low urine flow rate, which is accompanied by increased tubular reabsorption of urea. Similarly, serum uric acid may also rise, reflecting increased reabsorption in the proximal renal tubule. The urine osmolality increases due to increased reabsorption of sodium and water, while the urine sodium concentration falls and sodium excretion may fall to less than 0.1% of the filtered sodium load.</ce:para></ce:section><ce:section id="s0115"><ce:section-title id="st0115">Management</ce:section-title><ce:para id="p0655">Management of sodium and water depletion has two main components:<ce:list id="ulist0145"><ce:list-item id="u0465"><ce:label>•</ce:label><ce:para id="p0660">treat the cause where possible, to stop ongoing salt and water losses</ce:para></ce:list-item><ce:list-item id="u0470"><ce:label>•</ce:label><ce:para id="p0665">replace the salt and water deficits, and provide ongoing maintenance requirements, usually by intravenous fluid replacement when depletion is severe.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0120"><ce:section-title id="st0120">Intravenous fluid therapy</ce:section-title><ce:para id="p0670">Intravenous fluid therapy can be used to maintain water, sodium and potassium intake when the patient is fasting, such as during an acute illness or post-operatively. If any deficits or continuing pathological losses are identified, additional fluid and electrolytes will be required. In prolonged periods of fasting (more than a few days), attention also needs to be given to providing sufficient caloric and nutritional intake to prevent excessive catabolism of body energy stores (<ce:intra-ref id="ii0095" xlink:href="pii:B978-0-7020-7028-0.00019-6#p0840">p. 704</ce:intra-ref>). The daily maintenance requirements for water and electrolytes in a typical adult are shown in <ce:cross-ref id="crf0360" refid="b0030">Box 14.5</ce:cross-ref><ce:float-anchor refid="b0030"/> and the composition of some widely available intravenous fluids are given in <ce:cross-ref id="crf0365" refid="b0035">Box 14.6</ce:cross-ref><ce:float-anchor refid="b0035"/>. The choice of fluid and the rate of administration depend on the clinical circumstances, as assessed at the bedside and from laboratory data, as described in <ce:cross-ref id="crf0370" refid="b0040">Box 14.7</ce:cross-ref><ce:float-anchor refid="b0040"/>.</ce:para><ce:para id="p0780">The choice of intravenous fluid therapy in the treatment of significant hypovolaemia relates to the concepts in <ce:cross-ref id="crf0390" refid="f0020">Figure 14.1</ce:cross-ref>. If fluid containing neither sodium nor protein is given, it will distribute in the body fluid compartments in proportion to the normal distribution of total body water. For example, administration of 1 L of 5% dextrose contributes little (approximately 3/40 of the infused volume) towards expansion of the plasma volume, which makes this fluid unsuitable for restoring the circulation and perfusion of vital organs. Intravenous infusion of an isotonic (normal) saline solution, on the other hand, is more effective at expanding the ECF, although only a small proportion (about 3/15) of the infused volume actually contributes to plasma volume.</ce:para><ce:para id="p0785">You would expect that solutions containing plasma proteins (colloids) would be better retained within the vascular space and to be more effective at correcting hypovolaemia than protein-free fluids (crystalloids). However, recent clinical studies have not shown any advantage of giving albumin-containing infusions in the treatment of acute hypovolaemia. Furthermore, synthetic colloids such as dextrans have been shown to be associated with an increased risk of acute kidney injury and mortality in the critically ill. Therefore, crystalloids are the fluid of choice for resuscitation in acute hypovolaemia. More studies, however, are required to clarify the most appropriate crystalloid in this situation, given that normal saline can cause a mild metabolic acidosis, perhaps related to excessive chloride loading, whereas ‘balanced solutions’, such as Hartmann's, may cause a mild hyponatraemia, as its composition is slightly hypotonic.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0150"><ce:section-title id="st0150">Hypervolaemia</ce:section-title><ce:para id="p0790">Hypervolaemia is the result of sodium and water excess and is rare in patients with normal cardiac and renal function, since the kidney has a large capacity to increase renal excretion of sodium and water via the homeostatic mechanisms described on <ce:cross-ref id="crf9070" refid="s0050">page 349</ce:cross-ref>.</ce:para><ce:section id="s0155"><ce:section-title id="st0155">Pathogenesis</ce:section-title><ce:para id="p0795">The most common systemic disorders responsible for hypervolaemia are outlined in <ce:cross-ref id="crf0395" refid="b0045">Box 14.8</ce:cross-ref><ce:float-anchor refid="b0045"/>. In cardiac failure, cirrhosis and nephrotic syndrome, sodium retention occurs in response to circulatory insufficiency caused by the primary disorder, as illustrated in <ce:cross-ref id="crf0415" refid="f0040">Figure 14.5</ce:cross-ref><ce:float-anchor refid="f0040"/>. The pathophysiology is different in renal failure, when the primary cause of volume expansion is the profound reduction in GFR impairing sodium and water excretion, while secondary tubular mechanisms are of lesser importance. In Conn's syndrome (<ce:intra-ref id="ii0110" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1165">p. 674</ce:intra-ref>), the pathophysiology also differs, in that increased secretion of aldosterone directly stimulates sodium reabsorption.</ce:para></ce:section><ce:section id="s0160"><ce:section-title id="st0160">Clinical features</ce:section-title><ce:para id="p0805">Peripheral oedema is the most common physical sign of hypervolaemia since the excess fluid leaks out of the capillaries to expand the interstitial compartment of the ECF. This is particularly the case in nephrotic syndrome and chronic liver disease, in which hypoalbuminaemia is a prominent feature. The main exception is primary hyperaldosteronism (Conn's syndrome), which presents with hypertension and often hypokalaemia, but in which peripheral oedema is not commonly seen.</ce:para></ce:section><ce:section id="s0165"><ce:section-title id="st0165">Investigations</ce:section-title><ce:para id="p0810">Although hypervolaemia is accompanied by an excess of total body sodium, serum sodium concentrations are normal due to the accompanying water retention. Serum concentrations of potassium are normal except in Conn's syndrome, where there is hypokalaemia due to the increased aldosterone production (<ce:intra-ref id="ii0115" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1165">p. 674</ce:intra-ref>). Creatinine, GFR and urea are usually normal, unless the underlying cause of hypervolaemia is renal failure. General investigations may reveal evidence of cardiac, renal or liver disease.</ce:para></ce:section><ce:section id="s0170"><ce:section-title id="st0170">Management</ce:section-title><ce:para id="p0815">The management of hypervolaemia involves a number of components:<ce:list id="ulist0175"><ce:list-item id="u0545"><ce:label>•</ce:label><ce:para id="p0820">specific treatment directed at the underlying cause, such as ACE inhibitors in heart failure and glucocorticoids in minimal change nephropathy</ce:para></ce:list-item><ce:list-item id="u0550"><ce:label>•</ce:label><ce:para id="p0825">restriction of dietary sodium (to 50–80 mmol/24 hrs) to match the diminished excretory capacity</ce:para></ce:list-item><ce:list-item id="u0555"><ce:label>•</ce:label><ce:para id="p0830">treatment with diuretics.</ce:para></ce:list-item></ce:list></ce:para><ce:section id="s0175"><ce:section-title id="st0175">Diuretic therapy</ce:section-title><ce:para id="p0835">Diuretics play a pivotal role in the treatment of hypervolaemia due to salt and water retention and in hypertension (<ce:intra-ref id="ii0120" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1880">p. 513</ce:intra-ref>). They act by inhibiting sodium reabsorption at various locations along the nephron (see <ce:cross-ref id="crf0425" refid="f0030">Fig. 14.3</ce:cross-ref>). Their potency and adverse effects relate to their mechanism and site of action.</ce:para><ce:section id="s0180"><ce:section-title id="st0180">Carbonic anhydrase inhibitors</ce:section-title><ce:para id="p0840">Acetazolamide is a carbonic anhydrase inhibitor that inhibits intracellular production of H<ce:sup loc="post">+</ce:sup> ions in the proximal tubule, reducing the fraction of sodium reabsorption that is exchanged for H<ce:sup loc="post">+</ce:sup> by the apical membrane sodium–hydrogen exchanger. It is a weak diuretic but is seldom used clinically for this purpose, since only a small fraction of proximal sodium reabsorption uses this mechanism, and much of the sodium that is not reabsorbed in the proximal tubule can be reabsorbed by downstream segments of the nephron.</ce:para></ce:section><ce:section id="s0185"><ce:section-title id="st0185">Sodium-dependent glucose transporter inhibitors</ce:section-title><ce:para id="p0845">Inhibitors of the sodium-dependent glucose transporter 2 (SGLT2), such as dapagliflozin and canagliflozin, simultaneously block glucose and sodium reabsorption in the proximal tubule. They have mild diuretic properties but are principally used to lower blood glucose in the treatment of diabetes (<ce:intra-ref id="ii0125" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0600">p. 745</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0190"><ce:section-title id="st0190">Loop diuretics</ce:section-title><ce:para id="p0850">Loop diuretics, such as furosemide, inhibit sodium reabsorption in the thick ascending limb of the loop of Henle, by blocking the action of the apical membrane NKCC2 co-transporter. Because this segment reabsorbs a large fraction of the filtered sodium, these drugs are potent diuretics, and are commonly used in diseases associated with significant oedema. Loop diuretics cause excretion not only of sodium (and with it water) but also of potassium. This occurs largely as a result of delivery of increased amounts of sodium to the late distal tubule and cortical collecting ducts, where sodium reabsorption is associated with excretion of potassium, and is amplified if circulating aldosterone levels are high.</ce:para></ce:section><ce:section id="s0195"><ce:section-title id="st0195">Thiazide diuretics</ce:section-title><ce:para id="p0855">Thiazide diuretics inhibit sodium reabsorption in the early distal tubule, by blocking the NCCT co-transporter in the apical membrane. Since this segment reabsorbs a much smaller fraction of the filtered sodium, these are less potent than loop diuretics, but are widely used in the treatment of hypertension and less severe oedema. Like loop diuretics, thiazides increase excretion of potassium through delivery of increased amounts of sodium to the late distal tubule and collecting duct. They are the diuretics that are most likely to be complicated by the development of hyponatraemia, as outlined on <ce:cross-ref id="crf9075" refid="s0230">page 357</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0200"><ce:section-title id="st0200">Potassium-sparing diuretics</ce:section-title><ce:para id="p0860">Potassium-sparing diuretics act on the late distal renal tubule and cortical collecting duct segment to inhibit sodium reabsorption. Since sodium reabsorption and potassium secretion are linked at this site, the reduced sodium reabsorption is accompanied by reduced potassium secretion. The apical sodium channel (see <ce:cross-ref id="crf0430" refid="f0030">Fig. 14.3</ce:cross-ref>) is blocked by amiloride and triamterene, while spironolactone and eplerenone also act at this site by blocking binding of aldosterone to the mineralocorticoid receptor.</ce:para></ce:section><ce:section id="s0205"><ce:section-title id="st0205">Osmotic diuretics</ce:section-title><ce:para id="p0865">These act independently of a specific transport mechanism. As they are freely filtered at the glomerulus but not reabsorbed by any part of the tubular system, they retain fluid osmotically within the tubular lumen and limit the extent of sodium reabsorption in multiple segments. Mannitol is the most commonly used osmotic diuretic. It is given by intravenous infusion to achieve short-term diuresis in conditions such as cerebral oedema.</ce:para></ce:section></ce:section><ce:section id="s0210"><ce:section-title id="st0210">Clinical use of diuretics</ce:section-title><ce:para id="p0870">The following principles should be observed when using diuretics:<ce:list id="ulist0180"><ce:list-item id="u0560"><ce:label>•</ce:label><ce:para id="p0875">Use the minimum effective dose.</ce:para></ce:list-item><ce:list-item id="u0565"><ce:label>•</ce:label><ce:para id="p0880">Use for as short a period of time as necessary.</ce:para></ce:list-item><ce:list-item id="u0570"><ce:label>•</ce:label><ce:para id="p0885">Monitor regularly for adverse effects.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p0890">The choice of diuretic is determined by the potency required, the presence of coexistent conditions, and the side-effect profile.</ce:para><ce:para id="p0895">Adverse effects encountered with the most frequently used classes of diuretic (loop drugs and thiazide drugs) are summarised in <ce:cross-ref id="crf0435" refid="b0050">Box 14.9</ce:cross-ref><ce:float-anchor refid="b0050"/>. Volume depletion and electrolyte disorders are the most common, as predicted from their mechanism of action. The metabolic side-effects listed are rarely of clinical significance and may reflect effects on K<ce:sup loc="post">+</ce:sup> channels that influence insulin secretion (<ce:intra-ref id="ii0135" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0060">p. 723</ce:intra-ref>). Since most drugs from these classes are sulphonamides, there is a relatively high incidence of hypersensitivity reactions, and occasional idiosyncratic side-effects in a variety of organ systems.</ce:para><ce:para id="p0970">The side-effect profile of the potassium-sparing diuretics differs in a number of important respects from that of other diuretics. The disturbances in potassium, magnesium and acid–base balance are in the opposite direction, so that normal or increased levels of potassium and magnesium are found in the blood, and there is a tendency to metabolic acidosis, especially when renal function is impaired.</ce:para><ce:para id="p0975">An important feature of the most commonly used diuretic drugs (furosemide, thiazides and amiloride) is that they act on their target molecules from the luminal side of the tubular epithelium. Since they are highly protein-bound in the plasma, very little reaches the urinary fluid by glomerular filtration, but there are active transport mechanisms for secreting organic acids and bases, including these drugs, across the proximal tubular wall into the lumen, resulting in adequate drug concentrations being delivered to later tubular segments. This secretory process may be impaired by certain other drugs, and also by accumulated organic anions as occurs in chronic kidney disease and chronic liver failure, leading to resistance to diuretics.</ce:para><ce:para id="p0980">Diuretic resistance is encountered under a variety of circumstances, including impaired renal function, activation of sodium-retaining mechanisms, impaired oral bioavailability (such as in patients with gastrointestinal disease) and decreased renal blood flow. In these circumstances, short-term intravenous therapy with a loop-acting agent such as furosemide may be useful. Combinations of diuretics administered orally may also increase potency. Either a loop or a thiazide drug can be combined with a potassium-sparing drug, and all three classes can be used together for short periods, with carefully supervised clinical and laboratory monitoring.</ce:para></ce:section></ce:section></ce:section></ce:section></ce:section><ce:section id="s0215"><ce:section-title id="st0215">Water homeostasis</ce:section-title><ce:para id="p0985">Daily water intake can vary from about 500 mL to several litres a day. About 800 mL of water is lost daily through the stool, sweat and the respiratory tract (insensible losses) and about 400 mL is generated daily through oxidative metabolism (metabolic water). The kidneys are chiefly responsible for adjusting water excretion to balance intake, endogenous production and losses so as to maintain total body water content and serum osmolality within the reference range of 280–296 mOsmol/kg.</ce:para><ce:section id="s0220"><ce:section-title id="st0220">Functional anatomy and physiology</ce:section-title><ce:para id="p0990">While regulation of total ECF volume is largely achieved through renal control of sodium excretion, mechanisms exist to allow for the excretion of urine that is hypertonic or hypotonic in relation to plasma to maintain constant plasma osmolality.</ce:para><ce:para id="p0995">These functions are largely achieved by the loop of Henle and the collecting ducts (see <ce:cross-ref id="crf0440" refid="f0035">Fig. 14.2</ce:cross-ref>). The countercurrent configuration of flow in adjacent limbs of the loop (<ce:cross-ref id="crf0445" refid="f0045">Fig. 14.6</ce:cross-ref><ce:float-anchor refid="f0045"/>) involves osmotic movement of water from the descending limbs and reabsorption of solute from neighbouring ascending limbs, to set up a gradient of osmolality from isotonic (like plasma) in the renal cortex to hypertonic (around 1200 mOsmol/kg) in the inner part of the medulla. At the same time, the fluid emerging from the thick ascending limb is hypotonic compared to plasma because it has been diluted by the reabsorption of sodium, but not water, from the thick ascending limb and is further diluted in the early distal tubule. As this dilute fluid passes from the cortex through the collecting duct system to the renal pelvis, it traverses the medullary interstitial gradient of osmolality set up by the operation of the loop of Henle, and water is able to be reabsorbed.</ce:para><ce:para id="p1000">Further changes in the urine osmolality on passage through the collecting ducts depend on the circulating level of vasopressin, which is released by the posterior pituitary gland under conditions of increased plasma osmolality or hypovolaemia (<ce:intra-ref id="ii0140" xlink:href="pii:B978-0-7020-7028-0.00018-4#p5315">p. 688</ce:intra-ref>).<ce:list id="ulist0215"><ce:list-item id="u0640"><ce:label>•</ce:label><ce:para id="p1005">When water intake is high and plasma osmolality is normal or low–normal (<ce:cross-ref id="crf9025" refid="f0045">Fig. 14.6B</ce:cross-ref>), vasopressin levels are suppressed and the collecting ducts remain impermeable to water. The luminal fluid osmolality remains low, resulting in the excretion of a dilute urine (minimum osmolality approximately 50 mOsmol/kg in a healthy young person).</ce:para></ce:list-item><ce:list-item id="u0645"><ce:label>•</ce:label><ce:para id="p1010">When water intake is restricted and plasma osmolality is high (<ce:cross-ref id="crf9030" refid="f0045">Fig. 14.6A</ce:cross-ref>), or in the presence of plasma volume depletion, vasopressin levels rise. This causes water permeability of the collecting ducts to increase through binding of vasopressin to the V2 receptor, which enhances collecting duct water permeability through the insertion of AQP-2 channels into the luminal cell membrane. This results in osmotic reabsorption of water along the entire length of the collecting duct, with maximum urine osmolality approaching that in the medullary tip (up to 1200 mOsmol/kg).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p1015">Parallel to these changes in vasopressin release are changes in water-seeking behaviour triggered by the sensation of thirst, which also becomes activated as plasma osmolality rises.</ce:para><ce:para id="p1020">In summary, for adequate dilution of the urine there must be:<ce:list id="ulist0220"><ce:list-item id="u0650"><ce:label>•</ce:label><ce:para id="p1025">adequate solute delivery to the loop of Henle and early distal tubule</ce:para></ce:list-item><ce:list-item id="u0655"><ce:label>•</ce:label><ce:para id="p1030">normal function of the loop of Henle and early distal tubule</ce:para></ce:list-item><ce:list-item id="u0660"><ce:label>•</ce:label><ce:para id="p1035">absence of vasopressin in the circulation.</ce:para></ce:list-item></ce:list>If any of these processes is faulty, water retention and hyponatraemia may result.</ce:para><ce:para id="p1040">Conversely, to achieve concentration of the urine there must be:<ce:list id="ulist0225"><ce:list-item id="u0665"><ce:label>•</ce:label><ce:para id="p1045">adequate solute delivery to the loop of Henle</ce:para></ce:list-item><ce:list-item id="u0670"><ce:label>•</ce:label><ce:para id="p1050">normal function of the loop of Henle</ce:para></ce:list-item><ce:list-item id="u0675"><ce:label>•</ce:label><ce:para id="p1055">vasopressin release into the circulation</ce:para></ce:list-item><ce:list-item id="u0680"><ce:label>•</ce:label><ce:para id="p1060">vasopressin action on the collecting ducts.</ce:para></ce:list-item></ce:list>Failure of any of these steps may result in inappropriate water loss and hypernatraemia.</ce:para></ce:section><ce:section id="s0225"><ce:section-title id="st0225">Presenting problems in regulation of osmolality</ce:section-title><ce:para id="p1065">Changes in plasma osmolality are largely determined by changes in serum sodium concentration and its associated anions. Changes in sodium concentration usually occur because of disturbances in water balance either because there is a relative excess of body water compared to total body sodium (hyponatraemia) or a relative lack of body water compared to total body sodium (hypernatraemia). Abnormalities of water balance can result from disturbances in urinary concentration or dilution.</ce:para><ce:para id="p1070">If extracellular osmolality falls abruptly, water flows rapidly across cell membranes, causing cell swelling, whereas cell shrinkage occurs when osmolality rises. Cerebral function is particularly sensitive to such volume changes, particularly brain swelling during hypo-osmolality, which can lead to an increase in intracerebral pressure and reduced cerebral perfusion.</ce:para><ce:section id="s0230"><ce:section-title id="st0230">Hyponatraemia</ce:section-title><ce:para id="p1075">Hyponatraemia is defined as a serum Na &#x003C; 135 mmol/L. It is a common electrolyte abnormality with many potential underlying causes, as summarised in <ce:cross-ref id="crf0450" refid="b0055">Box 14.10</ce:cross-ref><ce:float-anchor refid="b0055"/>.</ce:para><ce:section id="s0235"><ce:section-title id="st0235">Pathophysiology</ce:section-title><ce:para id="p1165">In all cases, hyponatraemia is caused by greater retention of water relative to sodium. The causes are best categorised according to associated changes in the ECF volume (<ce:cross-ref id="crf0460" refid="b0055">Box 14.10</ce:cross-ref>).</ce:para><ce:section id="s0240"><ce:section-title id="st0240">Hyponatraemia with hypovolaemia</ce:section-title><ce:para id="p1170">In this situation there is depletion of sodium and water but the sodium deficit exceeds the water deficit, causing hypovolaemia and hyponatraemia (see <ce:cross-ref id="crf0465" refid="b0020">Box 14.3</ce:cross-ref>). The cause of sodium loss is usually apparent and common examples are shown in <ce:cross-ref id="crf0470" refid="b0055">Box 14.10</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0245"><ce:section-title id="st0245">Hyponatraemia with euvolaemia</ce:section-title><ce:para id="p1175">In this situation there are no major disturbances of body sodium content and the patient is clinically euvolaemic. Excess body water may be the result of abnormally high intake, either orally (primary polydipsia) or as a result of medically infused fluids (as intravenous dextrose solutions, or by absorption of sodium-free bladder irrigation fluid after prostatectomy).</ce:para><ce:para id="p1180">Water retention also occurs in the syndrome of inappropriate secretion of antidiuretic hormone, or vasopressin (SIADH). In this condition, an endogenous source of vasopressin (either cerebral or tumour-derived) promotes water retention by the kidney in the absence of an appropriate physiological stimulus (<ce:cross-ref id="crf0475" refid="b0060">Box 14.11</ce:cross-ref><ce:float-anchor refid="b0060"/>). The clinical diagnosis requires the patient to be euvolaemic, with no evidence of cardiac, renal or hepatic disease potentially associated with hyponatraemia. Other non-osmotic stimuli that cause release of vasopressin (pain, stress, nausea) should also be excluded. Supportive laboratory findings are shown in <ce:cross-ref id="crf0485" refid="b0060">Box 14.11</ce:cross-ref>.</ce:para></ce:section><ce:section id="s0260"><ce:section-title id="st0260">Hyponatraemia with hypervolaemia</ce:section-title><ce:para id="p1270">In this situation, excess water retention is associated with sodium retention and volume expansion, as in heart failure, liver disease or kidney disease.</ce:para></ce:section></ce:section><ce:section id="s0265"><ce:section-title id="st0265">Clinical features</ce:section-title><ce:para id="p1275">Hyponatraemia is often asymptomatic but can also be associated with profound disturbances of cerebral function, manifesting as anorexia, nausea, vomiting, delirium, lethargy, seizures and coma. The likelihood of symptoms occurring is related to the speed at which hyponatraemia develops rather than the severity of hyponatraemia. This is because water rapidly flows into cerebral cells when plasma osmolality falls acutely, causing them to become swollen and ischaemic. However, when hyponatraemia develops gradually, cerebral neurons have time to respond by reducing intracellular osmolality, through excreting potassium and reducing synthesis of intracellular organic osmolytes (<ce:cross-ref id="crf0490" refid="f0050">Fig. 14.7</ce:cross-ref><ce:float-anchor refid="f0050"/>). The osmotic gradient favouring water movement into the cells is thus reduced and symptoms are avoided. This process takes about 24–48 hours and hyponatraemia is therefore classified as acute (&#x003C; 48 hours) and chronic (&#x003E; 48 hours). Hyponatraemia can also be defined as mild (130–135 mmol/L), moderate (125–129 mmol/L) or severe (&#x003C; 124 mmol/L), based on biochemical findings or on the degree of severity of symptoms (<ce:cross-ref id="crf0495" refid="b0065">Box 14.12</ce:cross-ref><ce:float-anchor refid="b0065"/>).</ce:para></ce:section><ce:section id="s0270"><ce:section-title id="st0270">Investigations</ce:section-title><ce:para id="p1325">An algorithm for the clinical assessment of patients with hyponatraemia is shown in <ce:cross-ref id="crf0500" refid="f0055">Figure 14.8</ce:cross-ref><ce:float-anchor refid="f0055"/>. Artefactual causes of hyponatraemia should be considered in all cases. These include severe hyperlipidaemia or hyperproteinaemia, when the aqueous fraction of the serum specimen is reduced because of the volume occupied by the macromolecules (although this artefact is dependent on the assay technology). Transient hyponatraemia may also occur due to osmotic shifts of water out of cells during hyperosmolar states caused by acute hyperglycaemia or by mannitol infusion, but in these cases plasma osmolality is normal.</ce:para><ce:para id="p1330">When these conditions have been excluded, serum and urine electrolytes and osmolality (<ce:cross-ref id="crf0505" refid="f0055">Fig. 14.8</ce:cross-ref>) are usually the only tests required to clarify the underlying cause. Hypovolaemic hyponatraemia is characterised by a low urinary sodium concentration (&#x003C; 30 mmol/L) when there are extrarenal causes of sodium loss and high urinary sodium concentration (&#x003E; 30 mmol/L) in patients with excessive renal sodium loss.</ce:para><ce:para id="p1335">Measurement of vasopressin is not generally helpful in distinguishing between different categories of hyponatraemia. This is because concentrations of vasopressin are raised both in hypovolaemic states and in most chronic hypervolaemic states, as the impaired circulation in those disorders activates vasopressin release through non-osmotic mechanisms. Indeed, patients with these disorders may have higher circulating vasopressin (ADH) levels than patients with SIADH. The only disorders listed in <ce:cross-ref id="crf0510" refid="b0055">Box 14.10</ce:cross-ref> in which vasopressin is suppressed are primary polydipsia and iatrogenic water intoxication, where the hypo-osmolar state inhibits vasopressin release from the pituitary.</ce:para></ce:section><ce:section id="s0275"><ce:section-title id="st0275">Management</ce:section-title><ce:para id="p1340">The treatment of hyponatraemia is critically dependent on its rate of development, severity, presence of symptoms and underlying cause. If hyponatraemia has developed rapidly (&#x003C; 48 hours) and there are signs of cerebral oedema, such as obtundation or convulsions, sodium levels should be restored rapidly to normal by infusion of hypertonic (3%) sodium chloride. A common approach is to give an initial bolus of 150 mL over 20 minutes, which may be repeated once or twice over the initial hours of observation, depending on the neurological response and rise in plasma sodium.</ce:para><ce:para id="p1345">Rapid correction of hyponatraemia that has developed more slowly (&#x003E; 48 hours) can be hazardous, since brain cells adapt to slowly developing hypo-osmolality by reducing the intracellular osmolality, thus maintaining normal cell volume (see <ce:cross-ref id="crf0515" refid="f0050">Fig. 14.7</ce:cross-ref>). Under these conditions, an abrupt increase in extracellular osmolality can lead to water shifting out of neurons, abruptly reducing their volume and causing them to detach from their myelin sheaths. The resulting ‘myelinolysis’ can produce permanent structural and functional damage to mid-brain structures, and is generally fatal. The rate of correction of the plasma Na concentration in chronic asymptomatic hyponatraemia should not exceed 10 mmol/L/24 hrs, and an even slower rate is generally safer.</ce:para><ce:para id="p1350">The underlying cause should also be treated. For hypovolaemic patients, this involves controlling the source of sodium loss, and administering intravenous saline if clinically warranted. Patients with euvolaemic hyponatraemia generally respond to fluid restriction in the range of 600–1000 mL/24 hrs, accompanied where possible by withdrawal of the precipitating stimulus (such as drugs causing SIADH). In patients with persistent hyponatraemia due to prolonged SIADH, oral urea therapy (30–45 g/day) can be used, which provides a solute load to promote water excretion. Oral vasopressin receptor antagonists such as tolvaptan may also be used to block the vasopressin-mediated component of water retention in a range of hyponatraemic conditions, but concerns exist with regard to the risk of overly rapid correction of hyponatraemia with these agents. Hypervolaemic patients with hyponatraemia need treatment of the underlying condition, accompanied by cautious use of diuretics in conjunction with strict fluid restriction. Potassium-sparing diuretics may be particularly useful in this context when there is significant secondary hyperaldosteronism.</ce:para></ce:section></ce:section><ce:section id="s0280"><ce:section-title id="st0280">Hypernatraemia</ce:section-title><ce:para id="p1355">Hypernatraemia is defined as existing when the serum Na is &#x003E; 145 mmol/L. The causes are summarised in <ce:cross-ref id="crf0520" refid="b0070">Box 14.13</ce:cross-ref><ce:float-anchor refid="b0070"/>, grouped according to any associated disturbance in total body sodium content.</ce:para><ce:section id="s0285"><ce:section-title id="st0285">Pathophysiology</ce:section-title><ce:para id="p1415">Hypernatraemia occurs due to inadequate concentration of the urine in the face of restricted water intake. This can arise because of failure to generate an adequate medullary concentration gradient in the kidney due to low GFR or loop diuretic therapy, but more commonly is caused by failure of the vasopressin system. This can occur because of pituitary damage (cranial diabetes insipidus, <ce:intra-ref id="ii0155" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1580">p. 687</ce:intra-ref>) or because the collecting duct cells are unable to respond to circulating vasopressin concentrations in the face of restricted water intake (nephrogenic diabetes insipidus). Whatever the underlying cause, sustained or severe hypernatraemia generally reflects an impaired thirst mechanism or responsiveness to thirst.</ce:para></ce:section><ce:section id="s0290"><ce:section-title id="st0290">Clinical features</ce:section-title><ce:para id="p1420">Patients with hypernatraemia generally have reduced cerebral function, either as a primary problem or as a consequence of the hypernatraemia itself, which results in dehydration of neurons and brain shrinkage. In the presence of an intact thirst mechanism and preserved capacity to obtain and ingest water, hypernatraemia may not progress very far. If adequate water is not obtained, dizziness, delirium, weakness and, ultimately, coma and death can result.</ce:para></ce:section><ce:section id="s0295"><ce:section-title id="st0295">Management</ce:section-title><ce:para id="p1425">Treatment of hypernatraemia depends on both the rate of development and the underlying cause. If there is reason to think that the condition has developed rapidly, neuronal shrinkage may be acute and relatively rapid correction may be attempted. This can be achieved by infusing an appropriate volume of intravenous fluid (isotonic 5% dextrose or hypotonic 0.45% saline) at an initial rate of 50–70 mL/hr. In older, institutionalised patients, however, it is more likely that the disorder has developed slowly, and extreme caution should be exercised in lowering plasma sodium to avoid the risk of cerebral oedema. Where possible, the underlying cause should also be addressed (<ce:cross-ref id="crf0525" refid="b0070">Box 14.13</ce:cross-ref>).</ce:para><ce:para id="p1430">Elderly patients are predisposed, in different circumstances, to both hyponatraemia and hypernatraemia, and a high index of suspicion of these electrolyte disturbances is appropriate in elderly patients with recent alterations in behaviour (<ce:cross-ref id="crf0530" refid="b0075">Box 14.14</ce:cross-ref><ce:float-anchor refid="b0075"/>).</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0300"><ce:section-title id="st0300">Potassium homeostasis</ce:section-title><ce:para id="p1465">Potassium is the major intracellular cation (see <ce:cross-ref id="crf0535" refid="f0020">Fig. 14.1</ce:cross-ref>), and the steep concentration gradient for potassium across the cell membrane of excitable cells plays an important part in generating the resting membrane potential and allowing the propagation of the action potential that is crucial to normal functioning of nerve, muscle and cardiac tissues. Control of body potassium balance is described below.</ce:para><ce:section id="s0305"><ce:section-title id="st0305">Functional anatomy and physiology</ce:section-title><ce:para id="p1470">The kidneys normally excrete some 90% of the daily intake of potassium, typically 80–100 mmol/24 hrs. Potassium is freely filtered at the glomerulus; around 65% is reabsorbed in the proximal tubule and a further 25% in the thick ascending limb of the loop of Henle. Little potassium is transported in the early distal tubule but a significant secretory flux of potassium into the urine occurs in the late distal tubule and cortical collecting duct to ensure that the amount removed from the blood is proportional to the ingested load.</ce:para><ce:para id="p1475">The mechanism for potassium secretion in the distal parts of the nephron is shown in <ce:cross-ref id="crf0540" refid="f0030">Figure 14.3D</ce:cross-ref>. Movement of potassium from blood to lumen is dependent on active uptake across the basal cell membrane by the Na,K-ATPase, followed by diffusion of potassium through the ROMK channel into the tubular fluid. The electrochemical gradient for potassium movement into the lumen is contributed to both by the high intracellular potassium concentration and by the negative luminal potential difference relative to the blood.</ce:para><ce:para id="p1480">A number of factors influence the rate of potassium secretion. Luminal influences include the rate of sodium delivery and fluid flow through the late distal tubule and cortical collecting ducts. This is a major factor responsible for the increased potassium loss that accompanies diuretic treatment. Agents interfering with the generation of the negative luminal potential also impair potassium secretion, and this is the basis of reduced potassium secretion associated with potassium-sparing diuretics such as amiloride. Factors acting on the blood side of this tubular segment include plasma potassium and pH, such that hyperkalaemia and alkalosis both enhance potassium secretion directly. However, the most important factor in the acute and chronic adjustment of potassium secretion to match metabolic potassium load is aldosterone.</ce:para><ce:para id="p1485">As shown in <ce:cross-ref id="crf0545" refid="f0060">Figure 14.9</ce:cross-ref><ce:float-anchor refid="f0060"/>, a negative feedback relationship exists between the plasma potassium concentration and aldosterone. In addition to its regulation by the renin–angiotensin system (see <ce:intra-ref id="ii0160" xlink:href="pii:B978-0-7020-7028-0.00018-4#f0115">Fig. 18.18</ce:intra-ref>, <ce:intra-ref id="ii0165" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0930">p. 666</ce:intra-ref>), aldosterone is released from the adrenal cortex in direct response to an elevated plasma potassium. Aldosterone then acts on the kidney to enhance potassium secretion, hydrogen secretion and sodium reabsorption, in the late distal tubule and cortical collecting ducts. The resulting increased excretion of potassium maintains plasma potassium within a narrow range (3.6–5.0 mmol/L). Factors that reduce angiotensin II levels may indirectly affect potassium balance by blunting the rise in aldosterone that would otherwise be provoked by hyperkalaemia. This accounts for the increased risk of hyperkalaemia during therapy with ACE inhibitors and related drugs.</ce:para></ce:section><ce:section id="s0310"><ce:section-title id="st0310">Presenting problems in potassium homeostasis</ce:section-title><ce:para id="p1490">Changes in the distribution of potassium between the ICF and ECF compartments can alter plasma potassium concentration, without any overall change in total body potassium content. Potassium is driven into the cells by extracellular alkalosis and by a number of hormones, including insulin, catecholamines (through the β<ce:inf loc="post">2</ce:inf>-receptor) and aldosterone. Any of these factors can produce hypokalaemia, whereas extracellular acidosis, lack of insulin, and insufficiency or blockade of catecholamines or aldosterone can cause hyperkalaemia due to efflux of potassium from the intracellular compartment.</ce:para><ce:section id="s0315"><ce:section-title id="st0315">Hypokalaemia</ce:section-title><ce:para id="p1495">Hypokalaemia is a common electrolyte disturbance and is defined as existing when serum K<ce:sup loc="post">+</ce:sup> falls below 3.5 mmol/L. The main causes of hypokalaemia are shown in <ce:cross-ref id="crf0550" refid="b0080">Box 14.15</ce:cross-ref><ce:float-anchor refid="b0080"/>.</ce:para><ce:section id="s0320"><ce:section-title id="st0320">Pathophysiology</ce:section-title><ce:para id="p1745">Hypokalaemia is generally indicative of abnormal potassium loss from the body, through either the kidney or the gastrointestinal tract. Renal causes of hypokalaemia can be divided into those with and those without hypertension. Hypokalaemia in the presence of hypertension may be due to increased aldosterone secretion in Conn's syndrome (<ce:intra-ref id="ii0170" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1165">p. 674</ce:intra-ref>) or a genetic defect affecting sodium channels in the distal nephron (Liddle's syndrome). Excessive intake of liquorice or treatment with carbenoxolone may result in a similar clinical picture, due to inhibition of the renal 11βHSD2 enzyme, which inactivates cortisol in peripheral tissues.</ce:para><ce:para id="p1750">If blood pressure is normal or low, hypokalaemia can be classified according to the associated change in acid–base balance. Inherited defects in tubular transport should be suspected when hypokalaemia occurs in association with hypotension and alkalosis, provided that diuretic use has been excluded. One such disease is Bartter's syndrome, in which sodium reabsorption in the thick ascending limb of Henle is defective, usually due to a loss-of-function mutation of the NKCC2 transporter. The clinical and biochemical features are similar to those in chronic treatment with furosemide. In Gitelman's syndrome there is a loss-of-function mutation affecting the NCCT transporter in the early distal tubule. The clinical and biochemical features are similar to chronic thiazide treatment. Note that while both Bartter's and Gitelman's syndromes are characterised by hypokalaemia and hypomagnesaemia, urinary calcium excretion is increased in Bartter's syndrome but decreased in Gitelman's syndrome, analogous to the effects of the loop and thiazide diuretics, respectively, on calcium transport (see <ce:cross-ref id="crf0555" refid="b0050">Box 14.9</ce:cross-ref>).</ce:para><ce:para id="p1755">If hypokalaemia occurs in the presence of a normal blood pressure and metabolic acidosis, renal tubular acidosis (proximal or ‘classical’ distal) should be suspected (<ce:cross-ref id="crf9080" refid="p2065">p. 364</ce:cross-ref>).</ce:para><ce:para id="p1760">When hypokalaemia is due to potassium wasting through the gastrointestinal tract, the cause is usually obvious clinically. In some cases, when there is occult induction of vomiting, the hypokalaemia is characteristically associated with metabolic alkalosis, due to loss of gastric acid. If, however, potassium loss has occurred through the surreptitious use of aperients, the hypokalaemia is generally associated with metabolic acidosis. In both cases, urinary potassium excretion is low unless there is significant extracellular volume depletion, which can raise urinary potassium levels by stimulating aldosterone production.</ce:para><ce:para id="p1765">Hypokalaemia can also be caused by redistribution of potassium into cells as the result of insulin, β-adrenoceptor agonists and alkalosis, or as the result of K<ce:sup loc="post">+</ce:sup> flux into muscle in hypokalaemic periodic paralysis, which is associated with mutations in several genes that regulate transmembrane ion flow into muscle cells. Finally, reduced dietary intake of potassium can contribute to hypokalaemia but is seldom the only cause, except in extreme cases.</ce:para></ce:section><ce:section id="s0325"><ce:section-title id="st0325">Clinical features</ce:section-title><ce:para id="p1770">Patients with mild hypokalaemia (plasma K<ce:sup loc="post">+</ce:sup> 3.0–3.3 mmol/L) are generally asymptomatic, but more profound reductions in plasma potassium often lead to muscular weakness and associated tiredness. Ventricular ectopic beats or more serious arrhythmias may occur and the arrhythmogenic effects of digoxin may be potentiated. Typical electrocardiogram (ECG) changes occur, affecting the T wave in particular (<ce:cross-ref id="crf9085" refid="f0015">p. 347</ce:cross-ref>). Functional bowel obstruction may occur due to paralytic ileus. Long-standing hypokalaemia may cause renal tubular damage (hypokalaemic nephropathy) and can interfere with the tubular response to vasopressin (acquired nephrogenic diabetes insipidus), resulting in polyuria and polydipsia.</ce:para></ce:section><ce:section id="s0330"><ce:section-title id="st0330">Investigations</ce:section-title><ce:para id="p1775">Measurement of plasma electrolytes, bicarbonate, urine potassium and sometimes of plasma calcium and magnesium is usually sufficient to establish the diagnosis. If the diagnosis remains unclear, plasma renin should be measured. Levels are low in patients with primary hyperaldosteronism (<ce:intra-ref id="ii0185" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1165">p. 674</ce:intra-ref>) and other forms of mineralocorticoid excess, but raised in other causes of hypokalaemia. When there is no obvious clinical clue to which pathway is involved, measurement of urinary potassium may be helpful; if the kidney is the route of potassium loss, the urine potassium is high (&#x003E; 30 mmol/24 hrs), whereas if potassium is being lost through the gastrointestinal tract, the kidney retains potassium, resulting in a lower urinary potassium (generally &#x003C; 20 mmol/24 hrs). It should be noted, however, that if gastrointestinal fluid loss is also associated with hypovolaemia, activation of the renin–angiotensin–aldosterone system may occur, causing increased loss of potassium in the urine.</ce:para><ce:para id="p1780">The cause of hypokalaemia may remain unclear despite the above investigations when urinary potassium measurements are inconclusive and the history is incomplete or unreliable. Many such cases are associated with metabolic alkalosis, and in this setting the measurement of urine chloride concentration can be helpful. A low urine chloride (&#x003C; 30 mmol/L) is characteristic of vomiting (spontaneous or self-induced, in which chloride is lost in HCl in the vomit), while a urine chloride &#x003E; 40 mmol/L suggests diuretic therapy (acute phase) or a tubular disorder such as Bartter's or Gitelman's syndrome. Differentiation between occult diuretic use and primary tubular disorders can be achieved by performing a screen of urine for diuretic drugs.</ce:para></ce:section><ce:section id="s0335"><ce:section-title id="st0335">Management</ce:section-title><ce:para id="p1785">Treatment of hypokalaemia involves first determining the cause and correcting this where possible. If the problem is mainly one of redistribution of potassium into cells, reversal of the process responsible may be sufficient to restore plasma potassium without providing supplements. In most cases, however, some form of potassium replacement will be required. This can generally be achieved with slow-release potassium chloride tablets, but in more acute circumstances intravenous potassium chloride may be necessary. The rate of administration depends on the severity of hypokalaemia and the presence of cardiac or neuromuscular complications, but should generally not exceed 10 mmol of potassium per hour. In patients with severe, life-threatening hypokalaemia, the concentration of potassium in the infused fluid may be increased to 40 mmol/L if a peripheral vein is used, but higher concentrations must be infused into a large ‘central’ vein with continuous cardiac monitoring.</ce:para><ce:para id="p1790">In the less common situation where hypokalaemia occurs in the presence of systemic acidosis, alkaline salts of potassium, such as potassium bicarbonate, can be given by mouth. If magnesium depletion is also present, replacement of magnesium may also be required, since low cell magnesium can promote tubular potassium secretion, causing ongoing urinary losses. In some circumstances, potassium-sparing diuretics, such as amiloride, can assist in the correction of hypokalaemia, hypomagnesaemia and metabolic alkalosis, especially when renal loss of potassium is the underlying cause.</ce:para></ce:section></ce:section><ce:section id="s0340"><ce:section-title id="st0340">Hyperkalaemia</ce:section-title><ce:para id="p1795">Hyperkalaemia is a common electrolyte disorder, which is defined as existing when serum K<ce:sup loc="post">+</ce:sup> is &#x003E; 5 mmol/L. The causes of hyperkalaemia are summarised in <ce:cross-ref id="crf0560" refid="b0085">Box 14.16</ce:cross-ref><ce:float-anchor refid="b0085"/>.</ce:para><ce:section id="s0345"><ce:section-title id="st0345">Pathophysiology</ce:section-title><ce:para id="p1970">It is important to remember that hyperkalaemia can be artefactual due to haemolysis of blood specimens during collection or in vitro, or due to release of potassium from platelets in patients with thrombocytosis.</ce:para><ce:para id="p1975">True hyperkalaemia, however, can occur either because of redistribution of potassium between the ICF and ECF, or because potassium intake exceeds excretion. Redistribution of potassium from the ICF to the ECF may take place in the presence of systemic acidosis, or when the circulating levels of insulin, catecholamines and aldosterone are reduced, or when the effects of these hormones are blocked (<ce:cross-ref id="crf9090" refid="s0310">p. 361</ce:cross-ref>).</ce:para><ce:para id="p1980">High dietary potassium intake may contribute to hyperkalaemia, but is seldom the only explanation unless renal excretion mechanisms are impaired. The mechanism of hyperkalaemia in acute kidney injury and chronic kidney disease is impaired excretion of potassium into the urine as the result of a reduced GFR. In addition, acute kidney injury can be associated with severe hyperkalaemia when there is an increased potassium load, such as in rhabdomyolysis or in sepsis, particularly when acidosis is present. In chronic kidney disease, adaptation to moderately elevated plasma potassium levels commonly occurs. However, acute rises in potassium triggered by excessive dietary intake, hypovolaemia or drugs (see below) may occur and destabilise the situation.</ce:para><ce:para id="p1985">Hyperkalaemia can also develop when tubular potassium secretory processes are impaired, even if the GFR is normal. This can arise in association with low levels of aldosterone, as is found in Addison's disease, hyporeninaemic hypoaldosteronism or inherited disorders such as congenital isolated hypoaldosteronism, in which there is a defect in aldosterone biosynthesis, and pseudohypoaldosteronism type 2 (Gordon's syndrome), caused by mutations in the <ce:italic>WNK2</ce:italic> and <ce:italic>WNK4</ce:italic> genes, which causes decreased potassium secretion in the renal tubules.</ce:para><ce:para id="p1990">Drug-induced causes include ACE inhibitors, angiotensin-receptor blockers (ARBs), non-steroidal anti-inflammatory drugs (NSAIDs) and β-adrenoceptor antagonists (β-blockers).</ce:para><ce:para id="p1995">In another group of conditions, tubular potassium secretion is impaired as the result of aldosterone resistance. This can occur in a variety of diseases in which there is inflammation of the tubulointerstitium, such as systemic lupus erythematosus; following renal transplantation; during treatment with potassium-sparing diuretics; and in a number of inherited disorders of tubular transport.</ce:para><ce:para id="p2000">In aldosterone deficiency or aldosterone resistance, hyperkalaemia may be associated with acid retention, giving rise to the pattern of hyperkalaemic distal (‘type 4’) renal tubular acidosis (<ce:cross-ref id="crf9095" refid="p2065">p. 364</ce:cross-ref>).</ce:para></ce:section><ce:section id="s0350"><ce:section-title id="st0350">Clinical features</ce:section-title><ce:para id="p2005">Mild to moderate hyperkalaemia (&#x003C; 6.5 mmol/L) is usually asymptomatic. More severe hyperkalaemia can present with progressive muscular weakness, but sometimes there are no symptoms until cardiac arrest occurs. The typical ECG changes are shown on <ce:cross-ref id="crf9100" refid="f0015">page 347</ce:cross-ref>. Peaking of the T wave is an early ECG sign, but widening of the QRS complex presages a dangerous cardiac arrhythmia. However, these characteristic ECG findings are not always present, even in severe hyperkalaemia.</ce:para></ce:section><ce:section id="s0355"><ce:section-title id="st0355">Investigations</ce:section-title><ce:para id="p2010">Measurement of electrolytes, creatinine and bicarbonate, when combined with clinical assessment, usually provides the explanation for hyperkalaemia. In aldosterone deficiency, plasma sodium concentration is characteristically low, although this can occur with many causes of hyperkalaemia. Addison's disease should be excluded unless there is an obvious alternative diagnosis, as described on <ce:intra-ref id="ii0205" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1025">page 671</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0360"><ce:section-title id="st0360">Management</ce:section-title><ce:para id="p2015">Treatment of hyperkalaemia depends on its severity and the rate of development, but opinions vary as to what level of serum potassium constitutes severe hyperkalaemia and requires urgent treatment. Patients who have potassium concentrations &#x003C; 6.5 mmol/L in the absence of neuromuscular symptoms or ECG changes can be treated with a reduction of potassium intake and correction of predisposing factors. However, in acute and/or severe hyperkalaemia (plasma potassium &#x003E; 6.5–7.0 mmol/L), more urgent measures must be taken (<ce:cross-ref id="crf0565" refid="b0090">Box 14.17</ce:cross-ref><ce:float-anchor refid="b0090"/>). The first step should be infusion of 10 mL 10% calcium gluconate to stabilise conductive tissue membranes (calcium has the opposite effect to potassium on conduction of an action potential). Measures to shift potassium from the ECF to the ICF should also be applied, as they generally have a rapid effect and may avert arrhythmias. Ultimately, a means of removing potassium from the body is generally necessary. When renal function is reasonably preserved, loop diuretics (accompanied by intravenous saline if hypovolaemia is present) may be effective. In renal failure, dialysis may be required. Oral ion exchange resins, such as sodium polystyrene sulfonate (SPS), have traditionally been used to bind and excrete gastrointestinal potassium. There are concerns, however, with regard to SPS's lack of proven efficacy and safety, with a number of reports of intestinal necrosis associated with its use. Alternative cation exchanges have been developed and are currently being trialled, with the aim of providing more effective and safer alternatives for the treatment of hyperkalaemia.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0365"><ce:section-title id="st0365">Acid–base homeostasis</ce:section-title><ce:para id="p2055">The pH of arterial plasma is normally 7.40, corresponding to an H<ce:sup loc="post">+</ce:sup> concentration of 40 nmol/L, and under normal circumstances H<ce:sup loc="post">+</ce:sup> concentrations do not vary outside the range of 37–45 nmol/L (pH 7.43–7.35). Abnormalities of acid–base balance can occur in a wide range of diseases. Increases in H<ce:sup loc="post">+</ce:sup> concentration cause acidosis with a decrease in pH, whereas decreases in H+ concentration cause alkalosis with a rise in pH.</ce:para><ce:section id="s0370"><ce:section-title id="st0370">Functional anatomy and physiology</ce:section-title><ce:para id="p2060">A variety of physiological mechanisms maintain pH of the ECF within narrow limits. The first is the action of blood and tissue buffers, of which the most important involves reaction of H<ce:sup loc="post">+</ce:sup> ions with bicarbonate to form carbonic acid, which, under the influence of the enzyme carbonic anhydrase (CA), dissociates to form CO<ce:inf loc="post">2</ce:inf> and water:<ce:display><ce:formula id="e0010"><mml:math altimg="si1.gif" display="block" overflow="scroll"><mml:mrow><mml:msub><mml:mrow><mml:mtext>CO</mml:mtext></mml:mrow><mml:mn>2</mml:mn></mml:msub><mml:mo>+</mml:mo><mml:msub><mml:mi mathvariant="normal">H</mml:mi><mml:mn>2</mml:mn></mml:msub><mml:mi mathvariant="normal">O</mml:mi><mml:mtext> </mml:mtext><mml:munder><mml:mo>↔</mml:mo><mml:mrow><mml:mtext>CA</mml:mtext></mml:mrow></mml:munder><mml:msub><mml:mtext> H</mml:mtext><mml:mn>2</mml:mn></mml:msub><mml:msub><mml:mrow><mml:mtext>CO</mml:mtext></mml:mrow><mml:mn>3</mml:mn></mml:msub><mml:mo>⇌</mml:mo><mml:msup><mml:mi mathvariant="normal">H</mml:mi><mml:mo>+</mml:mo></mml:msup><mml:mo>+</mml:mo><mml:msub><mml:mrow><mml:mtext>HCO</mml:mtext></mml:mrow><mml:mn>3</mml:mn></mml:msub><mml:msup><mml:mrow/><mml:mo>−</mml:mo></mml:msup></mml:mrow></mml:math></ce:formula></ce:display></ce:para><ce:para id="p2065">This buffer system is important because bicarbonate is present at a relatively high concentration in ECF (21–29 mmol/L), and two of its key components are under physiological control: CO<ce:inf loc="post">2</ce:inf> by the lungs, and bicarbonate by the kidneys. These relationships are illustrated in <ce:cross-ref id="crf0585" refid="f0065">Figure 14.10</ce:cross-ref><ce:float-anchor refid="f0065"/> (a form of the Henderson–Hasselbalch equation).</ce:para><ce:para id="p2070">Respiratory compensation for acid–base disturbances can occur quickly. In response to acid accumulation, pH changes in the brainstem stimulate ventilatory drive, reduce <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> and increase pH (<ce:intra-ref id="ii0210" xlink:href="pii:B978-0-7020-7028-0.00017-2#s0155">p. 555</ce:intra-ref>). Conversely, systemic alkalosis leads to inhibition of ventilation, causing a rise in <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> and reduction in pH, although it should be noted that this mechanism has limited capacity to change pH because hypoxia provides an alternative stimulus to drive ventilation.</ce:para><ce:para id="p2075">The kidneys provide a third line of defence against disturbances of arterial pH. When acid accumulates due to chronic respiratory or metabolic (non-renal) causes, the kidneys have the long-term capacity to enhance urinary excretion of acid, effectively increasing the plasma bicarbonate.</ce:para><ce:section id="s0375"><ce:section-title id="st0375">Renal control of acid–base balance</ce:section-title><ce:para id="p2080">Regulation of acid–base balance occurs at several sites in the kidney. The proximal tubule reabsorbs about 85% of the filtered bicarbonate ions, through the mechanism for H<ce:sup loc="post">+</ce:sup> secretion illustrated in <ce:cross-ref id="crf0590" refid="f0030">Figure 14.3A</ce:cross-ref>. This is dependent on the enzyme carbonic anhydrase, both in the cytoplasm of the proximal tubular cells and on the luminal surface of the brush border membranes. The system has a high capacity and is required to rescue filtered bicarbonate, but does not lead to significant acidification of the luminal fluid.</ce:para><ce:para id="p2085">Distal nephron segments also have an important role in acid excretion. Hydrogen ions are secreted into the lumen by an H<ce:sup loc="post">+</ce:sup>-ATPase in the intercalated cells of the cortical collecting duct and the outer medullary collecting duct cells. The H<ce:sup loc="post">+</ce:sup> ions are generated in the tubular cell from the hydration of CO<ce:inf loc="post">2</ce:inf> to form carbonic acid, which dissociates into an H<ce:sup loc="post">+</ce:sup> ion secreted luminally, and a bicarbonate ion that passes across the basolateral membrane into the blood. The secreted H<ce:sup loc="post">+</ce:sup> ions contribute to the reabsorption of any residual bicarbonate present in the luminal fluid, by generating intracellular OH<ce:sup loc="post">−</ce:sup> that reacts with CO<ce:inf loc="post">2</ce:inf> to form HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup>, which exits across the basolateral membrane. However, H<ce:sup loc="post">+</ce:sup> secretion also contributes net acid for removal from the body, bound to a variety of urinary buffers, of which phosphate and ammonia are the most important. Urinary buffers are required to prevent a reduction in urinary pH, which would create an unfavourable gradient that would prevent further H<ce:sup loc="post">+</ce:sup> secretion. Filtered phosphate (HPO<ce:inf loc="post">4</ce:inf><ce:sup loc="post">2−</ce:sup>) combines with H<ce:sup loc="post">+</ce:sup> in the distal tubular lumen to form dihydrogen phosphate (H<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf><ce:sup loc="post">−</ce:sup>), which is excreted in the urine with sodium. Ammonia (NH<ce:inf loc="post">3</ce:inf>) is generated within tubular cells by deamination of the amino acid glutamine by the enzyme glutaminase. The NH<ce:inf loc="post">3</ce:inf> then reacts with secreted H<ce:sup loc="post">+</ce:sup> in the tubular lumen to form ammonium (NH<ce:inf loc="post">4</ce:inf><ce:sup loc="post">+</ce:sup>), which becomes trapped in the luminal fluid and is excreted with chloride ions.</ce:para><ce:para id="p2090">These two mechanisms remove approximately 1 mmol/kg of hydrogen ions from the body per day, which equates to the non-volatile acid load arising from the metabolism of dietary protein. The slightly alkaline plasma pH of 7.4 (H<ce:sup loc="post">+</ce:sup> 40 nmol/L) that is maintained during health can be accounted for by the kidney's ability to generate an acidic urine (typically pH 5–6 (H<ce:sup loc="post">+</ce:sup> 1000–10 000 nmol/L), in which the net daily excess of metabolic acid produced by the body can be excreted.</ce:para></ce:section></ce:section><ce:section id="s0380"><ce:section-title id="st0380">Presenting problems in acid–base balance</ce:section-title><ce:para id="p2095">Patients with disturbances of acid–base balance may present clinically either with the effects of tissue malfunction due to disturbed pH (such as altered cardiac and central nervous system function), or with secondary changes in respiration that occur as a response to the underlying metabolic change (such as Kussmaul respiration during metabolic acidosis). The clinical picture is often dominated by the underlying cause rather than the acid–base abnormality itself. Frequently, acid–base disturbances only become evident when the venous plasma bicarbonate concentration is measured and found to be abnormal, or when blood gas analysis shows abnormalities in pH, <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> or bicarbonate.</ce:para><ce:para id="p2100">The most common patterns of abnormality in blood gas parameters are shown in <ce:cross-ref id="crf0595" refid="b0095">Box 14.18</ce:cross-ref><ce:float-anchor refid="b0095"/>. Note that the terms acidosis and alkalosis strictly refer to the underlying direction of the acid–base change, while acidaemia and alkalaemia more correctly refer to the net change present in the blood. Interpretation of arterial blood gases is also described on <ce:intra-ref id="ii0215" xlink:href="pii:B978-0-7020-7028-0.00017-2#s0155">page 555</ce:intra-ref>.</ce:para><ce:para id="p2110">In metabolic disturbances, respiratory compensation is almost immediate, so that the predicted compensatory change in <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> is achieved soon after the onset of the metabolic disturbance. In respiratory disorders, on the other hand, a small initial change in bicarbonate occurs as a result of chemical buffering of CO<ce:inf loc="post">2</ce:inf>, largely within red blood cells, but over days and weeks the kidney achieves further compensatory changes in bicarbonate concentration as a result of long-term adjustments in acid secretory capacity. When the clinically obtained acid–base parameters do not accord with the predicted compensation shown, a mixed acid–base disturbance should be suspected (<ce:cross-ref id="crf9105" refid="p2365">p. 367</ce:cross-ref>).</ce:para><ce:section id="s0385"><ce:section-title id="st0385">Metabolic acidosis</ce:section-title><ce:para id="p2115">Metabolic acidosis occurs when an acid other than carbonic acid (due to CO<ce:inf loc="post">2</ce:inf> retention) accumulates in the body, resulting in a fall in the plasma bicarbonate. The causes of metabolic acidosis are summarised in <ce:cross-ref id="crf0645" refid="b0100">Box 14.19</ce:cross-ref><ce:float-anchor refid="b0100"/>, subdivided into two categories, depending on whether the anion gap is normal or raised.</ce:para><ce:section id="s0390"><ce:section-title id="st0390">Pathophysiology</ce:section-title><ce:para id="p2125">Metabolic acidosis with a normal anion gap occurs when there is a primary loss of bicarbonate from the ECF, or when there is poisoning with or therapeutic infusion of a mineral acid such as hydrochloric acid or ammonium chloride. Renal tubular acidosis (RTA) is an important cause of metabolic acidosis with a normal anion gap. It can be caused by a defect in one of three processes:<ce:list id="ulist0490"><ce:list-item id="u1390"><ce:label>•</ce:label><ce:para id="p2130">impaired bicarbonate reabsorption in the proximal tubule (proximal RTA)</ce:para></ce:list-item><ce:list-item id="u1395"><ce:label>•</ce:label><ce:para id="p2135">impaired acid secretion in the late distal tubule or cortical collecting duct intercalated cells (classical distal RTA)</ce:para></ce:list-item><ce:list-item id="u1400"><ce:label>•</ce:label><ce:para id="p2140">impaired sodium reabsorption in the late distal tubule or cortical collecting duct, which is associated with reduced secretion of both potassium and H<ce:sup loc="post">+</ce:sup> ions (hyperkalaemic distal RTA).</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2145">Various subtypes of RTA are recognised and the most common causes are shown in <ce:cross-ref id="crf0660" refid="b0105">Box 14.20</ce:cross-ref><ce:float-anchor refid="b0105"/>. The inherited forms of RTA are due to mutations in the genes that regulate acid or bicarbonate transport in the renal tubules (see <ce:cross-ref id="crf0665" refid="f0030">Fig. 14.3</ce:cross-ref>).</ce:para><ce:para id="p2295">Acidosis with an increased anion gap is most commonly seen in ketoacidosis, renal failure and lactic acidosis, where there is endogenous production of anions distinct from Cl<ce:sup loc="post">−</ce:sup> and HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup>. Ketoacidosis is caused by insulin deficiency and is exacerbated by catecholamine and stress hormone excess, which combine to cause lipolysis and the formation of acidic ketones (acetoacetate, 3-hydroxybutyrate and acetone). The most common cause of ketoacidosis is diabetic ketoacidosis (DKA); its aetiology and management are discussed on <ce:intra-ref id="ii9000" xlink:href="pii:B978-0-7020-7028-0.00020-2#p0880">page 735</ce:intra-ref>. Starvation ketoacidosis occurs when there is reduced food intake in situations of high glucose demand, such as in neonates, and in pregnant or breastfeeding women. In alcoholic ketoacidosis, there is usually a background of chronic malnutrition and a recent alcohol binge. Two subtypes of lactic acidosis have been defined:<ce:list id="ulist0560"><ce:list-item id="u1545"><ce:label>•</ce:label><ce:para id="p2300"><ce:italic>type 1</ce:italic>, due to tissue hypoxia and peripheral generation of lactate, as in patients with circulatory failure and shock</ce:para></ce:list-item><ce:list-item id="u1550"><ce:label>•</ce:label><ce:para id="p2305"><ce:italic>type 2</ce:italic>, due to impaired metabolism of lactate, as in liver disease or by a number of drugs and toxins, including metformin, which inhibit lactate metabolism (<ce:intra-ref id="ii0240" xlink:href="pii:B978-0-7020-7028-0.00020-2#s0615">p. 746</ce:intra-ref>).</ce:para><ce:para id="p9025">Metabolic acidosis with an increased anion gap may also be a consequence of exogenous acid loads from poisoning with aspirin, methanol or ethylene glycol.</ce:para></ce:list-item></ce:list></ce:para></ce:section><ce:section id="s0395"><ce:section-title id="st0395">Clinical features</ce:section-title><ce:para id="p2310">Normal anion gap metabolic acidosis is usually due either to bicarbonate loss in diarrhoea, where the clinical diagnosis is generally obvious, or to RTA. Although some forms of RTA are inherited, it may also be an acquired disorder, and in these circumstances the discovery of metabolic acidosis may serve as an early clue to the underlying diagnosis. The presentation of increased anion gap acidosis is usually dominated by clinical features of the underlying disease, such as uncontrolled diabetes mellitus, kidney failure or shock, or may be suggested by the clinical history of starvation, alcoholism or associated symptoms, such as visual complaints in methanol poisoning (<ce:intra-ref id="ii0245" xlink:href="pii:B978-0-7020-7028-0.00007-X#p1895">p. 147</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0400"><ce:section-title id="st0400">Investigations</ce:section-title><ce:para id="p2315">The different types of metabolic acidosis can be distinguished by blood gas measurements, along with measurements of creatinine, electrolytes and bicarbonate. Under normal circumstances, the anion gap, defined as the numerical difference between the main measured cations (Na<ce:sup loc="post">+</ce:sup> + K<ce:sup loc="post">+</ce:sup>) and the anions (Cl<ce:sup loc="post">−</ce:sup> + HCO<ce:inf loc="post">3</ce:inf><ce:sup loc="post">−</ce:sup>) is about 5–11 mmol/L. This gap is normally made up of anions, such as phosphate and sulphate, as well as albumin. RTA should be suspected when there is a hyperchloraemic acidosis with a normal anion gap in the absence of gastrointestinal disturbance. The diagnosis can be confirmed by finding an inappropriately high urine pH (&#x003E; 5.5) in the presence of systemic acidosis. Sometimes, distal RTA may be incomplete, such that the plasma bicarbonate concentration may be normal under resting conditions. In this case, an acid challenge test can be performed by administration of an acid load in the form of ammonium chloride to reduce plasma bicarbonate. The diagnosis of incomplete distal RTA can be confirmed if the urine pH fails to fall below 5.3 in the presence of a low bicarbonate.</ce:para><ce:para id="p2320">The different subtypes of RTA can be differentiated by various biochemical features. Patients with proximal and distal RTA often present with features of profound hypokalaemia, while type IV RTA is associated with hyperkalaemia. Proximal RTA is frequently associated with urinary wasting of amino acids, phosphate and glucose (Fanconi's syndrome), as well as bicarbonate and potassium. Patients with this disorder can lower the urine pH when the acidosis is severe and plasma bicarbonate levels have fallen below 16 mmol/L, since distal H<ce:sup loc="post">+</ce:sup> secretion mechanisms are intact. In the classical form of distal RTA, however, acid accumulation is relentless and progressive, resulting in mobilisation of calcium from bone and osteomalacia with hypercalciuria, renal stone formation and nephrocalcinosis. Potassium is also lost in classical distal RTA, while it is retained in hyperkalaemic distal RTA.</ce:para><ce:para id="p2325">Investigations in patients with raised anion gap metabolic acidosis show features of the underlying cause, such as reduced GFR in renal failure and raised urine or blood ketones in ketoacidosis. In DKA, blood glucose is raised, while in starvation and alcoholic acidosis blood glucose is not elevated and may be low. Measurement of plasma lactate is helpful in the diagnosis of lactic acidosis when values are increased over the normal maximal level of 2 mmol/L.</ce:para></ce:section><ce:section id="s0405"><ce:section-title id="st0405">Management</ce:section-title><ce:para id="p2330">The first step in management of metabolic acidosis is to identify and correct the underlying cause when possible (see <ce:cross-ref id="crf0670" refid="b0100">Box 14.19</ce:cross-ref>). This may involve controlling diarrhoea, treating diabetes mellitus, correcting shock, stopping drugs that might cause the condition, or using dialysis to remove toxins. Since metabolic acidosis is frequently associated with sodium and water depletion, resuscitation with intravenous fluids is often needed. In alcoholism and starvation ketosis, intravenous glucose is indicated. By stimulating endogenous insulin secretion, this will reverse hepatic ketone production. Malnourished patients may also require thiamin, potassium, magnesium and phosphate supplements (<ce:intra-ref id="ii9005" xlink:href="pii:B978-0-7020-7028-0.00019-6#s0270">p. 706</ce:intra-ref>). Use of intravenous bicarbonate in metabolic acidosis is controversial. Because rapid correction of acidosis can induce hypokalaemia or a fall in plasma ionised calcium, the use of bicarbonate infusions is best reserved for situations where the underlying disorder cannot be readily corrected and acidosis is severe (H<ce:sup loc="post">+</ce:sup> &#x003E; 100 nmol/L, pH &#x003C; 7.00) or associated with evidence of tissue dysfunction.</ce:para><ce:para id="p2335">The acidosis in RTA can sometimes be controlled by treating the underlying cause (see <ce:cross-ref id="crf0675" refid="b0105">Box 14.20</ce:cross-ref>), but usually supplements of sodium and potassium bicarbonate are also necessary in types I and II RTA to achieve a target plasma bicarbonate level of &#x003E; 18 mmol/L and normokalaemia. In type IV RTA, loop diuretics, thiazides or fludrocortisone (as appropriate to the underlying diagnosis) may be effective in correcting the acidosis and the hyperkalaemia.</ce:para></ce:section></ce:section><ce:section id="s0410"><ce:section-title id="st0410">Metabolic alkalosis</ce:section-title><ce:para id="p2340">Metabolic alkalosis is characterised by an increase in the plasma bicarbonate concentration and the plasma pH (see <ce:cross-ref id="crf0680" refid="b0095">Box 14.18</ce:cross-ref>). There is a compensatory rise in <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> due to hypoventilation but this is limited by the need to avoid hypoxia. Classical causes include primary hyperaldosteronism (Conn's syndrome, <ce:intra-ref id="ii0250" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1165">p. 674</ce:intra-ref>), Cushing's syndrome (<ce:intra-ref id="ii0255" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0930">p. 666</ce:intra-ref>) and glucocorticoid therapy (<ce:intra-ref id="ii0260" xlink:href="pii:B978-0-7020-7028-0.00018-4#s1010">p. 670</ce:intra-ref>). Occasionally, overuse of antacid salts for treatment of dyspepsia produces a similar pattern.</ce:para><ce:section id="s0415"><ce:section-title id="st0415">Pathophysiology</ce:section-title><ce:para id="p2345">Metabolic alkalosis is best classified according to the accompanying changes in ECF volume. Hypovolaemic metabolic alkalosis is the most common pattern. This can be caused by sustained vomiting, in which acid-rich fluid is lost directly from the body, or by treatment with loop diuretics or thiazides. In the case of sustained vomiting, loss of gastric acid is the immediate cause of the alkalosis, but several factors act to sustain or amplify this in the context of volume depletion (<ce:cross-ref id="crf0685" refid="f0070">Fig. 14.11</ce:cross-ref><ce:float-anchor refid="f0070"/>). Loss of sodium and fluid leads to hypovolaemia and secondary hyperaldosteronism, triggering proximal sodium bicarbonate reabsorption and additional acid secretion by the distal tubule. Hypokalaemia occurs due to potassium loss in the vomitus and by the kidney as the result of secondary hyperaldosteronism, and itself is a stimulus to acid secretion. Additionally, the compensatory rise in <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> further enhances tubular acid secretion. The net result is sustained metabolic alkalosis with an inappropriately acid urine, which cannot be corrected until the deficit in circulating volume has been replaced.</ce:para><ce:para id="p2350">Normovolaemic (or hypervolaemic) metabolic alkalosis occurs when bicarbonate retention and volume expansion occur simultaneously.</ce:para></ce:section><ce:section id="s0420"><ce:section-title id="st0420">Clinical features</ce:section-title><ce:para id="p2355">Clinically, apart from manifestations of the underlying cause, there may be few symptoms or signs related to alkalosis itself. When the rise in systemic pH is abrupt, however, plasma ionised calcium falls and signs of increased neuromuscular irritability, such as tetany, may develop (<ce:intra-ref id="ii0265" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0835">p. 663</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0425"><ce:section-title id="st0425">Investigations</ce:section-title><ce:para id="p2360">The diagnosis can be confirmed by measurement of electrolytes and arterial blood gases.</ce:para></ce:section><ce:section id="s0430"><ce:section-title id="st0430">Management</ce:section-title><ce:para id="p2365">Metabolic alkalosis with hypovolaemia can be corrected by intravenous infusions of 0.9% saline with potassium supplements. This reverses the secondary hyperaldosteronism and allows the kidney to excrete the excess alkali in the urine. In metabolic alkalosis with normal or increased volume, treatment should focus on management of the underlying endocrine cause (<ce:intra-ref id="ii0270" xlink:href="pii:B978-0-7020-7028-0.00018-4#c00018">Ch. 18</ce:intra-ref>).</ce:para></ce:section></ce:section><ce:section id="s0435"><ce:section-title id="st0435">Respiratory acidosis</ce:section-title><ce:para id="p2370">Respiratory acidosis occurs when there is accumulation of CO<ce:inf loc="post">2</ce:inf> due to type II respiratory failure (<ce:intra-ref id="ii0275" xlink:href="pii:B978-0-7020-7028-0.00017-2#p1435">p. 565</ce:intra-ref>). This results in a rise in the <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf>, with a compensatory increase in plasma bicarbonate concentration, particularly when the disorder is of long duration and the kidney has fully developed its capacity for increased acid excretion.</ce:para><ce:para id="p2375">This acid–base disturbance can arise from lesions anywhere along the neuromuscular pathways from the brain to the respiratory muscles that result in impaired ventilation. It can also arise during intrinsic lung disease if there is significant mismatching of ventilation and perfusion.</ce:para><ce:para id="p2380">Clinical features are primarily those of the underlying cause of the respiratory disorder, such as paralysis, chest wall injury or chronic obstructive lung disease, but the CO<ce:inf loc="post">2</ce:inf> accumulation may itself lead to drowsiness that further depresses respiratory drive.</ce:para><ce:para id="p2385">Management involves correction of causative factors where possible, but ultimately ventilatory support may be necessary.</ce:para></ce:section><ce:section id="s0440"><ce:section-title id="st0440">Respiratory alkalosis</ce:section-title><ce:para id="p2390">Respiratory alkalosis develops when there is a period of sustained hyperventilation, resulting in a reduction of <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> and increase in plasma pH. If the condition is sustained, renal compensation occurs, such that tubular acid secretion is reduced and the plasma bicarbonate falls.</ce:para><ce:para id="p2395">Respiratory alkalosis is usually of short duration, occurring in anxiety states or as the result of over-vigorous assisted ventilation. It can be prolonged in the context of pregnancy, pulmonary embolism, chronic liver disease, and ingestion of certain drugs such as salicylates that directly stimulate the respiratory centre in the brainstem.</ce:para><ce:para id="p2400">Clinical features are those of the underlying cause but agitation associated with perioral and digital tingling may also occur, as alkalosis promotes the binding of calcium to albumin, resulting in a reduction in ionised calcium concentrations. In severe cases, Trousseau's sign and Chvostek's sign may be positive, and tetany or seizures may develop (<ce:intra-ref id="ii0280" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0835">p. 663</ce:intra-ref>).</ce:para><ce:para id="p2405">Management involves correction of identifiable causes, reduction of anxiety, and a period of rebreathing into a closed bag to allow CO<ce:inf loc="post">2</ce:inf> levels to rise.</ce:para></ce:section><ce:section id="s0445"><ce:section-title id="st0445">Mixed acid–base disorders</ce:section-title><ce:para id="p2410">It is not uncommon for more than one disturbance of acid–base metabolism to be present at the same time in the same patient: for example, a respiratory acidosis due to narcotic overdose with metabolic alkalosis due to vomiting. In these situations, the arterial pH will represent the net effect of all primary and compensatory changes. Indeed, the pH may be normal, but the presence of underlying acid–base disturbances can be gauged from concomitant abnormalities in the <ce:italic>P</ce:italic>CO<ce:inf loc="post">2</ce:inf> and bicarbonate concentration.</ce:para><ce:para id="p2415">In assessing these disorders, all clinical influences on the patient's acid–base status should be identified, and reference should be made to the table of predicted compensation given in <ce:cross-ref id="crf0690" refid="b0095">Box 14.18</ce:cross-ref>. If the compensatory change is discrepant from the rules of thumb provided, more than one disturbance of acid–base metabolism may be suspected.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0450"><ce:section-title id="st0450">Calcium homeostasis</ce:section-title><ce:para id="p2420">Disorders of calcium homeostasis are discussed in <ce:intra-ref id="ii0285" xlink:href="pii:B978-0-7020-7028-0.00018-4#c00018">Chapter 18</ce:intra-ref> and bone disease is discussed in <ce:intra-ref id="ii0290" xlink:href="pii:B978-0-7020-7028-0.00024-X#c00024">Chapter 24</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0455"><ce:section-title id="st0455">Magnesium homeostasis</ce:section-title><ce:para id="p2425">Magnesium is mainly an intracellular cation. It is important to the function of many enzymes, including the Na,K-ATPase, and can regulate both potassium and calcium channels. Its overall effect is to stabilise excitable cell membranes.</ce:para><ce:section id="s0460"><ce:section-title id="st0460">Functional anatomy and physiology</ce:section-title><ce:para id="p2430">Renal handling of magnesium involves filtration of free plasma magnesium at the glomerulus (about 70% of the total), with extensive reabsorption (50–70%) in the loop of Henle and other parts of the proximal and distal renal tubule. Magnesium reabsorption is also enhanced by parathyroid hormone (PTH).</ce:para></ce:section><ce:section id="s0465"><ce:section-title id="st0465">Presenting problems in magnesium homeostasis</ce:section-title><ce:para id="p2435">Disturbances in magnesium homeostasis usually occur because of increased loss of magnesium through the gut or kidney or inability to excrete magnesium normally in patients with renal impairment.</ce:para><ce:section id="s0470"><ce:section-title id="st0470">Hypomagnesaemia</ce:section-title><ce:para id="p2440">Hypomagnesaemia is defined as existing when plasma magnesium concentrations are below the reference range of 0.75–1.0 mmol/L (1.5–2.0 mEq/L).</ce:para><ce:section id="s0475"><ce:section-title id="st0475">Pathophysiology</ce:section-title><ce:para id="p2445">Hypomagnesaemia usually is a reflection of magnesium depletion (<ce:cross-ref id="crf0695" refid="b0110">Box 14.21</ce:cross-ref><ce:float-anchor refid="b0110"/>), which can be caused by excessive magnesium loss from the gastrointestinal tract (notably in chronic diarrhoea) or the kidney (during prolonged use of loop diuretics). Excessive alcohol ingestion can cause magnesium depletion through both gut and renal losses. Some inherited tubular transport disorders, such as Gitelman's and Bartter's syndromes, can also result in urinary magnesium wasting (<ce:cross-ref id="crf9110" refid="s0310">p. 361</ce:cross-ref>). Magnesium depletion has important effects on calcium homeostasis because magnesium is required for the normal secretion of PTH in response to a fall in serum calcium, and because hypomagnesaemia causes end-organ resistance to PTH.</ce:para></ce:section><ce:section id="s0480"><ce:section-title id="st0480">Clinical features</ce:section-title><ce:para id="p2590">Mild degrees of hypomagnesaemia may be asymptomatic but more severe hypomagnesaemia may be associated with symptoms of hypocalcaemia, such as tetany, cardiac arrhythmias (notably torsades de pointes, <ce:intra-ref id="ii0300" xlink:href="pii:B978-0-7020-7028-0.00016-0#s0830">p. 476</ce:intra-ref>), central nervous excitation and seizures, vasoconstriction and hypertension. Hypomagnesaemia and magnesium depletion are also associated (through uncertain mechanisms) with hyponatraemia and hypokalaemia, which may contribute to some of the clinical manifestations.</ce:para></ce:section><ce:section id="s0485"><ce:section-title id="st0485">Management</ce:section-title><ce:para id="p2595">The underlying cause should be identified and treated where possible. When symptoms are present, the treatment of choice is intravenous magnesium chloride at a rate not exceeding 0.5 mmol/kg in the first 24 hours. If intravenous access is not feasible, magnesium sulphate can be given intramuscularly. Oral magnesium salts have limited effectiveness due to poor absorption and may cause diarrhoea. If hypomagnesaemia is caused by diuretic treatment, adjunctive use of a potassium-sparing agent can also help by reducing magnesium loss into the urine.</ce:para></ce:section></ce:section><ce:section id="s0490"><ce:section-title id="st0490">Hypermagnesaemia</ce:section-title><ce:para id="p2600">This is a much less common abnormality than hypomagnesaemia. Predisposing conditions include acute kidney injury, chronic kidney disease and adrenocortical insufficiency. The condition is generally precipitated in patients at risk from an increased intake of magnesium, or from the use of magnesium-containing medications, such as antacids, laxatives and enemas.</ce:para><ce:para id="p2605">Clinical features include bradycardia, hypotension, reduced consciousness and respiratory depression.</ce:para><ce:para id="p2610">Management involves ceasing all magnesium-containing drugs and reducing dietary magnesium intake, improving renal function if possible, and promoting urinary magnesium excretion using a loop diuretic with intravenous hydration, if residual renal function allows. Calcium gluconate may be given intravenously to ameliorate cardiac effects. Dialysis may be necessary in patients with poor renal function.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0495"><ce:section-title id="st0495">Phosphate homeostasis</ce:section-title><ce:para id="p2615">Inorganic phosphate (mainly present as HPO<ce:inf loc="post">4</ce:inf><ce:sup loc="post">2−</ce:sup>) is intimately involved in cell energy metabolism, intracellular signalling and bone and mineral homeostasis (<ce:intra-ref id="ii0305" xlink:href="pii:B978-0-7020-7028-0.00024-X#c00024">Ch. 24</ce:intra-ref>). The normal plasma concentration is 0.8–1.4 mmol/L (2.48–4.34 mg/dL).</ce:para><ce:section id="s0500"><ce:section-title id="st0500">Functional anatomy and physiology</ce:section-title><ce:para id="p2620">Phosphate is freely filtered at the glomerulus and approximately 65% is reabsorbed by the proximal tubule, through an apical sodium–phosphate co-transport carrier. A further 10–20% is reabsorbed in the distal tubules, leaving a fractional excretion of some 10% to pass into the urine, usually as H<ce:inf loc="post">2</ce:inf>PO<ce:inf loc="post">4</ce:inf><ce:sup loc="post">−</ce:sup>. Proximal reabsorption is decreased by PTH, fibroblast growth factor 23 (FGF23), volume expansion, osmotic diuretics and glucose infusion.</ce:para></ce:section><ce:section id="s0505"><ce:section-title id="st0505">Presenting problems in phosphate homeostasis</ce:section-title><ce:para id="p2625">The following section deals primarily with conditions that cause acute disturbances in serum phosphate concentrations. Chronic disorders that are accompanied by phosphate depletion, such as osteomalacia and hypophosphataemic rickets, are discussed in <ce:intra-ref id="ii0310" xlink:href="pii:B978-0-7020-7028-0.00024-X#c00024">Chapter 24</ce:intra-ref>. Acute kidney injury and chronic kidney disease, which are associated with hyperphosphataemia, are discussed below and also in <ce:intra-ref id="ii0315" xlink:href="pii:B978-0-7020-7028-0.00015-9#c00015">Chapter 15</ce:intra-ref>.</ce:para><ce:section id="s0510"><ce:section-title id="st0510">Hypophosphataemia</ce:section-title><ce:para id="p2630">Hypophosphataemia is defined as existing when serum phosphate values fall below 0.8 mmol/L (2.48 mg/dL). The causes are shown in <ce:cross-ref id="crf0700" refid="b0115">Box 14.22</ce:cross-ref><ce:float-anchor refid="b0115"/>, subdivided into the underlying pathogenic mechanisms.</ce:para><ce:section id="s0515"><ce:section-title id="st0515">Pathophysiology</ce:section-title><ce:para id="p2715">Phosphate may redistribute into cells during periods of increased energy utilisation (such as refeeding after a period of starvation) and during systemic alkalosis. However, severe hypophosphataemia usually represents an overall body deficit due to either inadequate intake or absorption through the gut, or excessive renal losses, most notably in primary hyperparathyroidism (<ce:intra-ref id="ii0320" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0835">p. 663</ce:intra-ref>) or as the result of acute plasma volume expansion, osmotic diuresis and diuretics acting on the proximal renal tubule. Less common causes include inherited defects of proximal sodium–phosphate co-transport and tumour-induced osteomalacia due to ectopic production of the hormone FGF23 (<ce:intra-ref id="ii0325" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1835">p. 1053</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0520"><ce:section-title id="st0520">Clinical features</ce:section-title><ce:para id="p2720">The clinical features of phosphate depletion are wide-ranging, reflecting the involvement of phosphate in many aspects of metabolism. Defects appear in the blood (impaired function and survival of all cell lineages), skeletal muscle (weakness, respiratory failure), cardiac muscle (congestive cardiac failure), smooth muscle (ileus), central nervous system (decreased consciousness, seizures and coma) and bone (osteomalacia in severe prolonged hypophosphataemia, <ce:intra-ref id="ii0330" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1835">p. 1053</ce:intra-ref>).</ce:para></ce:section><ce:section id="s0525"><ce:section-title id="st0525">Investigations</ce:section-title><ce:para id="p2725">Measurement of creatinine, electrolytes, phosphate, albumin, calcium and alkaline phosphatase should be performed. In selected cases, measurement of PTH and 25(OH)D may be helpful to exclude osteomalacia or hypophosphataemic rickets. The combination of hypophosphataemia and hypercalcaemia suggests primary hyperparathyroidism, which should be further investigated by measurements of PTH, as described on <ce:intra-ref id="ii0340" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0835">page 663</ce:intra-ref>. The presence of hypocalcaemia suggests hypophosphataemic rickets, which should be further investigated as described on <ce:intra-ref id="ii0345" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1835">page 1053</ce:intra-ref>.</ce:para></ce:section><ce:section id="s0530"><ce:section-title id="st0530">Management</ce:section-title><ce:para id="p2730">Management of hypophosphataemia due to decreased dietary intake or excessive losses involves administering oral phosphate supplements and high-protein/high-dairy dietary supplements that are rich in naturally occurring phosphate. Intravenous treatment with sodium or potassium phosphate salts can be used in critical situations, but there is a risk of precipitating hypocalcaemia and metastatic calcification. Management of primary hyperparathyroidism and hypophosphataemic rickets are described in more detail on <ce:intra-ref id="ii0350" xlink:href="pii:B978-0-7020-7028-0.00018-4#p3085">pages 664</ce:intra-ref> and <ce:intra-ref id="ii9010" xlink:href="pii:B978-0-7020-7028-0.00024-X#s1835">1053</ce:intra-ref>.</ce:para></ce:section></ce:section><ce:section id="s0535"><ce:section-title id="st0535">Hyperphosphataemia</ce:section-title><ce:para id="p2735">Hyperphosphataemia is most commonly caused by acute kidney injury or chronic kidney disease (<ce:intra-ref id="ii0355" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0700">pp. 413</ce:intra-ref> and <ce:intra-ref id="ii0360" xlink:href="pii:B978-0-7020-7028-0.00015-9#p2630">419</ce:intra-ref>).</ce:para><ce:section id="s0540"><ce:section-title id="st0540">Pathophysiology</ce:section-title><ce:para id="p2740">In acute kidney injury and chronic kidney disease, the primary cause is reduced phosphate excretion as the result of a low GFR. In contrast, the hyperphosphataemia in hypoparathyroidism and pseudohypoparathyroidism is due to increased tubular phosphate reabsorption. Redistribution of phosphate from cells into the plasma can also be a contributing factor in the tumour lysis syndromes and other catabolic states. Phosphate accumulation can be aggravated in any of these conditions if the patient takes phosphate-containing preparations or inappropriate vitamin D therapy.</ce:para></ce:section><ce:section id="s0545"><ce:section-title id="st0545">Clinical features</ce:section-title><ce:para id="p2745">The clinical features relate to hypocalcaemia and metastatic calcification, particularly in chronic kidney disease with tertiary hyperparathyroidism (when a high calcium–phosphate product occurs).</ce:para></ce:section><ce:section id="s0550"><ce:section-title id="st0550">Management</ce:section-title><ce:para id="p2750">Hyperphosphataemia in patients with kidney disease should be treated with dietary phosphate restriction and the use of oral phosphate binders (<ce:intra-ref id="ii0365" xlink:href="pii:B978-0-7020-7028-0.00015-9#s0825">p. 418</ce:intra-ref>). Hyperphosphataemia in hypoparathyroidism and pseudohypoparathyroidism does not usually require treatment. Hyperphosphataemia associated with tumour lysis syndromes and catabolic states can be treated with intravenous normal saline, which is given to promote phosphate excretion.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0555"><ce:section-title id="st0555">Disorders of amino acid metabolism</ce:section-title><ce:para id="p2755">Congenital disorders of amino acid metabolism usually present in the neonatal period and may involve life-long treatment regimens. However, some disorders, particularly those involved in amino acid transport, may not present until later in life.</ce:para><ce:section id="s0560"><ce:section id="s0565"><ce:section-title id="st0560">Phenylketonuria</ce:section-title><ce:para id="p2760">Phenylketonuria (PKU) is inherited as an autosomal recessive disorder caused by loss-of-function mutations in the <ce:italic>PAH</ce:italic> gene, which encodes phenylalanine hydroxylase, an enzyme required for degradation of phenylalanine. As a result, phenylalanine accumulates at high levels in the neonate's blood, causing intellectual disability.</ce:para><ce:para id="p2765">The diagnosis of PKU is almost always made by routine neonatal screening (<ce:intra-ref id="ii0370" xlink:href="pii:B978-0-7020-7028-0.00003-2#s0265">p. 56</ce:intra-ref>). Treatment involves life-long adherence to a low-phenylalanine diet. Early and adequate dietary treatment prevents major intellectual disability, although there may still be a slight reduction in IQ.</ce:para></ce:section><ce:section id="s0570"><ce:section-title id="st0565">Homocystinuria</ce:section-title><ce:para id="p2770">Homocystinuria is an autosomal recessive disorder caused by loss-of-function mutations in the <ce:italic>CBS</ce:italic> gene, which encodes cystathionine β-synthase. The enzyme deficiency causes accumulation of homocysteine and methionine in the blood. Many cases of homocystinuria are diagnosed through newborn screening programmes.</ce:para><ce:para id="p2775">Clinical manifestations are wide-ranging and involve the eyes (ectopia lentis – displacement of the lens), central nervous system (intellectual disability, delayed developmental milestones, seizures, psychiatric disturbances), skeleton (resembling Marfan's syndrome, and also with generalised osteoporosis), vascular system (thrombotic lesions of arteries and veins) and skin (hypopigmentation).</ce:para><ce:para id="p2780">Treatment is dietary, involving a methionine-restricted, cystine-supplemented diet, as well as large doses of pyridoxine.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0575"><ce:section-title id="st0570">Disorders of carbohydrate metabolism</ce:section-title><ce:para id="p2785">The most common disorder of carbohydrate metabolism is diabetes mellitus, which is discussed in <ce:intra-ref id="ii0375" xlink:href="pii:B978-0-7020-7028-0.00020-2#c00020">Chapter 20</ce:intra-ref>. There are also some rare inherited defects, discussed below.</ce:para><ce:section id="s0580"><ce:section id="s0585"><ce:section-title id="st0575">Galactosaemia</ce:section-title><ce:para id="p2790">Galactosaemia is caused by loss-of-function mutations in the <ce:italic>GALT</ce:italic> gene, which encodes galactose-1-phosphate uridyl transferase. It is usually inherited in an autosomal recessive manner. The neonate is unable to metabolise galactose, one of the hexose sugars contained in lactose. Vomiting or diarrhoea usually begins within a few days of ingestion of milk, and the neonate may become jaundiced. Failure to thrive is the most common clinical presentation. The classic form of the disease results in hepatomegaly, cataracts and intellectual disability. Fulminant infection with <ce:italic>Escherichia coli</ce:italic> is a frequent complication. Treatment involves life-long avoidance of galactose- and lactose-containing foods.</ce:para><ce:para id="p2795">The widespread inclusion of galactosaemia in newborn screening programmes has resulted in the identification of a number of milder (‘Duarte’) variants.</ce:para></ce:section><ce:section id="s0590"><ce:section-title id="st0580">Glycogen storage diseases</ce:section-title><ce:para id="p2800">Glycogen storage diseases (GSDs, or glycogenoses) result from inherited defects in one of the many enzymes responsible for the formation or breakdown of glycogen, a complex carbohydrate that can be broken down quickly to release glucose during exercise or between meals.</ce:para><ce:para id="p2805">There are several major types of GSD, which are classified by a number, by the name of the defective enzyme, or eponymously after the physician who first described the condition (<ce:cross-ref id="crf0705" refid="b0120">Box 14.23</ce:cross-ref><ce:float-anchor refid="b0120"/>). Most forms of GSD are inherited in an autosomal recessive manner.</ce:para><ce:para id="p2815">The diagnosis of GSD is made on the basis of the symptoms, physical examination and results of biochemical tests. Occasionally, a muscle or liver biopsy is required to confirm the enzyme defect. Different types of GSD present at different ages, and some may require life-long modifications of diet and lifestyle.</ce:para></ce:section></ce:section></ce:section><ce:section id="s0595"><ce:section-title id="st0585">Disorders of complex lipid metabolism</ce:section-title><ce:para id="p2820">Complex lipids are key components of the cell membrane that are normally catabolised in organelles called lysosomes. The lysosomal storage diseases are a heterogeneous group of disorders caused by loss-of-function mutations in various lysosomal enzymes (<ce:cross-ref id="crf0720" refid="b0125">Box 14.24</ce:cross-ref><ce:float-anchor refid="b0125"/>), resulting in an inability to break down complex glycolipids or other intracellular macromolecules. These disorders have diverse clinical manifestations, typically including intellectual disability. Some can be treated with enzyme replacement therapy, while others (such as Tay–Sachs disease) can be prevented through community participation in genetic carrier screening programmes.</ce:para></ce:section><ce:section id="s0600"><ce:section-title id="st0590">Lipids and lipoprotein metabolism</ce:section-title><ce:para id="p2830">The three main biological classes of lipid are:<ce:list id="ulist0610"><ce:list-item id="u1765"><ce:label>•</ce:label><ce:para id="p2835">cholesterol, which is composed of hydrocarbon rings</ce:para></ce:list-item><ce:list-item id="u1770"><ce:label>•</ce:label><ce:para id="p2840">triglycerides (TGs), which are esters composed of glycerol linked to three long-chain fatty acids</ce:para></ce:list-item><ce:list-item id="u1775"><ce:label>•</ce:label><ce:para id="p2845">phospholipids, which are composed of a hydrophobic ‘tail’ consisting of two long-chain fatty acids linked through glycerol to a hydrophilic head containing a phosphate group.</ce:para></ce:list-item></ce:list>Phospholipids are present in cell membranes and are important signalling molecules.</ce:para><ce:para id="p2850">Despite their poor water solubility, lipids need to be absorbed from the gastrointestinal tract and transported throughout the body. This is achieved by incorporating lipids within lipoproteins. Plasma cholesterol and TGs are clinically important because they are major treatable risk factors for cardiovascular disease, while severe hypertriglyceridaemia also predisposes to acute pancreatitis.</ce:para><ce:section id="s0605"><ce:section-title id="st0595">Functional anatomy and physiology</ce:section-title><ce:para id="p2855">Lipids are transported and metabolised by apolipoproteins, which combine with lipids to form spherical or disc-shaped lipoproteins, consisting of a hydrophobic core and a less hydrophobic coat (<ce:cross-ref id="crf0725" refid="f0080">Fig. 14.12</ce:cross-ref><ce:float-anchor refid="f0080"/>). The structure of some apolipoproteins also enables them to act as enzyme co-factors or cell receptor ligands. Variations in lipid and apolipoprotein composition result in distinct classes of lipoprotein that perform specific metabolic functions.</ce:para><ce:section id="s0610"><ce:section-title id="st0600">Processing of dietary lipid</ce:section-title><ce:para id="p2860">The intestinal absorption of dietary lipid is described on <ce:intra-ref id="ii0390" xlink:href="pii:B978-0-7020-7028-0.00021-4#s0050">page 768</ce:intra-ref> (see also <ce:cross-ref id="crf0730" refid="f0085">Fig. 14.13</ce:cross-ref><ce:float-anchor refid="f0085"/>). Enterocytes lining the gut extract monoglyceride and free fatty acids from micelles and re-esterify them into TGs, which are combined with a truncated form of apolipoprotein B (Apo B48) as it is synthesised. Intestinal cholesterol derived from dietary and biliary sources is also absorbed through a specific intestinal membrane transporter termed NPC1L1. This produces chylomicrons containing TG and cholesterol ester that are secreted basolaterally into lymphatic lacteals and carried to the circulation through the thoracic duct. On entering the blood stream, nascent chylomicrons are modified by further addition of apolipoproteins. Chylomicron TGs are hydrolysed by lipoprotein lipase located on the endothelium of tissue capillary beds. This releases fatty acids that are used locally for energy production or stored as TG in muscle or fat. The residual ‘remnant’ chylomicron particle is avidly cleared by low-density lipoprotein receptors (LDLRs) in the liver, which recognise Apo E on the remnant lipoproteins. Complete absorption of dietary lipids takes about 6–10 hours, so chylomicrons are usually undetectable in the plasma after a 12-hour fast.</ce:para><ce:para id="p2865">The main dietary determinants of plasma cholesterol concentrations are the intake of saturated and <ce:italic>trans</ce:italic>-unsaturated fatty acids, which reduce LDLR levels (see below), whereas dietary cholesterol has surprisingly little effect on fasting cholesterol levels. Plant sterols and drugs that inhibit cholesterol absorption are effective because they also reduce the re-utilisation of biliary cholesterol. The dietary determinants of plasma TG concentrations are complex since excessive intake of carbohydrate, fat or alcohol may all contribute to increased plasma TG by different mechanisms.</ce:para></ce:section><ce:section id="s0615"><ce:section-title id="st0605">Endogenous lipid synthesis</ce:section-title><ce:para id="p2870">In the fasting state, the liver is the major source of plasma lipids (<ce:cross-ref id="crf0735" refid="f0085">Fig. 14.13</ce:cross-ref>). The liver may acquire lipids by uptake, synthesis or conversion from other macronutrients. These lipids are transported to other tissues by secretion of very low-density lipoproteins (VLDLs), which are rich in TG but differ from chylomicrons in that they are less massive and contain full-length Apo B100. Following secretion into the circulation, VLDLs undergo metabolic processing similar to that of chylomicrons. Hydrolysis of VLDL TG releases fatty acids to tissues and converts VLDLs into ‘remnant’ particles, referred to as intermediate-density lipoproteins (IDLs). Most IDLs are rapidly cleared by LDLRs in the liver but some are processed by hepatic lipase, which converts the particle to an LDL by removing TG and most materials other than Apo B100, and free and esterified cholesterol. The catabolism of TG-rich chylomicrons and VLDL by lipoprotein lipase is modulated by Apos C2 and C3 on the surface of these particles.</ce:para><ce:para id="p2875">The LDL particles act as a source of cholesterol for cells and tissues (<ce:cross-ref id="crf0740" refid="f0085">Fig. 14.13</ce:cross-ref>). LDL cholesterol is internalised by receptor-mediated endocytosis through the LDLR. Delivery of cholesterol via this pathway down-regulates expression of LDLR and reduces the synthesis and activity of the rate-limiting enzyme for cholesterol synthesis, hydroxy-methyl-glutaryl-co-enzyme A (HMGCoA) reductase. Another important regulator of LDLR levels is the sterol-sensitive protease proprotein convertase subtilisin kexin 9 (PCSK9), which degrades the LDLR. Intracellular free cholesterol concentrations are maintained within a narrow range by the inhibitory effects of LDL on expression of LRLR, fine-tuning of the half-life of LDLR through PCSK9, and modulation of cholesterol esterification.</ce:para></ce:section><ce:section id="s0620"><ce:section-title id="st0610">Cholesterol transport</ce:section-title><ce:para id="p2880">Peripheral tissues are further guarded against excessive cholesterol accumulation by high-density lipoproteins (HDLs; <ce:cross-ref id="crf0745" refid="f0085">Fig. 14.13</ce:cross-ref>). Lipid-poor Apo A1 (derived from the liver, intestine and th e outer layer of chylomicrons and VLDL) accepts cellular cholesterol and phospholipid from a specific membrane transporter known as the ATP-binding cassette A1 (ABCA1). This produces small HDLs that are able to accept more free cholesterol from cholesterol-rich regions of the cell membrane known as ‘rafts’ via another membrane transporter (ABCG1). The cholesterol that has been accepted by these small HDLs is esterified by lecithin cholesterol acyl transferase (LCAT), thus maintaining an uptake gradient and remodelling the particle into a mature spherical HDL. These HDLs release their cholesterol to the liver and other cholesterol-requiring tissues via the scavenger receptor B1 (SRB1).</ce:para><ce:para id="p2885">The cholesterol ester transfer protein (CETP) in plasma allows transfer of cholesterol from HDLs or LDLs to VLDLs or chylomicrons in exchange for TG. When TG is elevated, the action of CETP may reduce HDL cholesterol and remodel LDLs into ‘small, dense’ LDL particles that may be more atherogenic in the blood-vessel wall. Animal species that lack CETP are resistant to atherosclerosis.</ce:para></ce:section></ce:section><ce:section id="s0625"><ce:section-title id="st0615">Lipids and cardiovascular disease</ce:section-title><ce:para id="p2890">Plasma lipoprotein levels are major modifiable risk factors for cardiovascular disease. Increased levels of atherogenic lipoproteins (especially LDL, but also IDL, and possibly chylomicron remnants) contribute to the development of atherosclerosis (<ce:intra-ref id="ii0395" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1135">p. 484</ce:intra-ref>). A sub-population of LDL particles bears an additional protein known as apolipoprotein (a), which shares homology with plasminogen. The combination of LDL and apolipoprotein (a) is known as lipoprotein (a) (Lp(a)). It transports oxidised phospholipid and is regarded as atherogenic because its plasma concentration is an independent risk factor for cardiovascular disease. Following chemical modifications such as oxidation, Apo B-containing lipoproteins are no longer cleared by normal mechanisms. They trigger a self-perpetuating inflammatory response, during which they are taken up by macrophages to form foam cells, a hallmark of atherosclerotic lesions. These processes also have an adverse effect on endothelial function.</ce:para><ce:para id="p2895">Conversely, HDL removes cholesterol from the tissues to the liver, where it is metabolised and excreted in bile. HDL may also counteract some components of the inflammatory response, such as the expression of vascular adhesion molecules by the endothelium. Consequently, low HDL cholesterol levels, which are often associated with TG elevation, are also associated with atherosclerosis.</ce:para></ce:section><ce:section id="s0630"><ce:section-title id="st0620">Investigations</ce:section-title><ce:para id="p2900">Lipid measurements are usually performed for the following reasons:<ce:list id="ulist0615"><ce:list-item id="u1780"><ce:label>•</ce:label><ce:para id="p2905">screening for primary or secondary prevention of cardiovascular disease</ce:para></ce:list-item><ce:list-item id="u1785"><ce:label>•</ce:label><ce:para id="p2910">investigation of patients with clinical features of lipid disorders (<ce:cross-ref id="crf9115" refid="f0015">p. 347</ce:cross-ref>) and their relatives</ce:para></ce:list-item><ce:list-item id="u1790"><ce:label>•</ce:label><ce:para id="p2915">monitoring of response to diet, weight control and medication.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p2920">Abnormalities of lipid metabolism most commonly come to light following these tests. Non-fasting measurements of total cholesterol (TC) and HDL cholesterol (HDL-C) allow estimation of non-HDL cholesterol (non-HDLC, calculated as TC − HDL-C), but a 12-hour fasting sample is required to standardise TG measurement and allow calculation of LDL cholesterol (LDL-C) according to the Friedewald formula:<ce:display><ce:formula id="e0015"><mml:math altimg="si2.gif" display="block" overflow="scroll"><mml:mrow><mml:mtext>LDL-C</mml:mtext><mml:mo>=</mml:mo><mml:mtext>TC</mml:mtext><mml:mo>−</mml:mo><mml:mtext>HDL-C</mml:mtext><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mtext>TG</mml:mtext><mml:mo>/</mml:mo><mml:mn>2.2</mml:mn><mml:mo>)</mml:mo><mml:mtext> </mml:mtext><mml:mtext>mmol/L</mml:mtext></mml:mrow></mml:math></ce:formula></ce:display></ce:para><ce:para id="p2925"><ce:italic>or</ce:italic><ce:display><ce:formula id="e0020"><mml:math altimg="si3.gif" display="block" overflow="scroll"><mml:mrow><mml:mtext>LDL-C</mml:mtext><mml:mo>=</mml:mo><mml:mtext>TC</mml:mtext><mml:mo>−</mml:mo><mml:mtext>HDL-C</mml:mtext><mml:mo>−</mml:mo><mml:mo>(</mml:mo><mml:mtext>TG</mml:mtext><mml:mo>/</mml:mo><mml:mn>5</mml:mn><mml:mo>)</mml:mo><mml:mtext> </mml:mtext><mml:mtext>mg/dL</mml:mtext></mml:mrow></mml:math></ce:formula></ce:display></ce:para><ce:para id="p2930">The formula becomes unreliable when TG levels exceed 4 mmol/L (350 mg/dL). Measurements of non-HDLC or Apo B100 may assess risk of cardiovascular disease more accurately than LDL-C, particularly when TG levels are increased. The use of non-fasting samples is increasing because non-fasting TG is a more sensitive marker of the risk of cardiovascular disease. Nevertheless, a 12-hour fast is required for formal diagnosis of the presence of hypertriglyceridaemia or use of the Friedewald equation. Consideration must be given to confounding factors, such as recent illness, after which cholesterol, LDL and HDL levels temporarily decrease in proportion to severity. Results that will affect major decisions, such as initiation of drug therapy, should be confirmed with a repeat measurement.</ce:para><ce:para id="p2935">Elevated levels of TG are common in obesity, diabetes and insulin resistance (<ce:intra-ref id="ii0405" xlink:href="pii:B978-0-7020-7028-0.00019-6#c00019">Chs 19</ce:intra-ref> and <ce:intra-ref id="ii0410" xlink:href="pii:B978-0-7020-7028-0.00020-2#c00020">20</ce:intra-ref>), and are frequently associated with low HDL and increased ‘small, dense’ LDL. Under these circumstances, LDL-C may under-estimate risk. This is one situation in which measurement of non-HDLC or Apo B may provide more accurate risk assessment.</ce:para></ce:section><ce:section id="s0635"><ce:section-title id="st0625">Presenting problems in lipid metabolism</ce:section-title><ce:para id="p2940">Hyperlipidaemia can occur in association with various diseases and drugs, as summarised in <ce:cross-ref id="crf0750" refid="b0130">Box 14.25</ce:cross-ref><ce:float-anchor refid="b0130"/>. Overt or subclinical hypothyroidism (<ce:intra-ref id="ii0415" xlink:href="pii:B978-0-7020-7028-0.00018-4#s0135">p. 639</ce:intra-ref>) may cause hypercholesterolaemia, and so measurement of thyroid function is warranted in most cases, even in the absence of typical symptoms and signs.</ce:para><ce:para id="p3065">Once secondary causes are excluded, primary lipid abnormalities may be diagnosed. Primary lipid abnormalities can be classified according to the predominant lipid problem: hypercholesterolaemia, hypertriglyceridaemia or mixed hyperlipidaemia (<ce:cross-ref id="crf0755" refid="b0135">Box 14.26</ce:cross-ref><ce:float-anchor refid="b0135"/>). Although single-gene disorders are encountered in all three categories, most cases are due to multiple-gene (polygenic) loci interacting with environmental factors. Clinical consequences of dyslipidaemia vary somewhat between these causes (<ce:cross-ref id="crf9120" refid="s0010">pp. 346–347</ce:cross-ref>).</ce:para><ce:section id="s0640"><ce:section-title id="st0630">Hypercholesterolaemia</ce:section-title><ce:para id="p3075">Hypercholesterolaemia is a polygenic disorder that is the most common cause of a mild to moderate increase in LDL-C (<ce:cross-ref id="crf0770" refid="b0135">Box 14.26</ce:cross-ref>). Physical signs, such as corneal arcus and xanthelasma, may be found in this as well as other forms of lipid disturbance (<ce:cross-ref id="crf9125" refid="s0010">p. 346</ce:cross-ref>). The risk of cardiovascular disease is proportional to the degree of LDL-C (or Apo B) elevation, but is modified by other major risk factors, including low HDL-C and high Lp(a).</ce:para><ce:para id="p3080">Familial hypercholesterolaemia (FH) is a more severe disorder with a prevalence of at least 0.4% in most populations. It is usually caused by loss-of-function mutations affecting the <ce:italic>LDLR</ce:italic> gene, which results in an autosomal dominant pattern of inheritance. A similar syndrome can arise with loss-of-function mutations in the ligand-binding domain of Apo B100 or gain-of-function mutations in <ce:italic>PCSK9</ce:italic>, which promote LDLR degradation. Causative mutations can be detected in one of these three genes by genetic testing in about 70% of patients with FH. Most patients with these types of FH have LDL-C levels that are approximately twice as high as in normal subjects of the same age and gender. Affected patients suffer from severe hypercholesterolaemia and premature cardiovascular disease. FH may be accompanied by xanthomas of the Achilles or extensor digitorum tendons (<ce:cross-ref id="crf9130" refid="s0010">p. 346</ce:cross-ref>), which are strongly suggestive of FH. The onset of corneal arcus before age 40 is also suggestive of this condition. Identification of an index case of FH (the first case of FH in a family) should trigger genetic and biochemical screening of other family members, which is a cost-effective method for case detection. Affected individuals should be managed from childhood (<ce:cross-ref id="crf0775" refid="b0140">Box 14.27</ce:cross-ref><ce:float-anchor refid="b0140"/>).</ce:para><ce:para id="p3105">Homozygous FH may occur sporadically, especially in populations in which there is a ‘founder’ gene effect or consanguineous marriage. Homozygosity results in more extensive xanthomas and precocious cardiovascular disease, often in childhood. Hyperalphalipoproteinaemia refers to increased levels of HDL-C. In the absence of an increase in LDL-C, this condition rarely causes cardiovascular disease, but exceptions can occur so it should not be regarded as universally benign.</ce:para><ce:para id="p3110">Familial combined hyperlipidaemia, and dysbetalipoproteinaemia, may present with the pattern of predominant hypercholesterolaemia (see ‘<ce:cross-ref id="crf0780" refid="s0650">Mixed hyperlipidaemia</ce:cross-ref>’ below).</ce:para></ce:section><ce:section id="s0645"><ce:section-title id="st0635">Hypertriglyceridaemia</ce:section-title><ce:para id="p3115">Hypertriglyceridaemia also usually involves polygenic factors (see <ce:cross-ref id="crf0785" refid="b0135">Box 14.26</ce:cross-ref>). Other common causes include excess alcohol intake, medications (such as β-blockers and retinoids), type 2 diabetes, impaired glucose tolerance, central obesity or other manifestations of insulin resistance (<ce:intra-ref id="ii0435" xlink:href="pii:B978-0-7020-7028-0.00020-2#p0585">p. 728</ce:intra-ref>) and impaired absorption of bile acids. It is often accompanied by post-prandial hyperlipidaemia and reduced HDL-C, both of which may contribute to cardiovascular risk. Excessive intake of alcohol or dietary fat, or other exacerbating factors, may precipitate a massive increase in TG levels, which, if they exceed 10 mmol/L (880 mg/dL), may pose a risk of acute pancreatitis.</ce:para><ce:para id="p3120">Monogenic forms of hypertriglyceridaemia also occur due to loss-of-function mutations in the genes encoding lipoprotein lipase, Apo C2 or <ce:italic>ANGPTL4</ce:italic>, which coordinate the lipolytic breakdown of TG-rich lipoproteins. These cause recessively inherited forms of severe hypertriglyceridaemia that is not readily amenable to drug treatment. They can present in childhood and may be associated with episodes of acute abdominal pain and pancreatitis. In common with other causes of severe hypertriglyceridaemia, hepatomegaly, lipaemia retinalis and eruptive xanthomas may occur (<ce:cross-ref id="crf9135" refid="s0010">p. 346</ce:cross-ref>). Familial hypertriglyceridaemia may also be inherited in a dominant manner due to mutations in the <ce:italic>APOA5</ce:italic> gene, which encodes Apo A5 – a co-factor that is essential for lipoprotein lipase activity. These disorders may also be associated with increased risk of cardiovascular disease.</ce:para><ce:para id="p3125">Familial combined hyperlipidaemia, and dysbetalipoproteinaemia, may present with the pattern of predominant hypertriglyceridaemia (see ‘<ce:cross-ref id="crf0790" refid="s0650">Mixed hyperlipidaemia</ce:cross-ref>’, below).</ce:para></ce:section><ce:section id="s0650"><ce:section-title id="st0640">Mixed hyperlipidaemia</ce:section-title><ce:para id="p3130">It is difficult to define quantitatively the distinction between predominant hyperlipidaemias and mixed hyperlipidaemia. The term ‘mixed’ usually implies the presence of hypertriglyceridaemia, as well as an increase in LDL-C or IDL. Treatment of massive hypertriglyceridaemia may improve TG faster than cholesterol, thus temporarily mimicking mixed hyperlipidaemia.</ce:para><ce:para id="p3135">Primary mixed hyperlipidaemia is usually polygenic and, like predominant hypertriglyceridaemia, often occurs in association with type 2 diabetes, impaired glucose tolerance, central obesity or other manifestations of insulin resistance (<ce:intra-ref id="ii0445" xlink:href="pii:B978-0-7020-7028-0.00020-2#p0585">p. 728</ce:intra-ref>). Both components of mixed hyperlipidaemia may contribute to the risk of cardiovascular disease.</ce:para><ce:para id="p3140">Familial combined hyperlipidaemia is a term used to identify an inherited tendency towards the over-production of atherogenic Apo B-containing lipoproteins. It results in elevation of cholesterol, TG or both in different family members at different times. It is associated with an increased risk of cardiovascular disease but it does not produce any pathognomonic physical signs. In practice, this relatively common condition is substantially modified by factors such as age and weight. It may not be a monogenic condition, but rather one end of a heterogeneous spectrum that overlaps insulin resistance.</ce:para><ce:para id="p3145">Dysbetalipoproteinaemia (also referred to as type 3 hyperlipidaemia, broad-beta dyslipoproteinaemia or remnant hyperlipidaemia) involves accumulation of roughly equimolar levels of cholesterol and TG. It is caused by homozygous inheritance of the Apo E2 allele, which is the isoform least avidly recognised by the LDLR. In conjunction with other exacerbating factors, such as obesity or diabetes, it leads to accumulation of atherogenic IDL and chylomicron remnants. Premature cardiovascular disease is common, as is peripheral vascular disease. It may also result in the formation of palmar xanthomas, tuberous xanthomas or tendon xanthomas.</ce:para></ce:section><ce:section id="s0655"><ce:section-title id="st0645">Rare dyslipidaemias</ce:section-title><ce:para id="p3150">Several rare disturbances of lipid metabolism have been described (<ce:cross-ref id="crf0795" refid="b0145">Box 14.28</ce:cross-ref><ce:float-anchor refid="b0145"/>). They provide important insights into lipid metabolism and its impact on risk of cardiovascular disease.</ce:para><ce:para id="p3160">Fish eye disease, Apo A1 Milano and lecithin cholesterol acyl transferase (LCAT) deficiency demonstrate that very low HDL-C levels do not necessarily cause cardiovascular disease, but Apo A1 deficiency, and possibly Tangier disease, demonstrate that low HDL-C can be atherogenic under some circumstances. Autosomal recessive <ce:italic>FH</ce:italic> and <ce:italic>PCSK9</ce:italic> gain-of-function mutations reveal the importance of proteins that chaperone the LDLR. Sitosterolaemia and cerebrotendinous xanthomatosis demonstrate that sterols other than cholesterol can cause xanthomas and cardiovascular disease, while <ce:italic>PCSK9</ce:italic> loss-of-function mutations, abetalipoproteinaemia and hypobetalipoproteinaemia suggest that low levels of Apo B-containing lipoproteins reduce the risk of cardiovascular disease. The only adverse health outcomes associated with extremely low plasma lipid levels in the latter two conditions are attributable to fat-soluble vitamin deficiency, or impaired transport of lipid from intestine or liver.</ce:para></ce:section></ce:section><ce:section id="s0660"><ce:section-title id="st0650">Principles of management</ce:section-title><ce:para id="p3165">Lipid-lowering therapies have a key role in the secondary and primary prevention of cardiovascular diseases (<ce:intra-ref id="ii0450" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1245">p. 487</ce:intra-ref>). Assessment of absolute risk of cardiovascular disease, treatment of all modifiable risk factors and optimisation of lifestyle, especially diet and exercise, are central to management in all cases. Patients with the greatest absolute risk of cardiovascular disease derive the greatest absolute benefit from treatment. Public health organisations recommend thresholds for the introduction of lipid-lowering therapy based on the identification of patients in very high-risk categories, or those calculated to be at high absolute risk according to algorithms or tables such as the Joint British Societies Coronary Risk Prediction Chart (see <ce:intra-ref id="ii0455" xlink:href="pii:B978-0-7020-7028-0.00016-0#f0425">Fig. 16.77</ce:intra-ref>, <ce:intra-ref id="ii0460" xlink:href="pii:B978-0-7020-7028-0.00016-0#s1870">p. 511</ce:intra-ref>). These tables, which are based on large epidemiological studies, should be recalibrated for the local population, if possible. In general, patients who have cardiovascular disease, diabetes mellitus, chronic renal impairment, familial hypercholesterolaemia or an absolute risk of cardiovascular disease of more than 20% in the ensuing 10 years are arbitrarily regarded as having sufficient risk to justify drug treatment. Age is such an overwhelming determinant of absolute cardiovascular risk that some recent recommendations consider ‘lifetime’ risk. This diminishes the pressure to treat very elderly patients and supports earlier intervention in non-elderly patients.</ce:para><ce:para id="p3170">Public health organisations also recommend target levels for patients receiving drug treatment. High-risk patients should aim for HDL-C &#x003E; 1 mmol/L (38 mg/dL) and fasting TG &#x003C; 2 mmol/L (approximately 180 mg/dL), while target levels for LDL-C have been reduced to 1.8 mmol/L (76 mg/dL) or less. In general, total cholesterol should be &#x003C; 5 mmol/L (190 mg/dL) during treatment, and &#x003C; 4 mmol/L (approximately 150 mg/dL) in high-risk patients and in secondary prevention of cardiovascular disease. Recent trials have demonstrated continuous benefit of LDL-C reduction to a level of 1.4 mmol/L (54 mg/dL), so further reduction in treatment targets may be anticipated.</ce:para><ce:section id="s0665"><ce:section-title id="st0655">Non-pharmacological management</ce:section-title><ce:para id="p3175">Patients with lipid abnormalities should receive medical advice and, if necessary, dietary counselling to:<ce:list id="ulist0665"><ce:list-item id="u1925"><ce:label>•</ce:label><ce:para id="p3180">reduce intake of saturated and <ce:italic>trans</ce:italic>-unsaturated fat to less than 7–10% of total energy</ce:para></ce:list-item><ce:list-item id="u1930"><ce:label>•</ce:label><ce:para id="p3185">reduce intake of cholesterol to &#x003C; 250 mg/day</ce:para></ce:list-item><ce:list-item id="u1935"><ce:label>•</ce:label><ce:para id="p3190">replace sources of saturated fat and cholesterol with alternative foods, such as lean meat, low-fat dairy products, polyunsaturated spreads and low-glycaemic-index carbohydrates</ce:para></ce:list-item><ce:list-item id="u1940"><ce:label>•</ce:label><ce:para id="p3195">reduce energy-dense foods such as fats and soft drinks, while increasing activity and exercise to maintain or lose weight</ce:para></ce:list-item><ce:list-item id="u1945"><ce:label>•</ce:label><ce:para id="p3200">increase consumption of cardioprotective and nutrient-dense foods, such as vegetables, unrefined carbohydrates, fish, pulses, nuts, legumes, and fruit</ce:para></ce:list-item><ce:list-item id="u1950"><ce:label>•</ce:label><ce:para id="p3205">adjust alcohol consumption, reducing intake if excessive or if associated with hypertension, hypertriglyceridaemia or central obesity</ce:para></ce:list-item><ce:list-item id="u1955"><ce:label>•</ce:label><ce:para id="p3210">achieve additional benefits with preferential intake of foods containing lipid-lowering nutrients such as n-3 fatty acids, dietary fibre and plant sterols.</ce:para></ce:list-item></ce:list></ce:para><ce:para id="p3215">The response to diet is usually apparent within 3–4 weeks but dietary adjustment may need to be introduced gradually. Although hyperlipidaemia in general, and hypertriglyceridaemia in particular, can be very responsive to these measures, LDL-C reductions are often only modest in routine clinical practice. Explanation, encouragement and persistence are often required to assist patient adherence. Even minor weight loss can substantially reduce cardiovascular risk, especially in centrally obese patients (<ce:intra-ref id="ii0465" xlink:href="pii:B978-0-7020-7028-0.00019-6#p0560">p. 700</ce:intra-ref>).</ce:para><ce:para id="p3220">All other modifiable cardiovascular risk factors should be assessed and treated. If possible, intercurrent drug treatments that adversely affect the lipid profile should be replaced.</ce:para></ce:section><ce:section id="s0670"><ce:section-title id="st0660">Pharmacological management</ce:section-title><ce:para id="p3225">The main diagnostic categories provide a useful framework for management and the selection of first-line pharmacological treatment (<ce:cross-ref id="crf0800" refid="f0090">Fig. 14.14</ce:cross-ref><ce:float-anchor refid="f0090"/>).</ce:para><ce:section id="s0675"><ce:section-title id="st0665">Hypercholesterolaemia</ce:section-title><ce:para id="p3230">Hypercholesterolaemia can be treated with one or more of the cholesterol-lowering drugs as described below.</ce:para><ce:section id="s0680"><ce:section-title id="st0670">Statins</ce:section-title><ce:para id="p3235">These reduce cholesterol synthesis by inhibiting the HMGCoA reductase enzyme<ce:italic>.</ce:italic> The reduction in cholesterol synthesis up-regulates production of the LDLR, which increases clearance of LDL and its precursor, IDL, resulting in a secondary reduction in LDL synthesis. Statins reduce LDL-C by up to 60%, reduce TG by up to 40% and increase HDL-C by up to 10%. They also reduce the concentration of intermediate metabolites such as isoprenes, which may lead to other effects such as suppression of the inflammatory response. There is clear evidence of protection against total and coronary mortality, stroke and cardiovascular events across the spectrum of cardiovascular disease risk.</ce:para><ce:para id="p3240">Statins are generally well tolerated and serious side-effects are rare (well below 2%). Liver function test abnormalities and muscle problems, such as myalgia, asymptomatic increase in creatine kinase (CK), myositis and, infrequently, rhabdomyolysis, are the most common. Side-effects are more likely in patients who are elderly, debilitated or receiving other drugs that interfere with statin degradation, which usually involves cytochrome P450 3A4 or glucuronidation.</ce:para></ce:section><ce:section id="s0685"><ce:section-title id="st0675">Ezetimibe</ce:section-title><ce:para id="p3245">Ezetimibe inhibits activity of the intestinal mucosal transporter NPC1L1, which is responsible for absorption of dietary and biliary cholesterol. The resulting depletion of hepatic cholesterol up-regulates hepatic LDLR production. This mechanism of action is synergistic with the effect of statins. Monotherapy in a 10 mg/day dose reduces LDL-C by 15–20%. Slightly greater (17–25%) incremental LDL-C reduction occurs when ezetimibe is added to statins. Ezetimibe is well tolerated, and evidence of a beneficial effect on cardiovascular disease endpoints is now available. Plant sterol-supplemented foods, which also reduce cholesterol absorption, lower LDL-C by 7–15%.</ce:para></ce:section><ce:section id="s0690"><ce:section-title id="st0680">Bile acid-sequestering resins</ce:section-title><ce:para id="p3250">Drugs in this class include colestyramine, colestipol and colesevelam. These prevent the reabsorption of bile acids, thereby increasing de novo bile acid synthesis from hepatic cholesterol. As with ezetimibe, the resultant depletion of hepatic cholesterol up-regulates LDL receptor activity and reduces LDL-C in a manner that is synergistic with the action of statins. Resins reduce LDL-C and modestly increase HDL-C, but may increase TG. They are safe but may interfere with bioavailability of other drugs. Colesevelam has fewer gastrointestinal effects than older preparations that are less well tolerated. The depletion of bile acids is sensed via the farnesyl X receptor and the response may also improve glucose metabolism.</ce:para></ce:section><ce:section id="s0695"><ce:section-title id="st0685">PCSK9 inhibitors</ce:section-title><ce:para id="p3255">Monoclonal antibodies have been developed that neutralise PCSK9, an enzyme that degrades the LDLR. This causes levels of LDLR to increase, which markedly reduces LDL-C. The PCSK9 inhibitors currently available are evolocumab and alirocumab, which are administered by subcutaneous injection every 2–4 weeks. These drugs are well tolerated and highly effective. Reductions in LDL-C of about 50–60% have been observed in patients who have not responded adequately to standard lipid-lowering therapy and this has been accompanied by a reduction in the risk of cardiovascular events of about 15%. The PCSK9 inhibitors do not deplete intracellular concentrations and, because of that, do not trigger compensatory mechanisms that blunt the effect of other cholesterol-lowering medications.</ce:para></ce:section><ce:section id="s0700"><ce:section-title id="st0690">Nicotinic acid</ce:section-title><ce:para id="p3260">Pharmacological doses reduce peripheral fatty acid release, with the result that VLDL and LDL decline while HDL-C increases. Recent randomised clinical trials have been disappointing regarding effects on atherosclerosis and cardiovascular events. The same may be said of novel agents that inhibit cholesterol ester transfer protein. Neither of these HDL-C-raising drugs is indicated in current lipid management.</ce:para></ce:section><ce:section id="s0705"><ce:section-title id="st0695">Combination therapy</ce:section-title><ce:para id="p3265">In many patients, treatment of predominant hypercholesterolaemia can be achieved by diet plus the use of a statin in sufficient doses to achieve target LDL-C levels. Patients who do not reach LDL targets on the highest tolerated statin dose, or who are intolerant of statins, may receive ezetimibe, plant sterols, or resins. Ezetimibe and resins are safe and effective in combination with a statin because the mechanisms of action of individual therapies complement each other while blunting each other's compensatory mechanisms.</ce:para></ce:section></ce:section><ce:section id="s0710"><ce:section-title id="st0700">Hypertriglyceridaemia</ce:section-title><ce:para id="p3270">Predominant hypertriglyceridaemia can be treated with one of the TG-lowering drugs described below (see <ce:cross-ref id="crf0805" refid="f0090">Fig. 14.14</ce:cross-ref>).</ce:para><ce:section id="s0715"><ce:section-title id="st0705">Fibrates</ce:section-title><ce:para id="p3275">These stimulate peroxisome proliferator-activated receptor (PPAR) alpha, which controls the expression of gene products that mediate the metabolism of TG and HDL. As a result, synthesis of fatty acids, TG and VLDL is reduced, while that of lipoprotein lipase, which catabolises TG, is enhanced. In addition, production of Apo A1 and ABC A1 is up-regulated, leading to increased reverse cholesterol transport via HDL. Consequently, fibrates reduce TG by up to 50% and increase HDL-C by up to 20%, but LDL-C changes are variable.</ce:para><ce:para id="p3280">Fewer large-scale trials have been conducted with fibrates than with statins. The results are less conclusive, but reduced rates of cardiovascular disease have been reported with fibrate therapy in the subgroup of patients with low HDL-C levels and elevated TG (TG &#x003E; 2.3 mmol/L (200 mg/dL)). Fibrates are usually well tolerated but share a similar side-effect profile to statins. In addition, they may increase the risk of cholelithiasis and prolong the action of anticoagulants. Accumulating evidence suggests that they may also have a protective effect against diabetic microvascular complications.</ce:para></ce:section><ce:section id="s0720"><ce:section-title id="st0710">Highly polyunsaturated long-chain n-3 fatty acids</ce:section-title><ce:para id="p3285">These include eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), which comprise approximately 30% of the fatty acids in fish oil. EPA and DHA are potent inhibitors of VLDL TG formation. Intakes of more than 2 g n-3 fatty acid (equivalent to 6 g of most forms of fish oil) per day lower TG in a dose-dependent fashion. Up to 50% reduction in TG may be achieved with 15 g fish oil per day. Changes in HDL-C are variable but fish oils do not routinely reduce LDL-C. Fish oil fatty acids have also been shown to inhibit platelet aggregation and improve cardiac arrhythmia in animal models. Dietary and pharmacological trials suggested that n-3 fatty acids may reduce mortality from coronary heart disease, but the benefit of fish oil supplements has been less conclusive in recent trials. Fish oils appear to be safe and well tolerated but dietary fish consumption is the preferred source.</ce:para><ce:para id="p3290">Patients with predominant hypertriglyceridaemia who do not respond to lifestyle intervention can be treated with fibrates or fish oil, depending on individual response and tolerance. If target levels are not achieved, the fibrates, fish oil and possibly nicotinic acid can be combined. Massive hypertriglyceridaemia may require more aggressive limitation of dietary fat intake (&#x003C; 10–20% energy as fat). Any degree of insulin deficiency should be corrected because insulin is required for optimal activity of lipoprotein lipase. The initial target for patients with massive hypertriglyceridaemia is TG &#x003C; 10 mmol/L (880 mg/dL), to reduce the risk of acute pancreatitis.</ce:para></ce:section><ce:section id="s0725"><ce:section-title id="st0715">Mixed hyperlipidaemia</ce:section-title><ce:para id="p3295">Mixed hyperlipidaemia can be difficult to treat. First-line therapy with statins alone is unlikely to achieve target levels once fasting TGs exceed approximately 4 mmol/L (350 mg/dL). Fibrates are first-line therapy for dysbetalipoproteinaemia, but they may not control the cholesterol component in other forms of mixed hyperlipidaemia. Combination therapy is often required. Effective combinations include:<ce:list id="ulist0670"><ce:list-item id="u1960"><ce:label>•</ce:label><ce:para id="p3300">statin plus fenofibrate (recognising that the risk of myopathy is increased with gemfibrozil, but fenofibrate is relatively safe in this regard)</ce:para></ce:list-item><ce:list-item id="u1965"><ce:label>•</ce:label><ce:para id="p3305">statin plus fish oil when TG is not too high</ce:para></ce:list-item><ce:list-item id="u1970"><ce:label>•</ce:label><ce:para id="p3310">fibrate plus ezetimibe when cholesterol is not too high.</ce:para></ce:list-item></ce:list></ce:para></ce:section></ce:section><ce:section id="s0730"><ce:section-title id="st0720">Monitoring of therapy</ce:section-title><ce:para id="p3315">The effects of lipid-lowering therapy should be assessed after 6 weeks (12 weeks for fibrates). At this point, it is prudent to review side-effects, lipid response (see target levels above), CK and liver function tests. During longer-term follow-up, adherence to treatment, diet and exercise should be assessed, with monitoring of weight, blood pressure and lipid levels. The presence of cardiovascular symptoms or signs should be noted and absolute cardiovascular risk assessed periodically. Effective statin therapy may be associated with a paradoxical and as yet unexplained increase in coronary calcium score.</ce:para><ce:para id="p3320">It is not necessary to perform routine checks of CK and liver function unless symptoms occur, or if statins are used in combination with fibrates, or other drugs that may interfere with their clearance. If myalgia or weakness occurs in association with CK elevation over 5–10 times the upper limit of normal, or if sustained alanine aminotransferase (ALT) elevation more than 2–3 times the upper limit of normal occurs that is not accounted for by fatty liver (<ce:intra-ref id="ii0470" xlink:href="pii:B978-0-7020-7028-0.00022-6#s0840">p. 882</ce:intra-ref>), treatment should be discontinued and alternative therapy sought.</ce:para><ce:para id="p3325">The principles of the management of dyslipidaemia can be applied broadly, but the objectives of treatment in the elderly (<ce:cross-ref id="crf0810" refid="b0150">Box 14.29</ce:cross-ref><ce:float-anchor refid="b0150"/>) and the safety of pharmacological therapy in pregnancy (<ce:cross-ref id="crf0815" refid="b0155">Box 14.30</ce:cross-ref><ce:float-anchor refid="b0155"/>) warrant special consideration.</ce:para></ce:section></ce:section></ce:section></ce:section><ce:section id="s0735"><ce:section-title id="st0725">The porphyrias</ce:section-title><ce:para id="p3375">This group of disorders is caused by inherited abnormalities in the haem biosynthetic pathway (<ce:cross-ref id="crf0820" refid="f0095">Fig. 14.15</ce:cross-ref><ce:float-anchor refid="f0095"/>). Most of the described forms are due to partial enzyme deficiencies with a dominant mode of inheritance. They are commonly classified as hepatic or erythropoietic, depending on whether the major site of excess porphyrin production is in the liver or red cell.</ce:para><ce:para id="p3380">The porphyrias have a penetrance in the order of 25%, emphasising the importance of environmental factors in disease expression. In porphyria cutanea tarda (PCT), which is the most common cause of porphyria, environmental triggers include alcohol, iron accumulation, exogenous oestrogens and exposure to various chemicals. Many cases are associated with hepatitis C infection and this should always be screened for on presentation.</ce:para><ce:section id="s0740"><ce:section id="s0745"><ce:section id="s0750"><ce:section-title id="st0730">Clinical features</ce:section-title><ce:para id="p3385">The clinical features of porphyria fall into two broad categories: photosensitivity and acute neurovisceral syndrome. The enzyme defects responsible for the diseases are shown in <ce:cross-ref id="crf0825" refid="f0095">Figure 14.15</ce:cross-ref>.</ce:para><ce:para id="p3390">Photosensitive skin manifestations, attributable to excess production and accumulation of porphyrins in the skin, cause pain, erythema, bullae, skin erosions, hirsutism and hyperpigmentation, and occur predominantly on areas of the skin that are exposed to sunlight (<ce:intra-ref id="ii0475" xlink:href="pii:B978-0-7020-7028-0.00029-9#s0235">p. 1220</ce:intra-ref>). The skin also becomes sensitised to damage from minimal trauma.</ce:para><ce:para id="p3395">The other pattern of presentation is with an acute neurological syndrome. This almost always presents with acute abdominal pain together with features of autonomic dysfunction, such as tachycardia, hypertension and constipation. Neuropsychiatric manifestations, hyponatraemia due to inappropriate ADH release (<ce:cross-ref id="crf9140" refid="s0230">p. 357</ce:cross-ref>), and an acute neuropathy may also occur (<ce:intra-ref id="ii0485" xlink:href="pii:B978-0-7020-7028-0.00025-1#s2035">p. 1138</ce:intra-ref>). The neuropathy is predominantly motor and may, in severe cases, progress to respiratory failure.</ce:para><ce:para id="p3400">There is no proven explanation for the episodic nature of the attacks in porphyria, which can relapse and remit or follow a prolonged and unremitting course. Sometimes, specific triggers can be identified, such as alcohol, fasting, or drugs such as anticonvulsants, sulphonamides, oestrogen and progesterone. The oral contraceptive pill is a common precipitating factor. In a significant number, no precipitant can be identified.</ce:para></ce:section><ce:section id="s0755"><ce:section-title id="st0735">Investigations</ce:section-title><ce:para id="p3405">The diagnosis of porphyria and classification into the various forms have traditionally relied on measurements of porphyrins and porphyrin precursors found in blood, urine and faeces (<ce:cross-ref id="crf0830" refid="b0160">Box 14.31</ce:cross-ref><ce:float-anchor refid="b0160"/>). The diagnosis is straightforward when the metabolites are significantly elevated, but this is not always the case in asymptomatic individuals who may have normal porphyrin studies.</ce:para><ce:para id="p3415">More recently, measurement of the enzymes that are deficient in the various porphyrias has provided further diagnostic information. An example is measurement of porphobilinogen deaminase activity in red blood cells to diagnose acute intermittent porphyria. There is often considerable overlap between enzyme activities in affected and normal subjects, however. Furthermore, some of the enzymes occur in the mitochondria, for which it is more difficult to obtain suitable specimens for analysis. All the genes of the haem biosynthetic pathway have now been characterised. This has made it possible to identify affected individuals in families by genetic testing, a significant advance considering that penetrance of porphyria is low.</ce:para><ce:para id="p3420">Metabolite excretory patterns are always grossly abnormal during an acute attack or with cutaneous manifestations of porphyria, and are diagnostic of the particular porphyria. A normal metabolite profile under these circumstances effectively excludes porphyria. Metabolites usually remain abnormal for long periods after an acute attack, and in some individuals never return to normal. The diagnosis is not so straightforward in patients who are in remission, or in asymptomatic individuals with a positive family history. Neurological porphyria rarely manifests before puberty, nor can it be readily diagnosed after the menopause as porphyrin excretion may be normal. Genetic testing for disease-specific mutations can clarify the situation.</ce:para></ce:section><ce:section id="s0760"><ce:section-title id="st0740">Management</ce:section-title><ce:para id="p3425">For patients predisposed to neurovisceral attacks, general management includes avoidance of any agents known to precipitate acute porphyria. Specific management includes intravenous glucose, as provision of 5000 kilojoules per day can, in some cases, terminate acute attacks through a reduction in δ-aminolaevulinic acid (ALA) synthetase activity, leading to reduced ALA and porphyrin synthesis. More recently, administration of haem (in various forms such as haematin or haem arginate) has been shown to reduce metabolite excretory rates, relieve pain and accelerate recovery. Cyclical acute attacks in women sometimes respond to suppression of the menstrual cycle using gonadotrophin-releasing hormone analogues. In rare cases with frequent prolonged attacks or attacks intractable to treatment, liver transplantation has been effective.</ce:para><ce:para id="p3430">There are few specific or effective measures to treat the photosensitive manifestations. The primary goal is to avoid sun exposure and skin trauma. Barrier sun creams containing zinc or titanium oxide are the most effective products. New colourless creams containing nanoparticle formulations have improved patient acceptance. Beta-carotene is used in some patients with erythropoietic porphyria with some efficacy. Afamelanotide, a synthetic analogue of alpha-melanocyte stimulating hormone (α-MSH), has also been shown to provide protection in erythropoietic protoporphyria, and is now undergoing approval in many countries. In porphyria cutanea tarda, a course of venesections to remove iron can result in long-lasting clinical and biochemical remission, especially if exposure to identified precipitants, such as alcohol or oestrogens, is reduced. Alternatively, a prolonged course of low-dose chloroquine therapy is effective.</ce:para></ce:section></ce:section></ce:section></ce:section></ce:sections><ce:further-reading id="fr0010"><ce:section-title id="st0745">Further information</ce:section-title><ce:further-reading-sec id="fs0010"><ce:section-title id="st0750">Journal articles</ce:section-title><ce:bib-reference id="bib1"><ce:label>Spasovski et al, 2014</ce:label><sb:reference id="sr0010"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>G</ce:given-name><ce:surname>Spasovski</ce:surname></sb:author><sb:author><ce:given-name>R</ce:given-name><ce:surname>Vanholder</ce:surname></sb:author><sb:author><ce:given-name>B</ce:given-name><ce:surname>Allolio</ce:surname></sb:author><sb:et-al/></sb:authors><sb:title><sb:maintitle>Clinical practice guideline on diagnosis and treatment of hyponatraemia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur J Endocrinol</sb:maintitle></sb:title><sb:volume-nr>170</sb:volume-nr></sb:series><sb:date>2014</sb:date></sb:issue><sb:pages><sb:first-page>G1</sb:first-page><sb:last-page>G47</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>Walsh, Unwin, 2012</ce:label><sb:reference id="sr0015"><sb:contribution langtype="en"><sb:authors><sb:author><ce:given-name>S</ce:given-name><ce:surname>Walsh</ce:surname></sb:author><sb:author><ce:given-name>R.</ce:given-name><ce:surname>Unwin</ce:surname></sb:author></sb:authors><sb:title><sb:maintitle>Renal tubular disorders</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin Med</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:issue-nr>5</sb:issue-nr><sb:date>2012</sb:date></sb:issue><sb:pages><sb:first-page>476</sb:first-page><sb:last-page>479</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:further-reading-sec><ce:further-reading-sec id="fs0015"><ce:section-title id="st0755">Websites</ce:section-title><ce:bib-reference id="bib3"><ce:label>,</ce:label><sb:reference id="sr0020"><sb:host><sb:e-host><ce:inter-ref id="iw0010" xlink:href="http://emedicine.medscape.com">emedicine.medscape.com</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0185"><ce:italic>The Nephrology link on this site contains a useful compendium of articles.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>,</ce:label><sb:reference id="sr0025"><sb:host><sb:e-host><ce:inter-ref id="iw0015" xlink:href="http://lipidsonline.org">lipidsonline.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0190"><ce:italic>Summarises management strategies for dyslipidaemia.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>,</ce:label><sb:reference id="sr0030"><sb:host><sb:e-host><ce:inter-ref id="iw0020" xlink:href="http://ncbi.nlm.nih.gov">ncbi.nlm.nih.gov</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0195"><ce:italic>The link to OMIM (Online Mendelian Inheritance in Man) provides updated information on the genetic basis of metabolic disorders.</ce:italic></ce:simple-para></ce:note></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>,</ce:label><sb:reference id="sr0035"><sb:host><sb:e-host><ce:inter-ref id="iw0025" xlink:href="http://porphyria-europe.com">porphyria-europe.com</ce:inter-ref></sb:e-host></sb:host><sb:comment>and</sb:comment><sb:host><sb:e-host><ce:inter-ref id="iw0030" xlink:href="http://drugs-porphyria.org">drugs-porphyria.org</ce:inter-ref></sb:e-host></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>,</ce:label><ce:note><ce:simple-para id="sp0200"><ce:italic>Excellent resources on drug safety in porphyria.</ce:italic></ce:simple-para></ce:note></ce:bib-reference></ce:further-reading-sec></ce:further-reading></chapter>